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1 Abstract
1 Abstract
This thesis was aimed at identifying proto-oncogenes that contribute to cell cycle entry, proliferation
and survival of mouse B-lymphocytes at dierent stages of their development, i.e. in preB-I, preB-II,
immature B-cells, mature resting and mature activated B-cells.
A central notion of tumour development of the B-lymphocyte cell lineages is that the activation of a
single proto-oncogene, or the loss of a single tumour suppressor gene, is not sucient to transform cells to
full malignancy. One such example with which this cooperation of oncogenes has been studied is E-myc
induced lymphomagenesis. Transgenic E-myc mice express the c-myc gene under the control of the
IgH -chain gene enhancer in B-lineage cells. B-cell lymphomas are generated in these mice within several
weeks. Retroviral insertional mutagenesis has identied pim1 as cooperating oncogene which accelerates
lymphomagenesis in vivo.
Hence, I have chosen myc and pim1 to introduce them into B-cell progenitors by retroviral trans-
duction, to test their eects alone or together on preB-I, preB-II, immature and mature B-cells in vitro
and, upon transplantation into recipient mice, in vivo. As target cells for retroviral transduction, mouse
fetal liver-derived preB-I-cells were chosen, since they proliferate long term in vitro on stromal cells in
the presence of IL7.
I used inducible forms of these genes to turn on and o their expression in the transfected cells at
dierent times for dierent time periods. After initial tests with the inducible estrogen-receptor system,
the TetON inducible expression system was chosen which allows the expression of inducible transgenes
upon addition of doxycycline.
In the here presented work show that overexpression of Myc alone in pre-BI cells in vitro enhances
cell cycle entry without impairing apoptotis of pre-BI cells induced by the removal of IL-7 from the
culture. Pim1 overexpression alone did not show any eect. However, in cooperation with Myc, Pim1
led to growth-factor-independent long term in vitro proliferation of pre-BI cells deprived of IL-7. This
induction of proliferation could be reversed when doxycycline was removed again from the culture. During
long term proliferation of these cells, dierentiation to pre-BII and immature B-cells was slowed down
but not completely blocked in vitro. The dierentiated pre-BII and IgM+ immature B-cells also were
induced to growth factor-independent proliferation by Pim1 plus Myc.
Transplantation of Myc-overexpressing pre-BI cells into sublethally irradiated Rag KO mice did not
increase the numbers of B cells developing in the transplanted mice compared with mice transplanted with
doxycycline-non-induced pre-BI cells. On the other hand, transplantation of pre-BI cells overexpressing
Pim1 and Myc together expanded the immature IgM  (pre-B) cell compartment 100 fold and the imma-
ture IgM+ B-cell compartment 6 fold in the spleen within 1 month. Upon removal of doxycycline from
the drinking water, the expanded numbers of B-cells reverted to almost normal levels, i.e. to the levels of
B cell numbers of doxycycline-uninduced mice. Hence, overexpression of the proto-oncogenes Pim1 and
Myc is able to induce growth-factor-independent proliferation of pre-B cells and immature IgM+ cells, in
vitro and in vivo.
By contrast, mature B cells overexpressing Myc and Pim1 together, isolated from the spleens of
pre-BI cell-transplanted mice, were not induced to cytokine-independent proliferation in vitro. Even the
stimulation by LPS, IL-5, IL-4 + CD40, and anti-Ig in vitro did not induce prolonged proliferation
beyond the normal stimulation observed with non-transgenic, or with transgenic B cells in the absence
of doxycycline. Likewise, in vivo antigenic stimulation with KLH of mice transplanted with Myc and
Pim1-overexpressing pre-BI cells in the presence or absence of co-transplanted T-cells did not result in
expanded, KLH-specic, class-switched antibody responses. Hence, while pre-BI, pre-BII and immature
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B cells expand cytokine-independently in vitro and in vivo when Pim1 and Myc are overexpressed to-
gether, mature B cells generated from these transplanted pre-B cells in vivo do not manifest deregulated
proliferation or survival in vitro or in vivo upon T-cell-independent or T-cell-dependent stimulation.
Corinne Bouquet, MPI for Infection Biology, Chariteplatz 1, 10117 Berlin, Germany: PhD Thesis, March 23, 2012 9
1 Abstract
Abbreviations
AP alkaline phosphatase
BCR B-cell receptor
BM bone marrow
EtOH ethanol
FACS 
uorescence activated cell separation
FCS fetal calf serum
FL fetal liver
Flt3L Fms-related tyrosine kinase 3 ligand
h hours
IL interleukin
IRES internal ribosome entry site
KLH keyhole limpet hemocyanin
KO knockout
LPS lipopolysaccharide
MACS magnetic activated cell separation
MoMulV Moloney murine leukemia virus
MPI-IB Max-Planck Institute for Infection Biology
Myc, myc C-Myc, V-Myc myelocytomatosis viral oncogene homolog, gene
MZ, MZB marginal zone B cells
ON over night
PC peritoneal cavity
PI propidium iodide
Pim1, pim1 proviral integration site 1 protein, gene
RT room temperature
RT-PCR real time PCR
SIN self inactivating (retroviral vector)
TH T helper cell
TD T-dependent (antigen)
TdT terminal desoxyribonucleotidyl transferase
TI T-independent (antigen)
TLR toll-like receptor
TSLP thymic stromal lymphopoietin
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2 Introduction
2.1 B-Cells: Development and Function
B-cells and T-cells constitute their adaptive part of the vertebrate immune system. While T-cells confer
cellular immunity, B-cells are responsible for humoral immunity by secreting antibodies which circulate
in the body 
uids to capture and neutralise foreign antigens.
2.1.1 B-Cell Development in the Mouse
The rst wave of B-cells in the murine embryo is generated from primitive pluripotent hematopoietic stem
cells (pHSCs) rst aggregating at day 7.5-8 p.c. (post coitum) in the AGM (aorta-gonad-mesonephros),
which lies between the notochord and the somatic mesoderm and contains the dorsal aorta, the genital
ridges and mesonephros [106]. These pHSC-progenitors then migrate to the fetal liver around day 11 p.c..
Around birth, i.e. at day 18 p.c., B cell development reaches a maximum in fetal liver, and is initiated in
the bone marrow, where B-cell development takes place during the rest of life from resident pHSCs.
Bone marrow-derived B cells dier from fetal liver-derived ones in several aspects [72]. Only bone
marrow-derived antibodies have insertions of random bases (N regions) at the joints of the rearranged
segments, since the enzyme TdT (terminal desoxyribonucleotidyl transferase) is expressed and active in
the bone marrow, but not in the fetal liver [80].
Another dierence between bone marrow and fetal liver preB-cells is the absolute requirement of bone
marrow B-cell precursors for IL-7, whereas fetal liver preB-cells can develop IL-7-dependently, but do
not rely on this cytokine only. Hence, in IL-7 decient mice, B-cell development is only observed during
fetal and perinatal life [15]. These IL-7 decient mice only have B1- and marginal zone B-cells and show
enlarged IgM and IgG-serum levels if T-cells are present. They grow in the absence of IL-7 if supplemented
with IL-3 or thymic stromal lymphopoietin (TSLP) [113]. Hence, in in vitro culture, fetal liver pre-BI
cells can be grown in the absence of IL-7 if supplemented with IL-3 or thymic stromal lymphopoietin
(TSLP) [113].
DH➞JH
VHDHJH/
(VH)DHJH
DHJH/ VL➞JL
➞ ➞ ➞ ➞
preBI large
preBII
small
preBII
immature 
B
proB
Binding to autoantigens:
strong weak no binding
mature
B1
mature
B2
“A” “B” “C’ ” “D” “E” 
preBCR
IgD
IgM
Legend
➞
nomenclature:
Rolink et al. 
Hardy et al.
DHJH
“C ”
Figure 2.1 { Outline of the development of B lymphocytes in the bone marrow.
Shown are two nomenclatures, the \Basel" separation system developed by Rolink et
al., and the ABC nomenclature developed by Hardy et al., see the text for further
details. Proliferation of preB-cells can mainly be observed in large pre-BII cells and
to a lesser extent in pre-BI cells. All other immature stages do not divide. DH ! JH ,
etc: rearrangement of the designated segments is ongoing, DHJH , etc: rearrangement
of the designated segments (V, D, and J) is nished. H : heavy chain, L: light chain.
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Development of B cells can be tracked by their state of rearrangements of the V, D and J segments of
the B-cell receptor, and by FACS analysis, since dierent stages of B cells express characterising surface
receptors. Several dierent systems have been established to identify the dierent B cell maturation
stages. Herein, the surface marker separation system developed by Rolink et al. [111] [113] is used. In
gure 2.1, this system is compared to the Hardy ABC-system [49].
The earliest event which shows that a cell is committed to the B lineage is the transcription of the
non-rearranged germline  heavy chain gene locus, as well as the transcription of the VpreB and 5 genes,
which are parts of the pre-B cell receptor [91]. These cells are B220+ but still do not express the pan-B
cell marker CD19 and are called pre/pro-B cells. Rearrangement of DH segments to JH segments of the
Ig gene loci is already detectable at this stage.
The next distinguishable stage on the way to a mature B-cell has almost completely rearranged all
alleles of the heavy chain to DHJH , and expresses c-kit and CD19 [90]. This stage is referred to as pre-BI
stage.
VH to DJH rearrangements mark the transition from pre-BI cells to large pre-BII cells. pre-BII cells
are CD19+c-kit CD25+CD43+. As soon as a productive V DJH -rearranged allele is made and the -
heavy chain is deposited on the cell surface together with the surrogate light chain (H + VpreB + 5,
= preBCR, preB-cell receptor), allelic exclusion inhibits further rearrangement of the other allele. The
deposition of the preBCR on the cell surface induces these cells to enter the cell cycle and divide around
two to ve times. Cells decient for the preBCR do not proliferate [73]. As soon as the preBCR is formed,
expression of the VpreB and 5 proteins stops [42] and subsequently, proliferation of pre-BII cells ceases.
The cells now become small (since they are resting) and start to rearrange the light chain gene
segments VL to JL by activating the rearrangement machinery again and opening the light-chain gene
loci for these rearrangements. They are now named small pre-BII. In contrast to humans, mice do not
reactivate TdT anymore for rearranging the light chain. Hence, mouse V JL joints do not have N regions.
Rearrangements of the  and  light chain loci are independent of each other, but the  locus becomes
rst accessible, and the rate of rearrangement at the L-chain locus is 5 times higher than at the L
locus. Only one allele of the  locus is rearranged at a time [99].
When a functional light chain is produced which can pair with the heavy chain, the immature B-
cell is tested for reactivity with self-antigens. If the produced B-cell receptor (BCR) can strongly bind
to self-antigen, the respective immature B-cells can be rescued by \editing" their receptor by secondary
light-chain rearrangements [110]. If receptor editing is not possible or if the secondary rearrangement does
not change the autoreactivity, the cells acquire an unresponsive, anergic state or are clonally deleted [53].
Immature B-cells expressing a B-cell receptor which binds self-antigen with low anity are thought to be
positively selected and to enter the B1- and MZ (marginal zone) compartment. Immature B-cells carrying
a BCR receptor which does not bind autoantigen enter mainly the B2 compartment.
2.1.2 B-cell Subsets and their Characterisation
B-cells can be divided into at least 2 lineages: B1 cells, and conventional (B2) B-cells [3].
B1 cells are IgMhi IgDlo CD11b+ and comprise the majority of B-cells in the peritoneal cavity. The B1
compartment is further divided into B1-a and B1-b cells according to their expression of CD5. B1-a cells
express CD5, whereas B1-b cells are CD5-negative. The B1-a cells are thought to be one main source of
\natural antibodies" that are produced also in the absence of antigenic stimulations, e.g. infections. These
natural antibodies recognise high molecular weight polymeric antigens and are thought to be important
during the early response to encapsulated extracellular bacteria [44]. In contrast, B1-b cells produce
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antibodies only after exposure to antigens. Activation of B1-b cells can be T-helper cell (TH) independent
and can generate long lasting IgM memory [4]. Until recently there was a debate if B1- and B2 cells are
derived from the same ancestor, or if there are dierent progenitors for each lineage. It has recently been
shown that B1 B-cells have their own progenitor among the CD45Rlo negCD19+ population which is
highly abundant in fetal bone marrow and less abundant in postnatal bone marrow [96]. Therefore, it is
not very surprising that fetal liver pre-BI cells repopulate preferentially the B1 cell compartment, whereas
bone marrow pre-BI cells more eciently generate the B2 cell compartment [55], [50].
The B2 cell compartment is further subdivided into follicular B-cells and marginal zone B-cells (MZB).
In rodents, the latter are mainly found in the marginal zone of the spleen which surrounds the B-cell
follicles. MZB-cells are sessile [43] and express high levels of surface immunoglobulin M (sIgM) and CD21
(complement receptor 2) and low levels of sIgD. MZB-cells can respond more rapidly following exposure
to antigen [86] and, together with the B1-cells, are largely responsible for rapid early TH -cell-independent
B-cell responses.
The follicular B-cells are IgM+IgD+CD23+CD21lo and are found in the follicles of spleen and lymph
nodes, but also circulate in the blood. They can react to TH -cell dependent protein antigens, and organize
themselves in germinal centers where they develop to somatically hypermutated, Ig-class switched long
lived memory and plasma cells harbouring high anity antibodies to the immunising antigen.
2.1.3 Activation of B Cells
B-cells can be activated either with or without the help of T-cells (TD, T-dependent or TI, T-independent),
depending on the nature of the antigen and the receptors involved. T-independent antigens fall into two
classes, which activate B-cells by two dierent mechanisms.
TI-1 antigens can activate B-cells independently of the BCR. This polyclonal activation can occur e.g.
via the toll-like receptors (TLRs) present on all B-cells which recognise bacterial cell wall components,
bacterial DNA, 
agella and other bacterial components (gure 2.2). TI-1 antigens need to be present at
high concentrations in order to polyclonally activate B-cells. An example of a TI-1 antigen often used in
research is lipopolysaccharide (LPS).
TI-2 antigens on the other hand are highly repetitive molecules such as bacterial polysaccharides
which can crosslink several BCRs and hereby activate the B-cells [10]. A typical example of TI-2 antigens
used in research is anti-IgM coupled to dextran or sepharose beads.
Protein antigens without repetitive antigenic structures can only activate naive B-cells with the help of
activated T helper cells (TH). If a naive B-cell recognises a protein antigen with its BCRs, it internalises
the antigen, processes it by proteolytic degradation, and presents the peptide fragments via MHC-II
complexes on the cell surface. This preactivated B-cell is preferentially trapped in T-cell rich zones of
secondary lymphoid tissues such as spleen and lymph nodes. TH cells which have a T-cell receptor
(TCR) specic for the MHCII-antigen complexes on the B-cell are subsequently activated by the B-
cell. Thereafter, the T-cell expresses CD40-L [103] [104] and releases cytokines such as IL-2 or IL-4,
which in turn further activate the B-cell via CD40 and corresponding cytokine receptors (gure 2.2).
The TNF-family member CD40 plays a central role in T-cell dependent B-cell activation and germinal
center formation [74] [39]. The interaction of activated T-cells with B-cells via CD40 can be mimicked
with CD40-specic antibodies [115]. Finally, B-cells upregulate the expression of B7-1 and B7-2, which
interact with CD28 or CTLA-4 on helper T-cells which either enhance (CD28) or inhibit (CTLA-4) the
T-B collaboration.
Upon T-cell dependent activation of B-cells, there are several possible pathways a B-cell can take
Corinne Bouquet, MPI for Infection Biology, Chariteplatz 1, 10117 Berlin, Germany: PhD Thesis, March 23, 2012 13
2 Introduction
TLR-4
BCR
CD40
IL-4R
IL-5R
TH-cell
B cell MHC II
FAS FAS-L
CD40-L
TCR
BAFF-R
CD21
CD19
+
-B7.1/2
CTLA-4
CD28
Figure 2.2 { B-cells can be activated and in
uenced via a set of dierent surface
receptors. The main receptor is the B-cell receptor, which is surrounded by the core-
ceptor signalling complex consisting of Ig=, CD19, CD81, and the complement
receptor CD21. CD21 can bind the complement fragments C3d and C3g of antigen-
complement clusters and leads to enhanced activation of B-cells [11]. Toll like recep-
tors (TLR) recognise bacterial components and activate B-cells BCR-independently.
Dierent cytokine receptors specic for IL-2, IL-4, IL-5, IL6, etc can in
uence the re-
actions of activated B-cells. Signalling via BaR leads to enhanced survival, whereas
signalling via FAS leads to apoptosis of activated B-cells. FAS is upregulated after
B-cell activation in the germinal center. CD40 recognises CD40-ligand on activated
T-cells. Signalling via CD40 costimulates and activates B-cells which were preacti-
vated by signalling via BCR. B-cells in turn can activate T-cells by presenting antigen
fragments on their MHC II molecules. Many dierent signalling pathways activate the
NFB transcription factors which are involved in activation and survival of B-cells.
(gure 2.3). First, activated B-cells can move to the border of the T-cell zone and the medulla in the
spleen or to the medullary cords in the lymph nodes. Then they proliferate and subsequently dierentiate
into short lived plasma cells which secrete mainly IgM (gure 2.3).
Second, T-cell-activated B-cells can migrate to follicles in the B-cell zone and form a germinal center. In
the germinal center, proliferating B-cells form the dark zone. These cells downregulate their sIg molecules
and divide every 6-8 hours (centroblasts), whereas in the light zone of a germinal center, there is a mixture
of mainly non-proliferating B-cells (centrocytes) deriving from the centroblast, T-cells and follicular
dendritic cells (FDCs). The dark zone is thought to be the place where the B-cells begin to acquire somatic
hypermutations in the variable regions of their antibody genes, while the light zone is the place where
these mutated cells are selected for BCRs with enhanced anities to the original antigen by interactions
with FDCs which present a nondegraded, native form of the protein antigen to the B-cells, thereby
allowing selection of hypermutated B-cells with specic BCRs for 3-dimensional antigen determinants
on the protein antigen. Hypermutated B-cells with higher anity to the antigen are positively selected
and switch their antibody heavy chains to dierent isotypes. The mainly produced isotypes during a GC
reaction are dependent on the cytokines which are present [125]. The cytokine milieu itself is dependent
on the reactions of the cells of innate immunity. Here also, CD40 signalling is important for the survival
and Ig isotype switching of germinal center B-cells [76] [82].
Finally, hypermutated, Ig-class-switched B-cells either become long lived plasma cells and migrate to
niches in the bone marrow, or they dierentiate into long-lived memory cells which are quickly reactivated
upon re-encounter with the same antigen.
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Figure 2.3 { T-cell dependent activation of B-cells in the spleen after antigen exposure.
2.1.4 Growth Factors and Stimulants for B-Cells
For the dierent maturation stages and subsets of B-cells, many growth factors and survival factors are
known.
The main growth factor for preB-cells is interleukin 7 (IL-7). In IL-7 KO mice, B-cell development
in the bone marrow is blocked precisely at the transition between pro-B-cells and pre-B-cells [137]. Vice
versa, overexpression of IL-7 under the control of the MHCII promoter results in the expansion of the
early immature B-cell compartment [37]. IL-3 has been shown to be able to replace IL-7 in the cultivation
of fetal preB-cell lines, but in contrast to IL-7, it also induces dierentiation of hematopoietic precursors
to myeloid cell fates in mixed bone marrow cultures [139].
Some of the main growth factors for mature B-cells are IL-2, the TH2-cytokines IL-3, IL-4, IL-5,
and IL6. IL-2 is known to promote proliferation and dierentiation of stimulated B-cells [140]. IL-3 can
enhance growth of normal human B-cells and of human follicular B-cell lymphoma cell lines [20]. Human
tonsillar B-cells activated with Staphylococcus aureus have a higher proliferation rate if IL-3 is present.
IL-3 acts synergistically with IL-2, which promotes proliferation and dierentiation of stimulated B-
cells [140]. IL-3 also cooperates with IL6 in inducing dierentiation and Ig secretion in human B-cells and
-lines [128].
IL-4 prevents the death of naive B lymphocytes through the up-regulation of antiapoptotic proteins
[30]. Furthermore, in B-cells activated by CD40- or BCR-engagement, IL-4 (together with IL-21) enhanced
proliferation of puried mouse B-cells. On the other hand, IL-4 and IL-21 inhibited the proliferative
response to LPS or CpG DNA [64]. IL-4 also induces AID-expression and therefore plays a role during
class switching [71].
IL-5 promotes B1 cell growth and dierentiation. In consequence, IL-5R = mice have less than 30%
of peritoneal B1 cells compared to wild type littermates. In contrast, cell numbers in spleen and lymph
nodes are unaltered in these mice, as well as the B2 compartment sizes [56] [129]. In addition, IL-5 is
needed for responses of B1 B-cells to stimulation with IL-4 and CD40. In contrast, B2 cells mainly rely
on IL-4 in combination with CD40-stimulation [66] [34].
IL6 is a known growth factor for plasmacytomas and hybridomas, and can induce maturation to plasma
cells [78]. Furthermore, it has been shown to allow survival of murine bone marrow-derived plasma cells
in vitro [16].
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2.1.5 In vitro Culture of B-Cells
In vitro cultivation of B-cells is a helpful tool to examine their properties and functions. So far, the only
murine B-cell stage which can easily be cultured by continuous proliferation in vitro is the pre-BI-cell
stage. Fetal liver pre-BI cells can be grown for several months if supplemented with bone marrow stromal
cells and the cytokine IL-7 [112]. The pre-BI cells keep their phenotype of surface markers and proliferate
long-term, i.e. for hundreds of divisions. In contrast to the fetal liver pre-BI cells, bone marrow pre-BI
cells cultured in the presence of stromal feeder layer cells and IL-7 only grow for approximately 30 days
before they die (personal communication, F. Melchers).
Other dierentiation stages of B-cells can only be kept in vitro for some days. Mature naive B-cells for
example can be stimulated to proliferate for short periods of time in vitro with IgM molecules coupled
to sepharose beads in the presence of cytokines, or with CD40 antibody and IL-4 which simulate the
activation signals of T-cells [115]. B-cells with a memory phenotype can be generated in vitro out of
human GC cells by the addition of CD40, IL-2 and IL-10, whereas plasma cells can be generated in the
presence of IL-2 and IL-10 alone [5]. None of them proliferate long-term.
Long-term cultivation, i.e. proliferation, of specic antibody secreting cells is only possible if acti-
vated/proliferating B-cells are fused to hybrid myeloma (hybridoma) cell lines, a technique developed by
G. Kohler and C. Milstein in 1975 [70].
In the herein presented work, the cooperating oncogenes Pim1 andMyc were integrated into B-lineage
cells with the aim to generate long-term proliferating naive B-cells, memory B-cells, or plasma cells.
2.2 Myc and Pim1
Around 20 years ago, a number of experiments was conducted to nd new genes involved in tumorigenesis.
Myc and Pim1 loci were found to be involved very often in retroviral insertion of the Moloney Murine
Leukemia Virus (MoMuLV). Moreover, the 2 proto-oncogenes were shown to cooperate in the generation
of T-cell lymphomas [2] [133] [134].
2.2.1 Structure of Myc
The carboxyterminal end of the Myc protein contains a basic-helix-loop-helix-leucine zipper (b-HLH-LZ)
domain (gure 2.4). This region is required for dimerization with other members of the b-HLH-LZ family.
In the case of Myc, it is Max, another b-HLH-LZ family member [13]. The Myc/Max heterodimers can
then bind DNA by recognizing the so called E-Box sequence CACGTG [12]. Dimerization of the Myc-
partner Max with the HLH-LZ family member Mad and family members thereof results in transcriptional
repression which antagonizes the trancriptional and transforming activities of Myc [7].
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Figure 2.4 { Structure of Myc. bHLH: basic helix-loop-helix; zip: leucine zipper; NLS:
nuclear localisation signal; MB I-III: conserved Myc Boxes; TAD: transactivation
domain; P: one of the phosphorylation sites.
Myc contains 3 so called Myc homology boxes (MB I-III), which are highly conserved within the Myc
family members and also within Myc proteins of dierent species. All of them lie in the N-terminal part
of the protein. The rst box, Myc homology box I or MB I, contains 2 phosphorylation sites (Thr and
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Ser), which are important for the stability of Myc. MB II is important for the transforming activity of
Myc, but also seems to be involved in transcriptional repression of genes [79], [107]. Both Myc boxes carry
also independent signals for protein degradation [38]. The Myc boxes therefore also play an important
role in regulating the levels of the Myc protein. MB III plays a role in transcriptional repression of Myc
and has recently been found to negatively regulate the pro-apoptotic function of Myc [54].
Myc exists in two major protein forms, which are generated by dierential translational initiation. The
short form, Myc2, is initiated at a canonical ATG in exon 2, whereas the long form, Myc1, is derived from
an alternative non-AUG codon near the 3' end of exon 1 [47]. In humans and mice, this is a CTG codon
15 codons upstream of the ATG codon. There are no apparent dierences between these two proteins in
subcellular localization, stability, or post-translational modications [46]. In growing cells, Myc1 protein
has been shown to be only 10-15% of the level of Myc2 protein levels [48]. Upon methionine deprivation
as occurring during nutrient deprivation, Myc1 synthesis is increased 5-10x, whereas synthesis of the
AUG-initiated Myc2 is minimally aected [48]. The increase in Myc1-expression is not observable in cells
subjected to stress factors (hypertonic treatment, heat shock, serum deprivation, growth inhibition by
the lack of essential amino acids other than methionine). The small N-terminal tail of the larger Myc1
seems to oer an additional DNA-binding domain, which can specically activate transcription of the
C/EBP sequences within the EFII enhancer element of the Rous sarcoma virus LTR. Overexpression of
murine Myc1 protein in COS cells by replacing the alternative start codon to ATG results in reduced
proliferation of cells compared to overexpression of the short Myc form by destroying the alternative start
codon [45].
2.2.2 Regulation of Myc
Myc is highly regulated at transcriptional, post-transcriptional, and post-translational levels [124] [138]
[114] [121]. In general, Myc is expressed in proliferating cells and is downregulated in quiescent and
dierentiated cells. After serum- or mitogen stimulation of quiescent cells, Myc levels peak within several
hours and subsequently drop to a basal level which is dependent on the presence of growth factors [136].
2.2.3 Function of Myc
A null Myc mutation causes lethality before day 10.5 of gestation in homozygotes and reduces fertility in
heterozygous female mice. [28]
Myc has a wide range of activities in cells coupled to proliferation. During B lymphocyte development,
Myc enhances protein synthesis and cell size [62]. This increase in cell size occurs independently of cell
cycle phase.
Myc can provoke proliferation, but at the same time induces apoptosis. For example, Myc induces
suppression of bcl-XL and bcl-2 in hematopoietic cells [33]. This suppression works indirectly, since de
novo protein synthesis is required. Vice versa, coexpression of the anti-apoptotic BCL2 protein accelerates
Myc induced lymphomagenesis [127]. In addition to block survival proteins such as BCL2, Myc activates
the ARF-Mdm2-p53 tumour suppressor pathway, which is frequently disabled in human cancers [123].
Inhibition of p53 prevents Myc-induced apoptosis [63]. Taken together, these lines of evidence propose that
the most important mechanism of cooperation with Myc in tumour formation is suppression of apoptosis.
However, even ARFnull E-Myc mice whose B-cells show decreased apoptotic rates, only develop clonal
tumours [33]. Hence, it is likely that additional transformation events are necessary to develop tumours.
In normal hematopoietic cells, apoptosis induced by Myc can be suppressed by cytokines, but if Myc is
expressed at high levels, it overrides the protective eects of these survival factors [101].
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2.2.4 Myc and Cancer
Myc by itself is most often not sucient to transform cells. E-Myc mice develop B-cell tumours with
a mean latency of 12-16 weeks of age, suggesting that deregulation of at least one more proto-oncogene
is necessary for full transformation [134]. Before the development of tumours, B-cell progenitors appear
relatively normal, but the early B-cell compartment is expanded and shows increased apoptosis [75].
Burkitt's lymphoma (BL) is associated with translocations and, hence, deregulation, of the Myc gene
almost by denition. In BL, Myc overexpression leads to a centroblast-like phenotype of the B-cells
including upregulation of bcl-6 and expression of the human GC marker CD77 [118]. Deregulated Myc
cooperates with BCL-Xl to cause plasma cell neoplasms in mice [19].
2.2.5 Myc and B-Cell Development
Transcription of Myc is upregulated in immature B-lymphocytes upon IL-7 signalling [98], and in mature
B lymphocytes by growth factors such as LPS. Within 1-3 hours of stimulation, Myc RNA levels increase
10-40 fold and decline thereafter and during subsequent proliferative cell cycles of activated B-cells to
very low levels [68].
In human tonsils, Myc is predominantly expressed in IgD , CD38+, CD77  centroblasts [87]. Myc
expression is also regulated by CD40 signalling in B-cells [117]. Myc transcription is repressed by BLIMP-
1 during nal maturation to plasma cells [83]. This repression is necessary for terminal dierentiation,
but not sucient [81].
2.2.6 The Pim Kinase Family
The Pim family comprises 3 Ser/Thr kinases, Pim1, Pim2 and Pim3, with high degrees of sequence- and
structural similarities which are well conserved in vertebrates [93]. Pim1 and Pim2 are both known targets
of proviral integration which is associated with a rapid development of T-cell lymphomas [133] [25].
2.2.7 Structure and Function of Pim1
The Pim1 gene comprises around 5 kb and contains six exons. It encodes two related proteins of 34 kD
and 44 kD due to the use of alternative initiation sites at AUG and CUG [116]. The catalytic domain lies
in the central part of the protein starting encompassing the amino acids 38-290 of totally 313 amino acids
in mouse and human. The lysine at position 67 is crucial for kinase activity, and replacement of lysine 67
by methionine results in a kinase dead Pim1 mutant. Pim1 is highly expressed in thymus, spleen, bone
marrow and fetal liver, and also in some non-hematopoietic tissues such as prostate and hippocampus [31].
Pim1 protein is found in both cytoplasm and nucleus. Pim1 is also regulated at the post-transcriptional
level. Its 5'UTR (untranslated region) contains a GC rich region which inhibits translation. Eukaryotic
translation initiation factor 4E (eIF-4E) can relieve this translational inhibition [61]. The half life of Pim1
protein in human leukemic cells is around 1.7 hours [122].
2.2.8 Pim1 in B-Cells
Expression of Pim1 is associated with the survival and proliferation of hematopoietic cells. Pim1 has been
found to co-localise with the pro-apoptotic protein BAD resulting in a phosphorylation of BAD on serine
112, which is a gatekeeper site for BAD inactivation. This suggests a direct role of Pim1 in preventing cell
death, since the inactivation of Bad can enhance BCL-2 activity and thereby promotes cell survival [1].
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In addition, Pim1 binds and phosphorylates the phosphatase Cdc25A, which is a positive G1-specic cell
cycle regulator [95]. Furthermore, Pim1 also phosphorylates Cdc25-associated Kinase 1 (C-TAK1) and
thereby inhibits its activity, which suggests a activating role of Pim1 at the G2/M transition of the cell
cycle [8].
Mice decient for all three Pim kinases are viable and fertile, but have a reduced body size through-
out life. Furthermore, the in vitro response of distinct hematopoietic cell populations to growth factors
such as IL-3 or IL-7 is impaired, e.g. proliferation of peripheral T lymphocytes upon stimulation and
IL-7-mediated proliferation of late pre-B-cells [93]. LPS- and CD40-signalling in B-cells upregulate the
expression of the Pim1 kinase via the NFB pathway and increase kinase activity [141].
Pim1 expression is induced by a variety of cytokines, growth factors and mitogens including IL-2,
IL-3, IL-6 and IL-7 [27] [9].
2.2.9 Pim and Tumours - Pim-p my Myc!
Pim1 by itself is a weak oncogene, but as indicated above cooperates with Myc to cause preB-cell
lymphomas [134] and T-cell lymphomas. Zippo et al. have recently shown that Pim1 interacts with
the Myc BoxII domain and mediates phosphorylation of histone H3 at serine 10 of Myc target genes,
which contributes to the activation of a subset of Myc target genes [143]. Moreover, grafting Pim1 onto
the N-terminus of Myc bypasses the requirement for Myc-BoxII in cellular transformation. Though,
binding of Pim1 cannot be the only function of MycBoxII, since among others, TRRAP (transforma-
tion/transcription domain-associated protein) also binds to a dierent part of the MycBoxII. This protein
is a core component of several histone acetylase complexes [89]. So, Pim1-dependent phosphorylation of
Myc-target genes is possibly the second mechanism in Myc-induced transformation together with its role
in inhibition of Myc induced apoptosis. Pim1 and Pim2 are also required for ecient transformation of
pre-B-cells by the V-ABL oncogene [18]. E-Pim1 -transgenic mice often develop T-cell tumours with a
mean latency period of 7-8 weeks [133]. These tumours often have deregulated Myc expression patterns.
2.3 Thesis Objectives
This project was aimed at examining the eect of the proto-oncogenes Pim1 and Myc to cell cycle entry,
proliferation, and sustained survival in murine B-lymphocytes at dierent stages of B-cell maturation; i.e.
in preB-cells, immature IgM+ cells, mature naive B-cells, and activated B-cells such as germinal center
B-cells and plasma cell precursors.
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3.1 Machines
Cell culture
CO2 incubator for cell culture Binder CB210
Laminar 
ow hood Haereus
H2O-distillery Destamat Bi-Distiller Bi 18E, GCS
N2 tank Arpege 170, Air Liquide
Inverse microscopes Nicon Eclipse TS100, Leica DMIL with Leica DFL 300 FX
camera
Gamma irradiator Gamma Cell 40, MDS Nordion
FACS analyser LSRII, BD Dickinson, 405 nm violet laser (lters: A: 630LP,
655/8; B: 595LP, 605/12; C: 575LP, 585/15; D: 545LP,
560/20; E: 475LP, 525/50; F: 450/50; G,H: empty); 355 nm
UV laser (lters: A: 505LP, 530/30; B: 450/50, C: empty),
633 nm red laser (lters: A: 755 LP, 780/60; B: 710LP,
730/45; C: 660/20) and 488 nm blue laser (lters: A: 755LP,
780/60; B: 685LP, 695/40; C: 655LP, 660/20; D: 600LP,
610/20; E: 550LP, 575/26; F: 505LP, 530/30; G: SSC, H:
empty)
MACS multistand Miltenyi
Mini-MACS magnet Miltenyi
Midi-MACS magnet Miltenyi
Electrophoresis & Visualisation
Electrophoresis chamber (SDS page) Mini-Protean 3 Electrophoresis Module, Biorad
Blotter for SDS page gels Trans-Blot SD Semi Dry transfer cell, Biorad
Power supply for gel electrophoresis Power Pac Basic, Biorad
Gel analyzer (Agarose Gels) Gel Doc 2000, Biorad
Luminescent image analyzer LAS 3000, Fujilm
PCR, molecular Biology
Real time PCR machine 7900 HT sequence detection system, ABI Prism
Thermal cycler DNA Engine PTC 200, Biorad
Tube heating block Thermomixer comfort, Eppendorf
DNA-electroporator Gene Pulser X-cell total system, Biorad
Bio-Photometer Eppendorf
Tabletop centrifuges Eppendorf 5417R, Eppendorf 5810R
3.2 Software
FACS acquisition & analysis Diva 6.1, BD Biosciences
FACS analysis Flow Jo, Tree Star, Inc.
Design of illustrations Adobe Illustrator CS3
Processing of photos Adobe Photoshop CS3
Real-time PCR acquisition SDS v2.0, ABI Prism
Scientic graphics Prism 5.0, Graphpad software
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3.3 Kits
Gel extraction kit Qiagen
Midiprep kit endo-free for extraction of plasmid DNA Qiagen
Miniprep kit for extraction of plasmid DNA Qiagen, Zymo Research
Superscript III rst strand synthesis system Invitrogen
Topo-TA cloning kit Invitrogen
QuantiTect SYBR Green RT-PCR Kit Qiagen
3.4 Labware
product description manufacturer
cell culture 
asks 25 cm2 lter
cap (T25)
Nunclon surface Nunc
cell culture 
asks 75 cm2 lter
cap (T75)
TPP
cell culture plates 15 cm diam. Nunclon surface Nunc
cell culture plates 6 - 96-well Corning
cell culture plates 6-well, Cell-Bind surface (for transfec-
tion)
Corning
cell culture pipettes pyrogen free Corning and Sarstedt
cell strainer 40 , nylon BD Falcon
conical tube 0.5-2 ml Eppendorf
conical tube 15 & 50 ml Corning
dialysis tubing (20/30), wall thickness 0.05 mm Visking
Electroporation cuvettes Biorad
bottletop lters 250 - 1000 ml Express-Plus Steritop Millipore
MACS LD columns for cell depletion Miltenyi
MACS MS columns + plungers for cell enrichment Miltenyi
Needles 30G (0.3x13mm) Microlance 3 BD
Needles 18G (1.2x40mm) Sterican hypodermic needle, BC/SB B. Braun Melsungen AG
Needles 26G (0.45x12mm) Sterican disposable insulin needle,
BL/LB
B. Braun, Melsungen AG
Nitrocellulose membrane Nybond ECL 0.2  Amersham Biosciences
PCR 8-well stripe + caps Biozym
Polypropylene tubes 5 ml round bottom, for FACS analysis BD Falcon
PVDF membrane f. Western blot, Immobilon 0.45  Millipore
plastic eppendorf tube crushers Eppendorf
Pre-separation lters for MACS, 30 m Miltenyi Biotech
Syringe 1 ml Injekt-F, tuberculin, with plastic stop-
per
B.Braun, Melsungen AG
Syringe 1 ml Omnix, tuberculin, with rubber stop-
per
B. Braun, Melsungen AG
96-well plates for ELISA Immuno-Maxisorp U-bottom Nunc
96-well plates for RT-PCR Biozym
250 ml-1 l storage bottle Stericup Millipore
250 ml-1 l storage bottle Corning
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3.5 Antibodies for FACS Analysis
molecule dye company clone name isotype
CD4 PE eBioscience Gk1.5 Rat IgG2b
CD5 FITC eBioscience 53-7.3 Rat IgG2a
CD8a FITC eBioscience 53-6.7 Rat IgG2a
CD19 PerCP-Cy5.5 eBioscience eBio1D3 Rat IgG2a
CD21 FITC eBioscience eBio8D9 Rat IgG2a
CD23 PE eBioscience B3B4 Rat IgG2a
CD25 PeCy7 eBioscience eBio3C7 Rat IgG2b
CD43 FITC eBioscience eBioR2/60 Rat IgM
CD93 PE eBioscience aa4.1 [88] Rat IgG2b
CD95 PE BD Pharmingen Jo2 Armenian hamster IgG2
CD138 PE BD Pharmingen 281-2 Rat IgG2a
c-kit APC eBioscience ACK 2
c-kit APC in-house ACK4
GL-7 FITC BD Pharmingen GL-7
IgD PE eBioscience 11-26 Rat IgG2a
IgM APC eBioscience II41 Rat IgG2a
IgM FITC in-house M41 (C3 specic) [77] Rat IgG1
kappa APC in-house 187-1
3.6 Antibodies for ELISA
molecule dye company clone name isotype
goat anti-mouse IgM - and AP AbD Serotec polycl.
goat anti-mouse total IgG - and AP Southern Biotech polycl.
goat anti-mouse IgG2b AP Southern Biotech polycl.
goat anti-mouse IgG2c AP Southern Biotech polycl.
goat anti-mouse IgG3 AP Southern Biotech polycl.
goat anti-mouse IgA - and AP Southern Biotech polycl.
mouse IgA (Standard) - Southern Biotech S107
mouse IgG (Standard) - Southern Biotech polycl.
mouse IgG (Standard) - homemade UCHT-1 IgG1
mouse gM (Standard) - Chemicon Int. polycl.
mouse anti-KLH (TNP-KLH) - BD Pharmingen A112-3 IgG3, 
3.7 Antibodies for Western Blotting
molecule dye company clone/isotype immunogen, expected size
mouse anti-c-Myc - Santa Cruz 9E10, IgG1 AA408-439 of hc-Myc, 64, 67kD
rabbit anti-mouse Hdac1 - eBioscience polycl., IgG hHDAC1, c-terminal part, 60kD
goat-anti Pim-1 (m,h,rat) - Santa Cruz polycl., IgG hPim1, interal part, 33kD
rabbit anti-goat IgG (H&L) HRP Pierce polycl.
goat anti-mouse IgG (H&L) HRP Pierce polycl.
goat anti-rabbit IgG (H&L) HRP Pierce polycl.
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3.8 DNA Primers
m068 Linker for pSuperRetroPuro-fo, con-
tains the restriction endonuclease sites
EcoRI, HpaI, AvrII, XhoI, NruI, A
III,
HindII, ClaI and MluI
cgacgcgttaacatcgattcgcgaattctcgagcctagg
m074 Linker for pSuperRetroPuro-re tcgacctaggctcgagaattcgcgaatcgatgttaacgcgt
m069 pgk promoter + PuroR MluI-fo cgcacgcgtaattctaccgggtaggggagg
m070 pgk promoter + PuroR MluI-re cgcacgcgttcgtgcgctcctttcggtcg
m073 Sequencing primer for linker catcgattcgcgaattctcgagc
m095 histidinol resistance gene-re (BamHI) cgggatcctcatgcttgctccttgaggg
m099 pim1 BglII-fo gaagatctatgctcctgtccaagatcaactccctg
m100 pim1 HindIII-re gaccaagctttatttgcccttctacttgctggatcc
m101 myc HindIII-re gagcgaagctttatttccttacgcacaagagttccgtag
m102 myc, BamHI-fo cgggatccatgcccctcaacgttagcttcaccaac
m122 egfp, BamHI+NcoI-fo ctgggatccatggtgagcaagggcgagga
m123 egfp, HindIII-re gaagcttgcttacttgtacagctcgtccatgc
m136 pgk promoter-fo (XhoI) cactcgaggcgttcgcaattctaccgggtagg
m137 pgk promoter-re (EcoRI) gagaattctagcttgggctgcaggtcgaaag
m147 histidinol resistance gene-fo catcatgagcttcaataccctgattgac
m167 RT-PCR primer myc-fo atgcccctcaacgttagcttc
m168 RT-PCR primer myc-re cgcaacataggatggagagca
m169 RT-PCR primer pim1 -fo ctggagtcgcagtaccagg
m170 RT-PCR primer pim1 -re cagttctccccaatcggaaatc
m179 RT-PCR primer pim1neu-B-fo gagaacatcttaatcgacctgagc
m180 RT-PCR primer pim1neu-B-re ggtagcgatggtagcgaatc
m181 RT-PCR primer gapdh-fo catgttccagtatgactccactc
m182 RT-PCR primer gapdh gtagactccacgacatactcagc
fo=forward/5', re=reverse/3' primer
3.9 Enzymes
Restriction endonucleases New England Biolabs (NEB), Fermentas
Recombinant Taq polymerase Fermentas
RNAse-A, DNAse free Qiagen
Platinum Taq polymerase Fermentas
CIAP (calf intestinal phosphatase) Roche
T4-DNA ligase NEB
3.10 Tissue Culture Media and Addititves
Media
D-MEM + Glutamax I + 4.5g/lt glucose -
pyruvate
Gibco/Invitrogen
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IMDM powder with L-Glutamine w/o
NaHCO3
Gibco/Invitrogen 42200-030
MEM alpha powder Gibco/Invitrogen
Opti-MEM Gibco/Invitrogen
PBS w/o Ca, Mg PAA Laboratories
RPMI-1640 medium + L-glutamine Gibco/Invitrogen
Additives
L-glutamine 200mM (100x) Gibco/Invitrogen
Insulin from bovine pancreas Sigma-Aldrich I5500
MEM non-essential amino acids 100x, 100 ml Gibco/Invitrogen
2-mercapto-ethanol Fluka/Sigma-Aldrich
Primatone RL-Quest International 5X59057
www.sheeld-products.com
5% Trypsin-EDTA Gibco/Invitrogen
Antibiotics
Kanamycin-sulfate solution 100x, 100ml Gibco/Invitrogen
Penicillin-Streptomycin solution 100x, 100 ml Gibco/Invitrogen
L(-) Histidinol dihydrochloride 99% Sigma Aldrich
Hygromycin Roche, Mannheim; Carl Roth GmbH
Puromycin Calbiochem, Beeston
Interleukins
BAFF, murine, recombinant R&D Systems
Interleukin-21, murine, recombinant R&D Systems
TPO Peprotech, stocks of 10 g/ml in PBS
3.11 Chemicals
Ampicillin sodium salt Sigma-Aldrich
APS Carl Roth GmbH
CFSE / 5(6)-Carboxy
uorescein diacetate, N-succinimidyl ester Alexis Biochemicals
Chloroform / NH4Cl Carl Roth GmbH
CNBr-activated sepharose 4B, lyophilized, average bead size 90
m
GE Healthcare
DAPI Carl Roth GmbH
Diethanolamine Merck
DMSO Hybri Max Sigma-Aldrich
Doxycycline hyclate Sigma-Aldrich
EDTA disodium salt  2 H2O Carl Roth GmbH
Ethidium bromide solution 0.5% Carl Roth GmbH
Ethanol Carl Roth GmbH
Glycerol Sigma
Glycine electrophoresis grade Carl Roth GmbH
HCl Merck
HEPES 1M Sigma-Aldrich
H2O, RNAse free, DNAse free Gibco/Invitrogen
Isopropanol Acros Organics
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KCl Carl Roth GmbH
KHCO3 Carl Roth GmbH
KLH, highly soluble, low endotoxin Alexis Biochemicals
Methanol Carl Roth GmbH
MgCl2  6 H2O Carl Roth GmbH
Na-acetate Carl Roth GmbH
NaCl Fluka/Sigma-Aldrich
NaHCO3 Fluka/Sigma-Aldrich
NaOH Fluka/Sigma-Aldrich
Propidium iodide HPLC Sigma-Aldrich
RedSafe nucleic acid staining solution 20'000x INtRON Biotech
SDS solution ultra Fluka/Sigma-Aldrich
Temed Carl Roth GmbH
Tris Pueran Carl Roth GmbH
Tween20 Sigma-Aldrich
3.12 Molecular- and Cell-Biology Reagents
Bradford solution Biorad
BSA, fatty acid free, low endotoxin, for cell culture Sigma
BSA fraction V, for western blotting, ELISA, etc. Serva
BSA Standard 2 mg/ml for bradford measurements Biorad
DNA ladder (Gene Ruler 1kb plus) Fermentas
dNTP set 4x100 M Fermentas
dnpp tablets for 20 ml solution per tablet Sigma
Lipofectamine Invitrogen
MACS -mouse CD19 beads Miltenyi
Ripa buer Sigma
Protease inhibitor cocktail 40x, contains 4-(2-
aminoethyl)benzenesulfonyl 
uoride (AEBSF), E-64, bestatin,
leupeptin, aprotinin, and sodium EDTA
Sigma, P2714
Protein marker for western blot (Precision Plus Dual Color) Biorad
Protogel Biorad
Skinman Soft disinfectant Ecolab Germany
TiterMax gold adjuvant Sigma-Aldrich
Trizol Invitrogen
Western Lightning chemiluminescence reagent plus Perkin Elmer
3.13 Buers and Solutions
Designation Recipe, Storage
Ampicillin stock solution 100 mg/ml in water, -20C
APS stock solution 10% APS in water, 4C
Doxycycline stock solution 1 mg/ml doxycycline hyclate in H2O, sterile ltered. -20
C.
Erythrocyte lysis buer 0.01M KHCO3, 0.155M NH4Cl, 0.1 mM EDTA, sterile l-
tered, RT
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FACS Buer 2% heat-inactivated FCS in PBS, 4C
Laemmli buer 250 mM Tris-Cl pH 6.8, 40% v/v glycerol, 5% p/v SDS,
0.005% bromophenol blue, 10% -mercapto ethanol, -20C
LB-Medium done by the media kitchen sta of the MPI-IB (10g Bacto-
tryptone,5g yeast extract, 10g NaCl per liter, pH 7.5, au-
toclaved. Storage at 4C)
PBS done by the media kitchen sta of the MPI-IB, RT
TBS 6.05 g Tris, 8.76 g NaCl, distilled water ad 1000 ml, RT
3.14 Plasmid Vectors
Designation manufacturer
pTre-Tight BD Biosciences
pSuperRetroPuro w/o Stuer OligoEngine
pCR4-TOPO Invitrogen
pim1 -CS41 in pSP65 vector (for in vitro transcription, contains murine
pim-1, generates messages for 34 & 44 kD, kind gift of An-
ton Berns, Netherlands Cancer Institute
pBJ4-cmyc chimera of human and murine c-myc-2 in pBJ4!, kind gift
of Ulf Rapp
pSRL5P Vpmut IRES nsEGFP contains the IRES sequence and a non-sticky variant of egfp,
kindly provided by Ozan Guezelbey
3.15 Bacteria
Top10 electrocompetent E. coli F- mcrA  (mrr-hsdRMS-mcrBC) 80lacZM15lacX74 recA1
araD139 (ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG  -
3.16 Cell Lines
name description
Fetal liver preBI-cell lines
Fld18Ber3 fetal liver preBI cell line, made in Berlin at the MPI for Infection Biology
by Szandor Simmons in our Lab from a fetal liver of a C57Bl/6 mouse
embryo at day 18 of gestation
Fld18Ber3-rtta1 pim/myc fetal liver preBI cell pool carrying the rtTA-TetON vector and the
TetON-myc & TetON-pim1 vectors (non-clonal)
Fld18Ber3-rtta1 myc fetal liver preBI cell pool carrying the rtTA-TetON vector and the
TetON-myc vector (non-clonal)
Fld18Ber3-rtta1 pim1 fetal liver preBI cell pool carrying the rtTA-TetON vector and the
TetON-pim1 vector (non-clonal)
Makn fetal liver preBI cell line, made in Berlin at the MPI for Infection Biology
by Marko Knoll
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Makn rtTA myc Makn cell line carrying the rtTA-TetON vector and the TetON-myc
vector
Stromal cell lines
OP9 stromal cells established from the bone marrow of newborn B6C3F1
op/op mouse calvaria (which lacks M-CSF)
ST2 a stromal cell line established from murine fetal liver [51]
Packaging cell lines
Phoenix-eco ecotropic retroviral packaging cell line based on the Hek-293 cell line
Plat-E ecotropic retrovirus packaging cell line named Platinum-E (Plat-E)
based on the 293T cell line. This cell line contains the MoMulv gag-
pol and env coding sequences under the control of the strong EF1-alpha
promoter. The promoter also drives resistance genes for puromycin and
blasticidin, which are attached to the gag-pol and env coding regions
by an IRES (internal ribosomal entry site) [97]
Cytokine producers
CHO-SCF SCF producer cell line [144], kind gift of T. Feyerabend, University of
Ulm
J-558L-IL-7 IL-7 producer cell line [139]
SP2/0-Flt3L Flt3L producer cell line, kind gift of P. Vieira, Institute Pasteur [29]
X-63-IL-2 IL-2 producer cell line [67]
X-63-IL-3 IL-3 producer cell line [67]
X63-IL-4 IL-4 producer cell line [67]
X-63-IL-5 IL-5 producer cell line [67]
X-63-IL-6 IL-6 producer cell line [67]
B cell lines
Daudi human Burkitt's Lymphoma cell line
3.17 Mouse Strains
strain Ly5 allele remarks
C57Bl/6*J* Ly5.2
C57Bl/6*J* rag1 =  Ly5.2
Jax C57Bl/6*N* rag2 =  Ly5.2 Taconic
C57Bl/6*J* rag1 =  Ly5.1 Ly5.1 Jax, bad breeders, low viability
Mice were bred under specic pathogen free conditions in IVC (individually ventilated) cages in the
animal facilities of the Max Planck Institute in Marienfelde and at the MPI for Infection Biology. For
transplantation experiments, mice aged from 6 to 10 weeks were used. Experimental setups done in this
work were approved by the LAGeSo (Landesamt fur Gesundheit und Soziales), Berlin, approval number
G0099/08, \Beein
ussung der Blutzelldierenzierung der Maus durch Regulatoren und Modulatoren der
Gen-Expression und der Signaltransduktion in Vorlauferzellen des hamatopoietischen Zellsystems; Zusatz:
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Immunisierung der mit pra-B- und T-Zellen transplantierten Mause mit dem Protein-Antigen Keyhole
Limpet Hemocyanin (=KLH) zur Messung der Funktionsfahigkeit der adaptiven Immunreaktion der in
den Empfangermausen rekonstituierten gereiften B- und T- Zellen".
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4.1 Molecular Biology
4.1.1 Cultivation of E. coli
Bacteria were cultivated in LB medium containing the appropriate antibiotic for selection of plasmids,
usually 100 g/ml ampicillin. Bacteria carrying high-copy plasmids were grown for 12-16 hours in 2 ml
LB-medium for minipreps and 100 ml LB medium for midipreps.
4.1.2 Preparation of Electrocompetent Bacteria
Top10 bacteria picked with a stick from frozen stocks were grown over night in a 37C shaker in a volume
of 100 ml of LB broth without antibiotics. The next day, 25 ml of the resulting broth was resuspended
per 500 ml of LB broth without antibotics in 2 liter Erlenmeyer 
asks and shaken for 2-4 hours until the
OD600 reached 0.6-0.8. The bacteria were cooled down on ice for 20 minutes and then centrifuged at 2600
g in a tabletop centrifuge in 400 ml 
asks for 20 minutes at 4C. From this step on, bacteria were kept on
ice, and handling was done in a cold room (7C). All solutions in contact with the bacteria were sterile
ltered and cooled to 4C on ice before use. All quantities mentioned are calculated for 1 liter of starting
culture and have to be adjusted accordingly. Pelleted cells were resuspended slowly in 600 ml ice-cold 0.1
M HEPES. Then, the cells were centrifuged for 15 minutes at 2600 g at 4C, and the resulting pellet was
resuspended in 400 ml 0.1 M HEPES. Once again, the cell suspension was centrifuged at 2600 g at 4C,
and the pellet was resuspended in 20 ml 0.1 M HEPES supplemented with 10% glycerol. The solution
was pelleted a last time and resuspended in 3 ml 0.1 M HEPES supplemented with 10% glycerol and
portioned at 200 l per precooled 0.2 ml conical tubes. The cells were shock-frosted in dry ice and kept
at -80C.
4.1.3 Electroporation of Bacteria
40 l of electrocompetent Top10 bacteria were thawed on ice and put into ice-cold 1 mm electroporation
cuvettes. 1 l of ligation product or maximally 100 ng of plasmid DNA was added and incubated on ice for
5 minutes before electroporation. Bacteria were electroporated with 1800 V, 25 Farad, and 200 
 in a 1
mm cuvette. After electroporation, bacteria were resuspended in 600 l of antibiotic-free LB-medium and
incubated for 30 minutes in a 37C shaker to allow expression of the resistance gene, and subsequently
plated onto agar plates containing the appropriate antibiotic for selection of plasmid-containing bacteria.
Plates were incubated for 12-16 hours at 37C.
4.1.4 Restriction Endonuclease Digests
Digests were done in a total volume of 30 l using 2 g of DNA and 5U of each enzyme and the recom-
mended buer from New England Biolabs. Digests were usually incubated over night at the recommended
temperature.
4.1.5 DNA Gel Electrophoresis
Digested DNA was separated at 60V in 0.8-1.5% electrophoresis grade agarose dissolved in TBS. Bands
were visualized using ethidium bromide or RedSafe in a gel imager.
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4.1.6 Gel Extraction of DNA Fragments
DNA fragments were extracted from agarose gels using the Qiagen Gel Extraction Kit using the standard
protocol, and eluted in 35 l water.
4.1.7 Primer Design for PCR and RT-PCR
Primers were designed according to the following rules: 18-25 bases long, GC content of 45-60%, no
intra-primer homology beyond 3 base pairs, no intra- and inter-primer complementary sequences beyond
2 base pairs, no AT or GC stretches beyond 3 base pairs, primers should end with G or C. Primer pairs
should have approximately the same melting temperature +/- 0.5 C.
4.1.8 PCR with Taq Polymerase
For colony PCR and detection of DNA, Taq polymerase was used. In totally 30 l, 100 ng of puried DNA
or 500-1000 ng of crude DNA, or 4 l of bacterial suspension generated from a picked colony resuspended
in 50 l water were set up in 1x KCl-PCR buer (Fermentas) supplemented with 200 M dNTPs, 1.5
mM MgSO4, 10 M of each primer and 2U of enzyme in 0.2 ml tubes.
For GC-rich templates, up to 5% DMSO was added to the reaction to inhibit formation of secondary
structures. The annealing temperature was lowered by 0.5-1C when DMSO was added.
Cycling conditions: 94C 2 min, 30x (94C 20 sec, 49C - 57C 30 sec, 72C (60 bases/kb + 10 sec))
72C 5 min, 10C storage temperature
4.1.9 PCR with PFU Polymerase
For cloning, 100 ng of puried plasmid DNA or 500-1000 ng of crude DNA (genomic DNA) or 1 l of
c-DNA were set up in 1x PFU-PCR buer w/o MgSO4 from Fermentas, 150 M dNTPs, 1.5 mM MgSO4,
10 M of each primer and 2U of enzyme in 0.2 ml tubes.
Cycling conditions: 95C 1 min 30 sec, 30x(94C 30 sec, 49C - 57C 35 sec, 72C (1kb/min)) 72C
5 min, 10C storage temperature
4.1.10 Preparation of messenger RNA
Cells were counted, and 1x106 to 1x107 cells were pelleted by centrifugation (260 g, 5 minutes at 4C), and
resuspended in 30 l PBS in 1.5 ml conical tubes until no clumps remained. Then, 1 ml Trizol was added
and the cells were lysed by repetititve pipetting. After 5 minutes of incubation at RT, 0.2 ml chloroform
per ml Trizol were added, and the tubes were shaken by hand for 15 seconds. The tubes were incubated
on ice for 3 minutes and then centrifuged at 12'000 g for 10 minutes at 4C. the colourless upper aqueous
phase was transferred to a fresh tube, and RNA was precipitated by adding 0.5 ml isopropanol per ml
Trizol. After 10 minutes of incubation at RT, the tubes were centrifuged for 10 minutes at 12'000 g at
4C. RNA was washed once with 1 ml ice-cold 70 % EtOH, dried for 5 minutes at RT, redissolved in
RNAse-free water, and heated to 55C for 2 minutes. RNA was stored at -80C.
4.1.11 Preparation of c-DNA
c-DNA was prepared from whole RNA generated by the Trizol method using the SuperscriptIII Kit from
Invitrogen as proposed by the manufacturer.
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4.1.12 Real Time PCR
RT-PCR was performed using the QuantiTect SYBR Green RT-PCR Kit (Qiagen). Reactions were set up
in 96-well PCR plates covered with translucent plastic foil. Per reaction, 10-50 ng total RNA extracted
from cells (see section 4.1.10), 0.8x SYBR-green PCR master mix (still providing consistent results),
0.25 l RT-mix and 400 nM of each primer were used in a total volume of 25 l. Primers were chosen
to amplify a target of 80-150 base pairs. As a standard, gapdh mRNA levels were measured for each
cell line and condition. Primers were used at a concentration of 2 M. Before use, standard curves with
each primer set were done to assess their usability. Samples were recorded in a 7900HT Real-time PCR
machine (ABI Prism) using SDS 2.0 software using the following cycling parameters: 50C 30 min, 95C
15 min, 45x(94C 20 sec, 60C 40 sec, 72C 40 sec), 95C 15 sec, 60C 15 sec, 95C 15 sec.
Relative overexpression of genes was assessed using the CT method.
4.1.13 Oligo Linker Annealing
Oligos for the linker were designed to generate sticky ends when annealed, which were compatible to
restriction-endonuclease cutting sites in the vector. Oligos were puried by HPLC or comparable methods
to ensure that only full-length oligos were annealed.
2 l of 100 M forward oligo and 2 l of 100 M reverse oligo dissolved in H2O were mixed with 3 l
of 10x T4-DNA Ligase buer from NEB in a total reaction volume of 30 l. The reaction was heated to
65C in a waterbath and cooled down slowly to RT before use for ligation. For ligation, 4 dierent ratios
of linker versus backbone were set up. Dilutions of 1:10, 1:100 and 1:1000 of the linker were set up, and 1
l of undiluted annealed linker and each of the 3 dilutions was used in a ligation reaction together with
1 l of 35 l linearized dephosphorylated vector (sections 4.1.4 and 4.1.6).
4.1.14 Addition of Adenine-Overhangs to blunt-ended PCR Products for TOPO-TA Cloning
PCR products were cleaned by gel extraction as usual (see 4.1.6), and 5 l of PCR product were incubated
with 1 l of PCR buer I (10x, 500 mM KCl, 100 mM Tris HCl pH 8.3, 15 mM MgCl2), 1U of Taq (not
HotStart), 0.8 l dNTPs from a 2.5mM stock in a volume of totally 10 l for 10-15 minutes at 70C.
Then the product was frozen to kill Taq polymerase. Subsequently, 2-4 l of the product were used for
TOPO-TA cloning.
4.1.15 Dephosphorylation of DNA Fragments
Linearized DNA fragments were dephosphorylated using Calf Intestinal Alkaline Phosphatase. DNA from
originally 1-2 g digested DNA was set up in a 40 l reaction volume in 1x CIAP buer supplemented
with 4U of enzyme. The reaction was incubated for 1h at 30C. After incubation, the DNA was puried
using the Qiagen PCR Gelextraction Kit (PCR-purication protocol) and eluted in 20 l water.
4.1.16 DNA Ligation
Ligations were done in a volume of 40 l using 4U of T-4 DNA Ligase in the recommended buer with
1/30 of 2 g of digested and gel-extracted backbone and 3/30 of 2 g digested and gel-extracted insert
DNA. Ligations were incubated overnight at 16C, frozen, and then transferred into electrocompetent
Top10 bacteria.
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4.1.17 Topo-TA Cloning
Topo-TA cloning was done as proposed in the manufacturer`s protocol. In short, 4 l of puried PCR
product were mixed with 1:4 diluted salt from the kit and 1 l of Topo-TA-enzyme mix, incubated for
15 minutes at RT, frozen, and then shocked into electrocompetent bacteria.
4.1.18 SDS Page
5x106 to 1x107 cells were pelleted by centrifugation at 260 g for 5 minutes at 4C, resuspended in 5
l PBS to minimize clumping, and lysed with 150 l Ripa buer (Sigma) supplemented with protease
inhibitors from a 40x stock solution (Sigma) for 30 minutes on ice. Lysis was completed by crushing the
cells using plastic eppendorf crushers and another round of incubation at 4C for 30 minutes. The extract
was centrifuged at 10'000 g for 10 minutes and the supernatant (= protein extract) was transferred to a
clean conical tube. Protein concentration was assessed by the Bradford method. Standard BSA (Biorad)
was set up at dierent concentrations ranging from 1500 g/ml down to 100 g/ml in H2O. 5 g of each
dilution were pipetted into 245 l of Bradford solution, incubated for 5 minutes, and measured in an
conical Bio-Photometer using the preset Bradford program. Samples were diluted 1:5 in water, and 5 l
of each sample was pipetted into 245 l of Bradford solution, incubated for 5 minutes, and measured in
the Bio-photometer. The samples were diluted in 4x Laemmli buer, heated up to 95C, centrifuged at
10'000 g, and cooled down. Acrylamide solution for the separating gel was prepared freshly from stock
solutions using 11% acrylamide (Protogel 30), 0.1% SDS, 0.03-0.05% APS, and 0.1% Temed in 0.37 M
Tris base pH 8.8. Acrylamide solution for the stacking gel was prepared using 3.9% acrylamide (Protogel
30), 0.1% SDS, 0.05% APS and 0.1% Temed in 0.124 M Tris base pH 6.8.
Acrylamide gels were poured using the Protean-3 minigel module with combs with a thickness of 0.75
mm. The seperatation gel was covered with water during polymerization to ensure an even edge. After
polymerization of the stacking gel, the combs were removed, and the gel was placed into the Protean3
gel chamber and the chamber was lled according to the Protean3-protocol with running buer (25 mM
Tris, 192 mM glycine, 0.1% SDS, pH 8.3) prepared from a 5x stock.
20 to 40 g of protein were loaded onto the gel. One lane was reserved for 5-10 l of the protein marker
(Precision plus, Biorad). The gels were run at10 mA (around 70 V) until the migrating front was just in
front of the resolving gel. Then, the voltage was increased to 200 V for 1-1.5h until the migrating front was
leaking out of the gel. Unused sections of the gel and the blue migrating band were cut away with a sharp
scalpel, the left upper edge of the gel was removed to mark the orientation, and the gel was submerged in
Bjerrum Schafer-Nielsen transfer buer (48mM Tris, pH 9.2, 39mM Glycine, 20% Methanol, designed for
semi-dry transfer) for 5 minutes for equilibration. A piece of PVDF or nitrocellulose membrane with a
size slightly larger than the gel and 2 extra thick blotting papers with the size of the gel were prepared as
described by the manufacturer (PVDF membranes were pretreated with 100% Methanol for 15 seconds
and then submerged in H2O, nitrocellulose membranes were submerged in H2O) and equilibrated in
transfer buer for 5 minutes.
A stack of wet lter paper, the membrane, gel and another lter paper were piled onto the anode
of the blotter, and remaining air bubbles were removed. 1 ml of transfer buer was poured onto the
stack, and spilled liquid was removed with a paper towel. The cathode was placed onto the stack, and
the proteins were blotted for 30 minutes at 10-15 V for minigels as proposed by the manufacturer. After
blotting, correct migration of the protein ladder was ensured, the membrane was marked at the upper
left corner, and the membrane was washed 1x in TBS-T, and then incubated in blocking buer ( 5%
milk powder in TBS-T) for 1 h at RT. Then the membrane was probed with the rst antibody diluted in
TBS-T 1:1000-1:20000 according to the manufacturer for 2 h at RT up to ON at 4C. After 2x washing in
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TBST, the membrane was probed with the secondary HRP-labelled antibody diluted in TBST for 1h at
RT. After another round of washing in TBST and nally TBS, the membrane was developed with 1-2 ml
of detection agent (Western Lightning) per minigel size and viewed with a Luminescent Image analyser
(LAS3000).
4.1.19 ELISA
Maxisorp ELISA 96-well plates were coated with 2 g/ml unlabelled antibody in PBS overnight at 7C
or for 2 hours at RT. For coating of keyhole limpet hemocyanin (KLH), 2 g/ml PBS were coated ON in
the fridge at 7C. Then the plates were blocked for 30 minutes at RT with 200 l blocking buer (0.005
% Tween-20, 2.5% BSA fraction V, PBS) and rinsed 2x with tap water (the wells were completely lled
wit tap water and subsequently the plate was dumped and clapped onto paper towels to drain remaining
liquid).
Sera were set up at 3-4 dierent dilutions in standard ELISA buer (0.25% BSA fraction V, 0.05%
Tween-20, PBS) depending on the desired target (total IgM, IgG: 1:500-1:20'000, specic IGs: starting
from 1:100). In parallel, Standard antibodies were diluted in 7 serial 1:3 dilutions starting from 300 ng/ml
(linear range of detection). If no standard antibody was available, standard C57Bl/6 serum from one big
pooled frozen and aliquoted batch was used.
50 l of serum dilutions and standards were pipetted into each well and the plates were incubated at
RT for 1-3 hours. Then the plates were rinsed 4x with tap water, and clapped onto a paper towel to dry.
Alkaline phosphatase-labelled antibody was diluted to 1 g/ml standard ELISA buer and 50 l thereof
were pipetted into each well and incubated for 1h at RT. Plates were washed again 3x with tap water
as described above. 50 l of developing solution (l tablet of dnpp in 20 ml 1M diethanolamine, pH 9.8)
were pipetted quickly in each well, and after 15, 30, 45, and 60 minutes, plates were read at 405 nm in a
plate reader.
For data analysis, standard curves were set up using scatter plots for the amount of antibody versus
extinction at 405 nm, and the linear range of detection was determined. Only extinction measurements
of the samples in the linear range were taken.
4.2 Cell Biology
4.2.1 Coupling of anti-IgM Antibodies to CNBr-Activated Sepharose
Figure 4.1 {
modied 50 ml
polypropylene
tube.
Sepharose beads loaded with anti-mouse IgM antibodies can be used to induce murine
B cell proliferation [108]. 5 mg anti-IgM antibodies (clone M41 [77]) were dialyzed over
night in coupling buer (0.1M NaHCO3, 0.5M NaCl, pH9, sterile) using 20/30-dialysis
tubing from Visking with a wall thickness of 0.05 mm. Concentration of antibodies was
measured by assessing the optical density at 280 nm. The resulting OD was multiplied
with 1.4 and the dilution factor to get the concentration of antibody. Final concentration
was 1.7 mg/ml. 300 mg of lyophilized CNBr-sepharose were swollen in 3 ml 1 mM HCl
for 15 minutes at room temperature. Then, the beads were transferred with a sterile
spatula into a 30 m lter unit on a modied conical 50 ml polypropylene tube, see
gure 4.1. This tube had been prepared by punching a hole (around 6 mm diameter)
into the upper wall and inserting a conical hose-adapter taken from a Millipore steritop
ltration unit. The hose-adapter was sealed with glue. By using this modied 50 ml
conical tube, liquids residing in the lter unit could be sucked into the 50 ml conical
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tube using vacuum. The beads were washed with totally 200 l 1mM HCl and dried by
applying vacuum. Then, the beads were washed with 5 ml sterile coupling buer. After that, the beads
were transferred quickly into 4 ml coupling buer containing 1.7 mg/ml anti-IgM antibodies prepared
before in a 15 ml polypropylene tube. The tube was rotated gently at RT for 2 hours. Then, the beads
were spun at 200 g for 30 seconds, the supernatant was collected in a fresh 15 ml polypropylene tube,
and the beads were resuspended in coupling buer and transferred again onto the lter in the modied
50 ml conical tube and were washed 3x with coupling buer. Then, the beads were transferred into 5 ml
of coupling buer containing 10% FCS and 100  l 100 mM ethanolamine and incubated for 2 h at RT
to block residual binding sites. The beads were then washed 4x alternating between 5 ml low pH buer
(0.1M sodium acetate, pH 4, sterile) and 5 ml coupling buer in the lter unit. Then, the beads were
transferred into 1 ml sterile PBS and stored at 4C.
4.2.2 FACS Staining
The cells were washed in PBS 2% FCS (FACS buer), centrifuged at 260 g, and resuspended in FACS
Buer. 2x105 to 1x106 cells were stained at 4C for 40 minutes in FACS buer supplemented with the
titrated amount of antibodies and Fc
-receptorII blocking antibody. The cells were then washed 2x with
FACS Buer and resuspended in FACS buer containing DAPI at 100 ng/ml for exclusion of dead cells.
4.2.3 FACS Sorting of B-Cells and B-Cell Precursors
The cells were washed in sterile PBS 2% FCS (FACS buer), centrifuged at 260 g, and resuspended in
FACS Buer. Cell numbers to be stained were calculated according to the amount of sorted cells needed
and the frequency of the cells to be sorted in the initial sample. Cell loss of sorted cells was estimated
to be around 50%. The antibodies used for sorting were diluted in FACS buer and ltrated with 2 m
conical tube lters. For cell sorting, neither dead cell exclusion nor Fc
receptorII blocking antibody was
used to preserve the cells. 100 l of staining solution was used per 2x106 cells, and the cells were stained
for 40 minutes at 4C in the dark. Cells were then washed in 4C cold FACS buer and ltrated with
MACS preseparation lters (Miltenyi) and subsequently sorted using an Aria or DiVa cell sorter into
tubes containing 500 l of medium. The tubes were pretreated by 
ushing the inner tube surface with
500 l of heat-inactivated FCS to minimize binding of cells to the plastic surface. After sorting, cells
were washed, counted, and seeded into fresh medium containing Gentamycin and the appropriate growth
factors.
4.2.4 Cell Cycle Analysis by PI Staining
Cells were washed in PBS and resuspended at 1x106/100 l in ice-cold PBS in a 2 ml conical tube.
Samples were then put into a Eppendorf Thermomixer at 800 rpm set to 10C. 900 l ice-cold 70%
Ethanol were added dropwise per 100l of shaking cell suspension to minimize clumping, and the cells
were then xed for at least 24 hours to maximum 4 days at -20C. After xation, cells were resuspended
in PBS for further sorage or directly used for staining. For the staining of DNA, a staining solution of 25
g/ml PI, 0.05% Triton-X, 100g/ml RNAse A in PBS was made from stock solutions of 5 mg/ml PI in
H2O, 10 % Triton-X in H2O and 100 mg/ml DNAse free RNAse A (Qiagen). The xed cells were washed
once in PBS and then stained with 1 ml of staining solution per 1x106 cells at 37C for half an hour.
Cells were then washed 1x in PBS and subjected to FACS analysis. Doublets were excluded from the
analysis by plotting forward scatter-area against -width as well as side scatter-area against -width and
gating of the corresponding singlet populations. PI was recorded in linear mode, and DNA-histograms
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were analysed manually or using the FlowJo Cell Cycle tool (using the Watson algorithm, see FlowJo
software guide).
4.2.5 CFSE Staining of B Cells
CFSE (5-/6-carboxy
uorescein diacetate succinimidyl ester, CFDA-SE) can easily penetrate cell mem-
branes due to its lipophilic nature and thus is readily taken up by cells. Once inside the cells, cellular
esterases can remove the two acetate groups. The resulting carbocy
uorescein succinimidyl ester (CFSE),
in contrast to its precursor CFDA-SE, is highly 
uorescent, and has a reduced lipophilicity. This results
in reduced emigration of the dye, which enhances the chance that CFSE is coupled covalently to amino
grous of intracellular molecules through its highly reactive succinimidyl side chain. Once covalently bound
to intracellular macromolecules, the dye resides in the cell and is transmitted to daughter cells, so that
they then have around half of the 
uorenscence than the parent cell. This allows to see single divisions
of dierent cell populations.
A 5 mM stock solution was prepared by dissolving 1 mg CFSE in 359 l DMSO (anhydrous). Aliquots
of stock solutions were quickly frozen at -20C in the dark. Cells were washed in PBS + 0.1% BSA
prewarmed to 37C, resuspended at 5x106/ml, and ltrated at 30 l with MACS preseparation lters
(only single cell suspensions are labelled uniformely). A freshly thawed or freshly prepared stock solution
of CFSE was diluted 1:200 in PBS. 110 l of the 50 M stock solution were added to 1 ml of cells (2.5 M
end concentration), and mixed rapidly by vortexing at low speed. The cells were then incubated for 6-8
minutes in a 37C waterbath. Thereafter, 10 vol of icecold cultivation medium (SF-IMDM + 2% FCS)
were added to quench the CFSE, and the cells were incubated for 5 minutes on ice. Then, cells were
washed twice with 10 ml medium, centrifuged at 260 g for 4 minutes at 4C, and resupended in fresh
medium.
In vitro cell cultures were set up under appropriate conditions to study division. After 3 to 4 days,
cells were harvested in the dark, stained for surface markers, and analysed by FACS analysis. An un-
stained sample was also acquired to determine auto
uorescence of cells. CFSE staining was measured
in logarithmic mode in the FITC channel, and analysis was done using FlowJo software (Proliferation
Platform tool).
4.3 Cell Culture
4.3.1 Cell Culture Media
For preparation of cell cultivation media and stock solutions for cell cultivation, only water doubly-distilled
with the destamat quartz-distillery was used.
SF-IMDM Medium 1 can of IMDM powder w glutamine w/o NaHCO3 (for 10 liters) was dissolved
in 5 liters of H2O in a 10 lt narrow-necked volumetric 
ask. Then, 30.24 g of NaHCO3 were added and
dissolved.100 ml of 10x Kanamycin solution was added together with 10 ml insulin sock solution (see
section 4.3.2) while shaking. After that, 10 ml of 10 mM 2-mercapto-ethanol were prediluted in 30 ml
H2O, and then added and mixed. Finally, 30 ml of Primatone stock solution (10% w/v dissolved in water
and ltered) was added to the medium, and water was added to approximately 10 liters. The pH was set
to pH 7.0 +/- 0.05 using 10M NaOH, and the volume was adjusted to exaxtly 10 liters with H2O after
removing the magnetic stirring bar.
SF-MEM-Alpha Medium SF-MEM-alpha medium was prepared as described above for SF-IMDM
medium, but with the following modications:
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1 can of alpha-MEM powder instead of 1 can of IMDM powder, 22 g of NaHCO3 instead of 30.24 g,
no insulin added.
Medium was stored in the fridge in the dark for up to 3 months.
4.3.2 Preparation of Insulin Stock Solution 5 mg/ml
1 g insulin from bovine pancreas was put into a glass cylinder containing approximately 180 ml ultrapure
H2O in little portions under constant stirring. As soon as the suspension was homogenous, NaOH (at
rst 10N, then 1M) was added dropwise (1-3 drops) until the insulin dissolved (approximately pH 11).
Then the volume was adjusted to 200 ml with H2O, and pH was adusted to pH 7.5 with HCl 32% (2-3
drops). Aliquots of 10 ml in 15 ml polystyrene tubes were stored at -20C.
Final working concentration was 5 g/ml.
4.3.3 Cultivation Conditions of Cell Lines
name medium and cultivation
CHO-SCF SF-IMDM + 2% FCS + 200M L-Glutamine + 100M pyruvate, 10% CO2
Daudi RPMI1640 + 10% FCS, 5% CO2
Fld18Ber3 SF-IMDM + 2% FCS + 1% IL-7 supernatant, 10% CO2
J-558L-IL-7 SF-IMDM + 2% FCS, 10% CO2
Makn SF-IMDM + 2% FCS + 1% IL-7 supernatant, 10% CO2
OP9 SF--MEM + 2% FCS, 10% CO2
ST2 SF-IMDM + 2% FCS, 10% CO2
Phoenix Eco RPMI-1640 + 10% FCS + 200 M L-Glutamine, 5% CO2
SP2/0-Flt3L Opti-MEM + 10% FCS + 50M beta-mercapto-ethanol
Plat-E D-MEM + 10% FCS + 1 g/ml puromycin + 10g/ml blasticidin, 10% CO2
X-63-IL-2 SF-IMDM + 2% FCS, 10% CO2
X-63-IL-3 SF-IMDM + 2% FCS, 10% CO2
X-63-IL-4 SF-IMDM + 2% FCS, 10% CO2
X-63-IL-5 SF-IMDM + 2% FCS, 10% CO2
X-63-IL-6 SF-IMDM + 2% FCS, 10% CO2
4.3.4 Preparation of Cytokine Supernatants and Stock Solutions
The dierent cell lines were expanded in their appropriate medium, and the culture volume was increased
stepwise up to 200 ml per 225 cm2 dish. When the pH indicator in the culture medium turned from red
to orange (lower pH) and approximately 10% of the cells where dead, the cellular debris and cells where
centrifuged at 260 g for 5 minutes, and the supernatant was sterile ltered and frozen in aliquots.
Stock solutions of TPO were prepared in PBS containing 2% BSA at 10 g/ml, were sterile ltered
using 0.2 m lters and were used at a concentration of 10 ng/ml. Stock solutions of IL-21 were set up in
PBS + 0.5% BSA at 100 g/ml. Stock solutions of BAFF were set up in PBS + 0.5% BSA at 10 g/ml.
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average yield of cytokines in the supernatants
IL-3 approx. 160 ng/ml determined by ELISA
IL-7 approx. 300 ng/ml determined by comparing growth curves of cells of the 5/7 cell
line in recombinant mouse IL-7 and IL-7 supernatant at dierent
concentrations of IL-7
Flt3L approx. 500 ng/ml determined by comparing growth curves of bone marrow cells.
Total bone marrow cells grown for 4-7 days in SCF and Flt3L
were cultivated with SCF and variing cocentrations of Flt3L to
be tested at a concentration of 4x105/20 ml in 96-well plates. As
a standard, recombinant Flt3L was used.
SCF approx. 10 ng/ml determined using an SCF-dependent cell line, titrated against re-
combinant SCF
4.3.5 Cryopreservation of Cells
cells where freshly harvested, centrifuged at 260 g in a tabletop centrifuge, and resuspended in 1 ml freezing
medium at a concentration of 1x106 to 5x106 cell per ml and transferred to 1.8 ml cryopreservation tubes.
The cells where subsequently frozen for at least 24h at -80C in styrofoam boxes before being transferred
to liquid nitrogen.
4.3.6 Reactivation of Cryopreserved Cells
Frozen cells where thawed at 37C until only a small rest of frozen material was left in the tube, then
the cells were resuspended in 1 ml medium and transferred into a T75 
ask containing feeder layers if
necessary and 25 ml prewarmed medium supplemented with the adequate cytokines. On the next day,
the medium was exchanged.
4.3.7 Counting of Living Cells by Trypan Blue Exclusion
Suspensions of cells were diluted 1:10 for high densities of cells or 1:2 for low densities of cells in Trypan
Blue and counted using a Neubauer chamber. bright living cells of 2 to 4 4x4-squares were counted under
a microscope and averaged. In spleen and BM suspensions, erythrocytes were excluded from counting by
size.
4.3.8 Cultivation of PreB-I Cells
PreB-I cells were grown in 75 cm2 tissue culture 
asks with vented caps on an irradiated OP9 feeder
layer in 25 ml SF-IMDM medium containing 2% FCS and 1% IL-7 supernatant in incubators containing
10% CO2 at 37
C. The 
asks were preseeded with OP9 feeder layer cells 0 to maximum 3 days before
passage of preB-I cells at a cell number which ensured a density of 1x106 cells per 75cm2 
ask at the
day of sub-passage of the preB-I cells. The doubling time of OP9 feeder layer was expected to be 1 day.
PreB-I cells were subpassaged every third to maximal fourth day onto new feeder layer cells, at the latest
when they were 90% con
uent. At the time of subpassage, preB-I cells were detached from the feeder
layer by tapping on the rim of the 
ask for 5-7 times, then the supernatant was harvested in a 50 ml
polypropylene tube, centrifuged at 260 g for 5 minutes at 4C, and the cell pellet was resuspended in
5 ml medium, counted, and 5x105 cells were subpassaged into a new 75 cm2 
ask containing the above
mentioned medium and feeders.
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4.3.9 Cultivation of Hematopoietic Progenitors from the Bone Marrow
Hematopoietic progenitors were cultivated on OP-9 feeder layer cells prepared as described in section 4.3.8
in SF-IMDM medium containing 2% pretested FCS. For cultivaton of very early mulitpotent progenitors,
IL-3 (3%), IL-6 (3%), SCF (3-6%) and recombinant TPO (10 ng/ml) were used. For B cell specic
precursors, Flt-3L (2%), SCF (3-6%) and IL-7 (1-1.5%) were used. Cells were seeded at 1x106 per T75

ask and cultivated for 3-4 days before subpassaging. Harvest and handling was done as described for
preB-I cells.
4.3.10 Trypsinization of Adherent Cell Lines
The medium of maximally 90% con
uent cells was removed, and 10 ml trypsin solution per 180 cm2 dish
(accordingly less for smaller dishes) were added. The plates were incubated for 5 minutes at 37C. Then
the cells were 
ushed from the plates with a pipette and transferred to a 50 ml conical tube. 5 ml medium
per 10 ml trypsin was added to stop the reaction, and the tubes were centrifuged for 5 minutes at 260 g
at 4C. The supernatant was aspirated, and the cells were resuspended in 5 ml of fresh medium.
4.3.11 Cultivation of Adherent Cell Lines
Adherent cell lines were trypsinized as explained in section 4.3.10, and seeded onto new plates according
the following table:
OP9 and ST-2 2x105 per 15 cm round dish
Phoenix-eco 1x106 cells per 15 cm round dish
Plat-E 1x106 cells per 15 cm round dish
4.3.12 Transient Transfection of Phoenix-Eco & Plat-E Cells
Cells were harvested and counted one day before transfection. Cells were seeded in Cellbind 6-well plates
at 5x105 cells per well for Phoenix-eco cells and at 6e5 cells for plat-E cells. At the day of transfection,
10 l of lipofectamine was pipetted into 100 l D-MEM medium, and 2 g of endofree DNA were mixed
with 100 l of D-MEM. The two solutions were mixed cautiously and incubated at RT for 20 minutes.
Meanwhile, cells to be transfected were washed 2x with D-MEM, and then were covered with 800 l
D-MEM. Then the DNA-Lipofectamine complexes were pipetted onto the cells, the plate was shaked,
and was subsequently incubated at 37C and 10% CO2 for 5.5h. After that, the complexes were aspirated,
and the cells were covered with 2 ml fresh medium. After 12-24h, medium was exchanged again to remove
incomplete virions. At the second and third day after transfection, virus-containing medium was harvested
and directly used for transduction, or stored at 4C for up to 5 days.
4.3.13 Retroviral Transduction of B-Cell Precursors
Cells to be transduced were harvested, counted, and set to a concentration of more than 4x106/ml. 2x105
cells per transduction were pipetted into a 2 ml conical tube, then viral supernatants (see section 4.3.12)
were centrifuged for 5 minutes at 1157 g, and 1 ml thereof was added to each tube. According to the cell
type, the necessary interleukins were added at the required concentration. The cells were then submitted
to spin-infection for 3h at 1157 g at 30C. After spin-infection, the supernatant was aspirated, and the
cells were transferred to 6-well plates or 25 cm2 dishes containing irradiated OP9 feeder layers. One day
after transduction, the cells were selected with the appropriate selection agent if necessary.
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4.3.14 Selection of Retrovirus-Containing Cells by Treatment with Antibiotics
Retrovirally transduced cells were replated on fresh irradiated OP9 feeder layers (resistant to the antibi-
otics to be used) in 6-well plates at a concentration of 2x105 per well in 3 ml medium containing the
appropriate cytokines. One day after transduction, the appropriate selection agent was added. Necessary
concentrations for selecting provirus-containing cells were titrated separately for each cell type. For FL
preB-I cells, the following concentrations were used: hygromycin: 0.9-1 m/ml; puromycin: 1-2.5 g/ml,
histidinol: 1.25 mM, bleocin: 20 g/ml. After 3-4 days, selection was normally completed (as determined
by the death of untransduced control cells). Antibiotic-resistant OP9 feeders were generated by retroviral
transduction or plasmid-transfection.
4.3.15 Limiting Dilution
Cells to be analysed by limiting dilution were washed 2x in SF-IMDM medium to get rid of remaining
growth factors, counted by trypan blue exclusion (5 l cells, 45 l trypan blue), diluted to a concentration
of 1x105 and recounted (10 l cells, 10 l trypan blue). Cells were then set to 1x104/ml (starting concen-
tration: 1000 cells/well), or 5x103/ml (starting concentration: 500 cells/well). The twofold counting of the
cells should decrease counting errors in the beginning, since counting of cell numbers below 1x104/ml is
not feasible any more using a Neubauer chamber. Cells were prepared in 50 cm polypropylene tubes and
serially diluted 1:3 down to less than 1 cell per 100 l in 50 ml conical tubes. Cells were then aliquoted
into 96-well 
at bottom plates, 100 l into each well. For each dilution, at least 16 wells, but usually 32
wells were used. Then, 100 l medium containing twofold concentrated growth factors and/or doxycycline
were added to each well. The plates were then sealed to minimize evaporation of medium of the outer
wells and incubated for 6-7 days under the appropriate conditions.
To calculate the frequency of growing cells, wells with no growing clones were counted. Clones were
dened as colonies containing more than 20 living clustered cells. According to Poisson, the frequency
F0 of wells actually containing no growing cell in a suspension of cells of theoretically m dividing cells
per well is calculated as follows: F0 = e
 m. Consequentially, in a theoretical suspension of 1 cell per well
(m = 1), we get F0 = e
 1 = 0:368. So, at a percentage of 37% negative wells, we can assume that an
average of 1 cell per well has started to grow. To extrapolate that point, the log of the fraction of negative
cultures was plotted as a function of cell number per well, and the number of growing cells per well was
calculated from the equation derived from the linear regression of the resuling data. For a given linear
regression of y = mx + b, the number x of cells needed for one to grow out was calculated as follows:
x = (ln(37)  b)=m.
4.3.16 In vitro Dierentiation of B-Cell Progenitors
Fetal liver preB-I cells and bone marrow derived preB-I cells grown in vitro were washed 2x and resus-
pended in SF-IMDM medium with 2% FCS. After counting, cells were seeded at a concentration of 5x105
to 1x106 per 6-well dish in 3 ml SF-IMDM medium containing 2% FCS and optionally 1.5% IL-5 super-
natant, 1.5% IL-4-supernatant, and 4 g/ml 0.2  ltered CD40 antibody (clone FGK-45). Cultures
were incubated for 3 to 6 days and analysed by FACS for the surface markers IgM, IgD, MHCII, c-kit,
CD25, CD93, CD43 and CD23.
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4.3.17 Preparation of Thymic T-Cells for Co-Transplantation with B-Cells
C57Bl/6 mice were killed by cervical dislocation, sprayed with 70% ethanol, and pinned on styrofoam
plates covered with aluminium foil. The thorax was opened at the sternum. The ribs were cut at the base
of the sternum, and the sternum was lifted up carefully to expose the thymus. Both lobes of the thymus
were excised and put into cold IMDM-medium. The thymus was crushed between two sterile frosted glass
slides until a homogenous cell suspension was obtained. After 1x washing of the cells in 20 ml SF-IMDM
medium, cells were resupended in 10 ml medium and counted.
Residual CD19+ cells were removed from the thymic cell suspension by MACS-bead depletion (Mil-
tenyi), see section 4.3.18. Per mouse to be transplanted, 1-2x106 cells were used for CD19-magnetic-bead
coupling and subsequent B-cell depletion.
For transplantation, T cells were mixed with preB-I cells, centrifuged, and resuspended at a concen-
tration of 2-3x105 thymic cells and 5x106 B cells per transplantation volume of 100 l per mouse as
described in section 4.4.3.
4.3.18 Depletion of CD19+ B-Cells with Miltenyi MACS Beads
For 1x107 cells, cells were centrifuged and resuspended in 90 l FACS buer (2% FCS in PBS, sterile).
After addition of 10 l of mouse CD19-MACS-microbeads (Miltenyi), the cell suspension was incubated
for 15-30 minutes at 7C (not on ice). The stained cells were washed 1x with 2 ml FACS buer and
resuspended at 5x107 cells per 500 l. After that, the suspension was ltered through a MACS presepa-
ration lter to exclude clumps. Meanwhile, a MACS LD-column precooled in the fridge was put onto the
magnet in a laminar 
ow hood and was prewetted with 2 ml of FACS buer. Then, a fresh 15 ml conical
tube was put under the column, and the cells were loaded onto the column. After the suspension had
passed through, the column was washed with 2 ml medium (at least 2 ml, also if less than 1x107 cells
were taken), and after passage of residual medium, the depleted cells were counted and stored on ice.
4.3.19 Enrichment of ex vivo CD19+ B-Cells using Miltenyi MACS Beads
The MS MACS columns were precooled in the fridge for at least 15 minutes. Meanwhile, splenic, bone
marrow, and peritoneal cells were washed 1x with 4C cold MACS buer (PBS, 0.5% BSA, 2 mM EDTA)
and were resuspended at 1x107 cells per 90 l cold MACS buer. Per 90 l cell solution, 10 l -mouse
CD19-beads were added. After mixing, the cells were incubated in the fridge (not on ice) for 15-30 minutes.
Then, the cells were centrifuged at 260 g for 5 minutes and washed 1x with 2 ml MACS buer per 1x107
cells. The cells were then resuspended at 5x107 cells per 500 l and ltered using a MACS preseparation
lter. The precooled MS column, which is usable for up to 2x108 total cells and up to 1x107 labelled cells,
was xed on the appropriate magnet and washed 1x with 500 l MACS buer. The suspension was then
loaded onto the MS column, and 
ow-through was collected in a tube (unlabeled cells). The column was
then washed 3x with 500 l cold MACS buer. After that, the tube containing the unlabeled fraction
was removed, and a new sterile tube was prepared. The column was removed from the magnet, and 1 ml
MACS buer was added. Then the plunger (included in the kit) was inserted into the column and the
solution containing labeled cells was quickly pushed into the sterile tube. The cells were washed 1x in
medium, counted, and used for experiments.
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4.4 Animal Work
4.4.1 Preparation of Bone Marrow Progenitor Cells
6 to 14 weeks old animals were killed by cervical dislocation and sprayed with ethanol. On a sterile pad
coated with aluminium foil, both femora and tibiae were dissected, and the end joint of each bone was
removed. The bones were 
ushed with a syringe containing ice-cold IMDM-medium. The cells were sus-
pended by pipetting, centrifuged at 260 g for 5 minutes at 4C, washed 1x in IMDM-medium, resuspended
in 10 ml SF-IMDM medium containing irradiated OP9 feeder layers, 2% FCS, and counted. 4x106 cells
were seeded into a 75 cm2 
ask in 25 ml SF-IMDM medium containing 2% FCS supplemented with the
appropriate cytokines.
4.4.2 Cell Preparation of Spleen and Peritoneal Cavity
Mice were killed by cervical dislocation, sprayed with 70% ethanol, and pinned on styrofoam plates covered
with aluminium foil. The skin on the abdomen was cut with a longitudinal section without touching the
abdominal membrane.
Peritoneal lavage was done with a plastic pipette. A little hole was cut into the abdominal membrane,
and a pipette lled with 5 ml of cold SF-IMDM medium was inserted into the hole. Medium was pipetted
up and down several times before the cell suspension was transferred to 50 ml conical tubes. This procedure
was repeated 3 times. The cells were washed once with 5 ml of medium, resuspended in 500 l of medium
and counted.
For preparation of the spleen, the abdominal membrane was cut, and the spleen was dissected and
directly transferred into 5 ml of ice-cold SF-IMDM medium. The spleen was submerged in a petri dish in
10 ml of medium, cut twice with a scalpel and crushed between two frosted glass slides until a homogenous
cell suspension was obtained. The cells were washed 1x with 20 ml SF-IMDM medium. Cells were then
resuspended in 50 l medium to minimize clumping and then incubated in 1 ml 4C cold erythrocyte
lysis buer for 3 minutes on ice. After incubation, 10 ml of medium were added to stop the reaction. The
cells were then centrifuged at 260 g for 5 minutes at 4C, resuspended in 4-5 ml medium and counted.
4.4.3 Transplantation of PreB-I Cells into the Tail Vein of Mice
Mice to be transplanted were 
-irradiated sublethally 1 day before transplantation with 4 Gy. Cells were
harvested as explained in section 4.3.8. After 1x washing in 20 ml 4C cold IMDM medium without
serum and phenol red, the cells were resupended at a density of 5x107 per ml in the same medium
and ltered with a 30 m MACS preseparation lter. The suspension was subsequently stored on ice.
Mice to be transplanted were heated with an infrared lamp for 3 minutes. Then 100 l of ltered cell
suspension were transplanted into the tail vein after disinfection of the site of puncture. After that, mice
were observed on a daily basis during the rst week, and thereafter every third day. The experimental
setup was approved by the LAGeSO under the permission number G0099/08.
4.4.4 Immunisation of Mice
Antigen (KLH) was dissolved in PBS at a concentration of 25 mg/ml.
For immunisation with IFA adjuvant, KLH stock solution was diluted to 1 mg/ml in PBS. This
solution was mixed 1:1 with IFA as described later. Per mouse and shot, 100 l of immunisation agent
were needed (=50 g KLH). Since during the process of emulsication the amount of liquid is halved, for
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10 mice 1 ml KLH in PBS and 1 ml IFA were used. The emulsion was prepared in 2 ml conical tubes.
Maximum 500 l of KLH in PBS was drawn up in a 1 ml syringe (Braun, Injekt-F, no rubber parts)
charged with a 18 gauge needle and injected quickly into the same amount of IFA. The two solutions
were emulsied by pipetting up and down until the solution turned into a sticky non-
owing white mass.
The emulsion was subsequently drawn up into a new 1 ml syringe using the 18 gauge needle. The needle
was then exchanged to a 26 gauge needle (0.45x12 mm) for immunisation. Mice were immunized into the
base of the tail vein or IP with 100 l of emulsion. Immunized mice were examined daily during the next
week for signs of indisposition.
For immunisation with TiterMax Gold adjuvant, the general procedure was done as for IFA, with the
exception that the initial emulsication started with 250 l of 2 mg/ml KLH in PBS which was pushed
into 500 l of Titermax Gold until an emulsion had formed, and then the other half of KLH was mixed
with the emulsion. 50 l thereof (50 g KLH) were injected subcutaneously into the base of the tail or
into the neck fold. The experimental setup was approved by the LAGeSO under the permission number
G0099/08, \Erweiterungsantrag".
4.4.5 Bleeding of Mice
Mice were warmed under an infrared lamp for 2-3 minutes in order to dilate the tail veins. Mice were
then immobilised in a plastic container with an indentation for the tail. The tail was disinfected with
Skinman soft disinfection solution, and a small cut was made to incise the basal tail vein. Blood was
collected into a 1.5 ml conical tube. For ELISA, around 50-200 l of blood were collected. Blood 
ow
was then stopped by pressing a sterile swab onto the incision. Collected blood was incubated at RT for
4 hours to coagulate, then the blood samples were centrifuged at 1700 g for 15 minutes at 4C. Serum
was then collected in a 0.5 ml conical tube and frozen at -20C. The experimental setup was approved
by the LAGeSo with the permission number G0099/08.
4.4.6 Feeding of Doxycycline in the Drinking Water
Doxycycline hyclate was dissolved in water at a concentration of 0.2 g/l, and the pH was set to 3 with
HCl. Then, 10 g sucrose were added per liter, and the solution was sterile ltered at 0.2 m. Bottles were
protected from light by covering with aluminium foil to preseve the light-sensitive doxycycline. Every
3-7 days, the bottles were exchanged. Feeding of doxycycline was approved by the LAGeSo under the
permission number G0099/08.
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5.1 Vector Design
The aim of the experimental approach was to allow inducible overexpression of proto-oncogenes in murine
B-cells to be quick and stable, yet tightly controlled to ensure that the uninduced cells behave as normally
as possible. Two inducible gene expression systems were tested to conditionally express the two proto-
oncogenes, Pim1 and c-Myc (Myc): the estrogen receptor-system (ERt system) [84], and the TetON
system. In the estrogen receptor-system, the proto-oncogene to be overexpressed is fused to a mutated
ligand binding domain (ERt) of the estrogen receptor which can only bind to the antagonistic estrogen-
analog 4-OH tamoxifen. This ERt domain is normally bound to proteins of the HSP90 family and, thereby,
is kept back in the cytoplasm. Only after encountering tamoxifen, the fusion protein is able to enter the
nucleus after a conformational change of the estrogen receptor part and subsequent release of the HSP90
anchor. This system has the advantage, that only 1 vector per transgene has to be inserted into the target
cells. The drawback of the ERt system is, that it only works for proteins that are active solely in the
nucleus, since the fusion protein is constitutively expressed and present in the cytoplasm. Furthermore,
fusion proteins do not always function as expected due to conformational changes or hiding of active
sites/domains by the ERt domain.
SIN LTRPsi packaging Resistance geneLTR ERT -  Oncogene Fusion
promoter promoter
Figure 5.1 { ERt vector containing the retroviral elements needed for ecient pack-
aging of RNA into virions and viral integration into host cells (grey), a constitutively
active promoter driving the expression of the ERt-fusion protein (red), and a sec-
ond promoter driving a resistance gene conferring resistance against puroMycin or
hygroMycin to transduced host cells.
The fusion protein consisting of the Myc protein with the C-terminally attached ERt domain was
inserted into a retroviral self-inactivating (SIN) vector based on the MoMulV virus (gure 5.1). Retroviral
transduction of genes is the only way to introduce transgenes into B lineage cells, since homologous
recombination of DNA vectors only works in stem cells, and transfection is only transient.
SIN vectors have a 3'LTR (long terminal repeat) which lacks the main part of the so called U3 region.
This U3 region normally encompasses the viral promoter and enhancer (gure 5.2). During incorporation
of the retroviral DNA into the host genome, the U3- and R-regions of the 3'LTR replace those of the
5'LTR (gure 5.3). Hence, during integration of SIN vectors into the host genome, the functional 5'LTR
promoter is replaced by the incomplete 3'LTR which has no promoter functionality anymore. Removal of
the viral promoters and enhancers on both LTRs prevents constitutive expression of the virally transfected
genes of interest by the viral promoters. In addition, cellular (onco-)genes in the vicinity of the integration
site of the retrovirus cannot be activated anymore by viral promoters or enhancers.
The \AATAAA" sequence at the end of the R region within the 3'LTR is used as a weak poly A
signal by the cellular transcription machinery. Stronger poly A sequences inside the retroviral backbone
inhibit transcription of complete viral genomic RNA and therefore inhibit production of complete virions
necessary to infect and transduce target cells.
As a target for transduction, fetal liver preB-I-cells were chosen, since these cells can easily be main-
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Figure 5.2 { Important elements in retroviral vectors. The LTRs are necessary for
transcription of RNA and integration of viral DNA into host cells. The PSI packaging
signal is necessary to eciently pack complete viral RNA into virions. During mRNA-
processing, this signal is removed by splicing. This mechanism prevents incomplete,
spliced RNA to be packed into virions. PBS: the start of reverse transcription. This
sequence is partially complementary to certain tRNAs which serve as a template. The
PPT is only slowly degraded by RNAse H during reverse transcription and therefore
serves as a primer for the generation of plus-strand DNA. LTR: long terminal repeat,
U3: unique 3'LTR RNA, U5: unique 5'LTR RNA. (adapted from an illustration in
the book \Retroviruses" by J.M. Con et al, 1997, p439)
tained in vitro in the presence of bone marrow derived stromal feeder layers (OP9) when supplemented
with IL-7. Stably transduced cells were selected for the presence of genes conferring resistance to antibi-
otics such as puroMycin, hygroMycin or histidinol. Only dividing cells, in our case fetal liver preB-I-cells,
can be transduced eciently with retroviruses. Hence, normal resting B-cells are resistant to retroviral
transduction. Retrovirally transduced resting mature B-cells were obtained by in vitro or in vivo matura-
tion of stably transduced preB-I-cells. Thus, the eects of Pim1 and Myc overexpression could be studied
in immature as well as mature stages of B-cells.
Initial tests with preB-I-cell lines transduced with ERt-Myc and ERt-Pim1 vectors showed a high
background activity of this system in the analysed B-cells (data not shown). Therefore, the alternative
TetOn vector system was developed.
The Tet expression systems require two core components:
1. a regulatory fusion protein containing a viral transactivator domain fused to parts of the bacterial
tet repressor, thereafter named tTA or r(t)TA. The transactivation domain is derived from the vp16
protein of Herpes simplex virus, and the tet repressor component is taken from the tet repressor
protein of E. coli.
2. a modied, tetracycline- or doxycycline-responsive promoter consisting of a minimal, inactive CMV
(Cytomegalovirus) promoter preceeded by a set of seven copies of the short tet resistance operator
sequence of Tn10 transposon (TetO) called TRE (tetracycline-response element) [105], hereafter
named CMV promoter. This promoter only drives expression of the gene after the rtTA has
bound to its TetO sequence.
In the TetO system, the tTA can bind the TRE element in the absence of tetracycline and hereby
brings the transactivator component of the tTA in close proximity to the minimal CMV promoter, which
acitvates transcription of the appropriate transgene. Addition of tetracycline (or doxycycline) leads to
a conformational change of the TetO-sequences of the tTA and therefore inhibits further binding of the
tTA to the TRE element of the CMV promoter. Upon dissociation from the TRE, the transactivator
cannot activate transcription of the transgene anymore. The major drawback of the TetO system is the
need to supply tetracycline over a prolonged period of time if transgene expression is not desired. On the
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Figure 5.3 { Process of reverse transcription of the retroviral genome. a: minus-
strand DNA synthesis is initiated using the 3`end of a partially unwound tRNA which
is annealed to the primer-binding site (PBS). (b) DNA synthesis is mediated by
the reverse transcriptase. (c) RNAse H digests the 5`end of the RNA/DNA duplex.
Thereafter, rst strand transfer causes the newly formed ssDNA to be annealed to
the 3`end of the viral genomic RNA. This is mediated by the identical R sequences
at both ends of the RNA genome. (d) minus-strand DNA synthesis resumes, and the
RNA template is subsequently degraded by RNAse H. Degradation of RNA is slowed
down at the PPT (polypurine tract). This \RNA-primer" serves as a starting point
for plus strand DNA synthesis. e,f: the newly formed partially double-stranded DNA
anneals at the complementary PBS segments in the plus- and minus-strand DNA,
and lacking portions of plus- and minus-strand DNA are generated, each of them
serving as templates for the other strand (adapted from an illustration in the book
\Retroviruses" by J.M. Con et al, 1997, p123).
other hand, regulation of transgene expression is very tightly regulable and highly inducible.
The TetOn system, on the other hand, includes an additionally mutated tTA called rtTA or reverse
transactivator (gure 5.4). This protein cannot bind tetracycline anymore but only recognizes doxycycline.
The rtTA can only bind to the CMV promoter if doxycyline is present. Hence, doxycyline only needs
to be added if transgene expression is desired. A drawback of this system is, that it might not be quite as
tightly turned o in the absence of the inducer as the TetO system and does not yield expression levels
as high as the TetO system [94]. Anyhow, since we did not want to treat cell cultures and mice with
antibiotics for longer periods of time to inhibit transgene overexpression, the TetON system was chosen.
The rst attempts to build a TetON vector system were done with the standard rTA vector derived
from the pTetOn plasmid (Invitrogen). This rTA is known to have some residual background activity
in the absence of doxycycline and is unstably expressed in some eukaryotic cells due to a bad codon
usage and splicing activities inside the sequence. Due to these problems, the nal vectors were built with
the enhanced and mutated rtTA-M2 reverse transactivator designed in H. Bujard's Lab. This codon-
optimized version is devoid of splice donor/acceptor sites and contains mutations which reduce background
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Figure 5.4 { Mode of operation of the TetON system: the reverse transactivator part
(rtTA) is transcribed from a constitutively active promoter. In the absence of doxycy-
cline, the rtTA cannot bind the TRE element within the inducible promoter. Hence,
the transactivator cannot activate transcription of the inducible transgene. If doxycy-
cline is added, the rtTA can bind the TRE element and subsequently transactivates
transcription of the inducible transgene. The reaction is reversible.
transactivation of the rtTA [132].
rtTA-TetON vector
The MoMulV-based self-inactivating vector pSuperRetroPuro was cut with XhoI and ClaI and was
subsequently dephosphorylated using calf intestinal phosphatase (CIAP). A linker with sticky ends tting
SIN LTRPsi packaging Resistance geneLTR rt-Transactivator
promoter
IRES
Figure 5.5 { rtTA-TetOn-vector
onto the sticky ends of the above backbone was created by annealing two complementary oligonucleotides
(m068, m074). The linker contained the restriction endonuclease recognition sites EcoRI, NruI, ClaI, HpaI,
HincII, BamHI and MluI. The linker ligated to the backbone resulted in the plasmid pSR-L. pSR-L was
cut with XhoI and EcoRI, and the pgk-promoter amplied by PCR from pSuperRetroPuro with primers
m136 & m137 was inserted into pSR-L to result in pSRL-P. Then, the reverse transactivator rtTA-M2
(kind gift from Hermann Bujard, University of Heidelberg) was cut out from its origin plasmid pUHD15-
1 4535 with EcoRI and BamHI and cloned into pSRL-P via the EcoRI and BamHI sites. After that,
the IRES sequence (=intra-ribosomal entry site) was cut out from the construct pSRL5P Vpmut IRES
nsEGFP kindly provided by Dr. Ozan Guezelbey (former Lab member) with BamHI and NcoI. The
histidinol resistance gene amplied from the vector pSV2 His using the primers m095 and m147 was
cloned into the TOPO-TA vector and sequenced. The histidinol resistance gene was subsequently cut
with BspHI (compatible with NcoI) and BamHI. Both the IRES sequence and the histidinol resistance
gene were ligated in one step into the BamHI site on the pSRL-P plasmid, which resulted in the plasmid
pSRL-P-rtTAM2-His, thereafter called rtTA-TetOn, see gure 5.5.
pSR-TREtight vector For the transgene expression vector, the pSR-L vector mentioned above
was used as backbone. The resistance cassette containing a pgk-promoter and puromcycin resistance was
amplied by PCR with the primers m069 and m070, and cloned into p-SR-L via the MluI site (=pSR-LP).
For the inducible cassette, the Ptight promoter from the pTRE-Tight vector was used. Ptight contains a
modied Tet response element (TREmod), which consists of seven direct repeats of a 36bp sequence which
contains the 19bp tet operator sequence. This CMVtight promoter has even less background activity
than the normal CMV promoter. In order to exclude that a possible residual background activity of
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the 5'LTR promoter could lead to unwanted expression of the transgene in the absence of doxycycline,
the cassette consisting of the CMVtight promoter and the transgene was put into the vector in reverse
orientation (gure 5.6). The TREtight cassette consisting of the TREtight promoter and a multiple
cloning site was cut out with XhoI and NheI and subsequently cloned into pSR-LP via XhoI and AvrII,
which is compatible to NheI.
SIN LTRPsi packaging Resistance geneLTR
Δ-CMV
Oncogene TRE
promoter
doxycycline-inducible
promoter
Figure 5.6 { Retroviral SIN vector carrying Pim1, Myc or egfp under the control
of the doxycycline-inducible TetON promoter as well as a resistance gene conferring
resistance to hygroMycin or puroMycin with its own eucaryotic promoter (promoter
of phosphoglycerate kinase (pgk)). The cassette containing the doxycycline-inducible
gene was cloned into the retroviral backbone in reverse orientation to inhibit activation
of the transgene in the absence of doxycycline by possible residual promoter activity
of the SIN-retrovirus.
Myc was amplied by PCR with the primers m101 and m102 from the plasmid pBJ4-cMyc and
subsequently cloned into pSR-LP-treTight via BamHI and HindIII sites. The Myc gene chosen is a
hybrid of the mouse and human Myc, as shown in gure 5.7. Regions underlined in green, i.e. the MBI
and MBII, are taken from the mouse Myc, and the rest is taken from the human variant. The dierences
between mouse and human Myc are minimal and are not assumed to result in dierential functions.
Furthermore, murine Myc can even be replaced by the Myc-family member N-Myc, which results in
normal development, normal lymphocyte compartments and normal B lymphocyte activation compared
to WT mice [85]. The advantage of a hybrid transgenic Myc is, that RNA levels of only the endogenous
Myc, of only the transgenic Myc, or of total Myc can be measured just by selecting the according primers
for RT-PCR. Pim1 was amplied by PCR from the vector Pim1 -CS41 using the primers m099 and m100
and subsequently cloned into pSR-LP-TreTight via BglII and HindIII sites. Egfp was amplied by PCR
from the vector pSRL5P Vpmut IRES nsEGFP with the primers m122 and m123 and subsequently cloned
into pSR-LP-treTight via BamHI and HindIII sites.
5.2 Conrmation of Inducible Transcription and Translation of Transgenes
5.2.1 Detection of EGFP Protein in TetOn-egfp Transgenic PreB-I Cells by FACS
In order to conrm the functionality of the vectors carrying the dierent components of the TetON system,
the FLd18Ber3 cell line was stably transduced with the rtTA-TetOn vector (g. 5.5) and the TetOn-egfp
vector (g. 5.6) and selected for cells carrying both vectors by adding the respective antibiotics.
To titrate the amount necessary to induce overexpression of transgenes, cells were seeded in 6-well
plates onto OP9 feeder layers in the presence of doxycycline at dierent concentrations ranging from 20
ng/ml up to 5 g/ml. After 24 hours, cells were harvested and subjected to FACS analysis. Upregulation
of EGFP expression was already detected at 20 ng/ml, but reached steady state levels at around 1 g/ml
(gure 5.8a). To minimize eects of longterm doxycyline treatment on preB-I-cells, this concentration of
doxycyline was taken for induction of transgenes in the following experiments.
To assess the speed of transgene upregulation, 1 g/ml doxycycline was added to the preB-I-cells
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420       430       440       450
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bHLH
leucine zipper
myc BoxI
myc BoxII
antibody
for western
myc BoxIII
DNA sequence from mouse
Figure 5.7 { Protein sequence of the hybrid Myc consisting of murine (green) and
human sequences. Myc boxes I-III are highly conserved sequences within the Myc
family. bHLH: basic helix-loop-helix domain (DNA-binding), leucine zipper: dimeri-
sation domain. The rst 15 base pairs are only present in the longer Myc version,
which is not used in this work.
harbouring the rtTA-TetOn and TetOn-egfp vectors. At dierent time points, cells were harvested and
analysed by FACS for EGFP expression. EGFP expression was already detected 2 hours after activation
of the TetOn-egfp gene and subsequently rose to steady state levels during the following 18 hours (see
picture 5.8b).
Transgene downregulation after removal of doxycycline was assessed using cells carrying the TetON-
egfp. Cells were supplemented with doxycycline for 3 days. Then, doxycycline was removed, and at dif-
ferent timepoints after removal of doxycycline (0-9 hours, 72 hours), expression of EGFP was measured
by FACS analysis (gure 5.8c). EGFP expression declined sharply 3 hours after removal of doxycycline.
Thereafter, EGFP 
uorescence further decreased more slowly. After 3 days, no EGFP protein was de-
tectable anymore.
Though the half lifes of dierent proteins are variable, the fact that the expression of a relatively
stable protein such as EGFP is partially downregulated after only 3 hours and completely abolished after
3 days allows the conclusion that the TetON system in general allows relatively fast downregulation of
de novo protein production. Since Myc protein and mRNA are quite instable, downregulation of Myc
protein might be even faster.
In summary, doxycycline concentrations needed for maximal transgene expression were at least 1
g/ml. Transgene proteins were detected already after 2 hours, and maximal levels of protein were only
reached after 24 hours.
48
5.2 Conrmation of Inducible Transcription and Translation of Transgenes
Figure 5.8 { Testing the TetOn system using a preB-I-cell line carrying the TetOn-
egfp vector. a: Titration of doxycyline. Cells were induced for 24 hours with 1 g/ml
doxycycline before FACS analysis. Dotted grey line: concentration chosen for subse-
quent exeriments. (b) EGFP overexpression after start of doxycycline treatment (1
g/ml) with time after induction. (c) Decline of EGFP expression after removal of
doxycycline.
5.2.2 Detection of Upregulated Myc and Pim1 mRNA by RT-PCR
For detection of Myc mRNA, the FLd18Ber3 cell line transduced with the rtTA-TetOn vector and the
TetOn-Myc vector was cultured in the presence or absence of 1 g/ml doxycycline. At dierent time points
after activation of Myc, total RNA was extracted and subjected to RT-PCR. mRNA of the transgenic
Myc was already detected after 30 minutes and subsequently rose during the following 18 hours (gure
5.9a).
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Figure 5.9 { Upregulation of mRNA of Pim1 and Myc after addition of doxycyline. a:
RT-PCR of preB-I-cells harvested at dierent time points after transgene activation.
(b) Inducibility of transgene overexpression in transplanted B-cells harvested from
spleen 5 after transplantation. (1 mouse). Expression levels are shown as relative val-
ues compared to uninduced cells, which are set to one. (c) Analysis of Myc protein
overexpression by SDS PAGE and Western blotting. Myc protein is readily upregu-
lated after addition of doxycycline in both preB-I-cells carrying only a transgenicMyc
gene as well as in preB-I-cells carrying transgenic Myc and Pim1 genes together. The
human Daudi cell line is derived from a Burkitt's lymphoma patient and is frequently
used as a positive control for Myc expression.
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B-cells carrying a TetOn-Myc and -Pim1 could still upregulate both transgenes 5 months after trans-
plantation into RAG1 =  mice. To show this, 5x106 cells of the FLd18Ber3 cell line carrying the rtTA and
a Tet-ON-Pim1 and -Myc were transplanted into irradiated RAG1 =  mice. Five months later, splenic
and the bone marrow cells were extracted, CD19+ cells were sorted using MACS beads and cultured in-
vitro in SF-IMDM medium containing 2% FCS and 1% conditioned medium containing IL5 for enhanced
survival in the presence or absence of 1 g/ml doxycyline. After 3 days, total RNA was extracted, and
upregulation of Myc and Pim1 mRNA in the doxycycline-treated cultures was conrmed by RT-PCR
(gure 5.9).
5.2.3 Detection of Transgenic Myc by Western Blot
Using Western blot analysis, we conrmed induction of Myc protein after addition of doxycycline.
FLd18Ber3 preB-I-cells carrying the TetOn Myc and Pim1 were cultured in the presence or absence
of doxycycline for 3 days. 3x107 cells of each culture were lysed in 300 l Ripa buer containing protease
inhibitors, and 100 g of total protein per lane were used as described in section 4.1.18. As a positive
control, 7x106 cells of the human DAUDI cell line known to overexpress Myc at very high levels were
lysed in 300 l Ripa buer and subjected to SDS page. As a loading control, antibodies against HDAC1
were used on a parallel blot. The anti-Myc antibody used detects human Myc and, to a lesser extent,
murine Myc.
These experiments show that Myc protein overexpression is detected in doxycycline-treated cells,
though at much lower levels than in the DAUDI cell line (gure 5.9c).
5.2.4 Degree of Leakiness of the TetOn Vector-Mediated Gene Expression
Expression of genes which are controlled by the TetOn promoter should only be detected in the presence
of doxycycline. Though, it is known that the transcriptional control of the TetON system is not 100%
tight. Hence, background expression of genes integrated by the TetON vector into the host genome
in the absence of doxycycline was assessed as follows: Fetal liver preB-I-cells carrying the rtTA-TetOn
and the TetOn-tight Myc+Pim1 vectors as a negative control for EGFP expression and cells carrying
the rtTA-TetOn and the TetOn-tight-egfp vectors were compared for EGFP-expression in the absence
and presence of doxycycline. As expected, the cells carrying integrated Pim1 and Myc genes had no
background EGFP-expression in the absence of doxycycline. By contrast, 3-5% of the cells carrying
the integrated Egfp showed EGFP 
uorescence intensities above the treshhold dened by the EGFP

uorescence of the negative control (gure 5.10a). Though, there was only a very slight shift of the EGFP

uorescence intensity in the presence of the EGFP vector. In the presence of doxycycline, about 35-50%
of the cells carrying egfp showed EGFP 
uorescence intensities above the threshold as dened by the
cells not carrying egfp, with no distinct peak of EGFP 
uorescence intensity.
We can conclude that the integrated inducible vectors show low, but measurable background activity
in the absence of doxycycline in a small fraction of cells.
5.2.5 Stability of Doxycycline in Cultivation Medium at 37C
In order to test the stability of doxycycline in culture media, medium containing the standard amount of
doxycycline (1 g/ml) was preincubated in the 37C incubator in open tubes to allow gas exchange for 2
and 6 days, respectively. Then, the preincubated medium or fresh medium with or without doxycycline
was added to TetOn-egfp FL preB-I-cells which had been grown on stromal cells and IL-7 in the absence
of doxycycline for 2 days. After one day of incubation, cells were subjected to FACS analysis. As shown
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Figure 5.10 { (a) Leaky expression of EGFP in preB-I-cells transfected with the
TetOn-egfp vector in preB-I-cells. PreB-I-cells carrying either TetON pim/Myc or
TetON-egfp were cultured in the absence or presence of doxycycline for 24 hours
before FACS analysis. Compared to cells which did not carry egfp (black line), egfp-
carrying cells showed slightly enhanced EGFP 
uorescence intensities in the absence
of doxycycline (grey line). In the presence of doxycycline, egfp-carrying cells showed
a wide range of EGFP-
uorescence intensities (red line), where 50% of the cells had
higher EGFP-
uorescence intensities than the negative control. (b) Stability of doxy-
cycline in medium at 37C. Doxycycline was preincubated for 2 or 6 days in medium
at 37C or added freshly to medium before being added to TetON-egfp-transgenic
preB-I-cells. After 24 hours, EGFP expression was measured by FACS analysis.
in gure 5.10b, no reduction of EGFP expression in cells induced with doxycycline preincubated for
two days was detected as compared to EGFP expression in the presence of freshly added doxycycline.
Doxycycline preincubated at 37C for 6 days only led to a 20% reduction of EGFP expression. Therefore,
each subpassage of cells after 3-4 days was done with medium containing fresh doxycycline.
5.3 Eect of Pim1+Myc-Overexpression on Transgenic PreB-Cells in vitro
5.3.1 in vitro Dierentiation of Normal PreB-I Cells
In a rst experiment, the maturation behaviour of normal, untransfected fetal liver preB-I-cells was
characterized in order to have reference points for further maturation experiments with preB-I-cells
overexpressing Pim1 and Myc. Maturation of preB-I-cells can be induced by removal of IL-7. FLd18Ber3
cells grown on OP-9 feeder layers supplemented with IL-7 were washed and re-cultured in the absence
of IL-7. Maturing cell cultures were kept in medium either supplemented with IL5 or with IL5+CD40
antibodies for 8 days. The cells were counted and subjected to FACS analysis every day.
Without any ligands added, survival of cells decreased drastically from 100% to below 10% between
days 1 und 3. After 8 days, there were virtually no viable cells left (gure 5.11c). Addition of IL5 enhanced
early survival or proliferation, whereas CD40+IL-4 led to a proliferation of cells at later stages of
development between day 4 and 5 (gure 5.11c). C-kit, a marker for preB-I-cells, was downregulated
during the rst 2 days, whereas CD25, a marker for preB-II-cells, was upregulated (gure 5.11a). IgM
and IgD were rst detected around day 3. The percentage of IgM+ and IgD+ cells rose subsequently to
around 80 and 40% of all viable cells, respectively. These results of B-cell dierentiation and apoptosis
are comparable to the original observations with preB-I-cells [112]. The markers CD23 and MHCII were
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Figure 5.11 { Change in expression of surface markers and survival during in vitro
dierentiation of preB-I-cells upon removal of IL-7. (a) Timeline of expression of B-
cell maturation markers after removal of IL-7. (b) Dierential upregulation of MHCII
and CD23 in cells matured with IL5 only or with CD40+IL-4. (c) Survival of cells
during in vitro maturation.
only upregulated in the cultures supplemented with CD40+IL-4 (5.11b), which is in line with the results
obtained by Takeda et al. who found that IL-4 is a trigger for CD23 and MHCII expression [130]. Virtually
all of the cells retained CD93 [88] on their surface, which suggests that maturation did not proceed in
vitro to fully mature, CD93  B-cells.
In summary, normal fetal liver preB-I-cells previously cultured in the presence of IL-7 can be matured
in vitro in the absence of IL-7 in about 3 to 6 days to IgM+, partially IgD+, but still CD93+ B-cells with
concomitant apoptosis of the maturing cells.
5.3.2 in vitro Growth Behaviour of FL PreB-I Derived Cells Overexpressing Pim1 and/or
Myc
To examine the eects of Pim1 and Myc overexpression in FL preB-I-cells in vitro, the Fld18Ber3 cell
line transduced with the rtTA-TetOn vector and the TetOn-Pim1 and/or TetOn-Myc vectors were rst
cultured on stromal cells in the presence of IL-7 at 3.3x105 cells/ml. Then, IL-7 was removed from the
medium of preB-I-cells, and dierent growth factors and stimulants were added to the medium in the
presence or absence of doxycycline. After 3 to 4 days, cells were counted and, thereafter, recultured in fresh
media at 1.3x105 living cells/ml. Induced overexpression of Pim1 alone did not lead to IL-7-independent
proliferation or survival in preB-I-cells (gure 5.12a). Also, induced overexpression of Myc alone did not
render the cells IL-7 independent for further proliferation. In medium without IL-7 or any other growth
factors, they were induced to apoptosis. However, addition of IL5 or CD40+IL-4 to the cells induced the
survival of doxycycline-induced cultures for more than two weeks (gure 5.12b). Finally, if Myc and Pim1
were overexpressed together in the same cells, they proliferated IL-7-independently (gure 5.13). The
proliferating cells which originally had shown a preB-I phenotype gradually lost c-kit on the cell surface,
acquired CD25, and kept CD93 during this Myc and Pim1-induced, IL-7-independent proliferation (gure
5.14).
In summary, induced overexpression of Pim1 alone had no eect upon proliferation or survival of preB-
I-cells in the absence of the preB-I growth factor IL-7. Also, overexpression of Myc alone was not sucient
to induce proliferation of preB-I-cells in the absence of IL-7. However, induced Myc overexpression in
the presence of IL5 or CD40+IL-4 led to survival of a constant number of cells for at least two weeks
in culture. This could be due to an enhanced proliferation rate of cells which still have not overcome
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Figure 5.12 { Growth curves of FL Ber3 cell lines expressing either Pim1 or Myc in
media containing dierent growth stimuli
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Figure 5.13 { Growth of the doxycycline-induced, Pim1 + Myc-expressing FL preB-
I-cell line + Pim1 +Myc with doxycycline in the absence of IL-7, cultured either in
medium alone, in medium supplemented with IL5, or in medium supplemented with
CD40+IL-4.
apoptosis, or it could be a consequence of enhanced survival of the cells. This problem is adressed below.
Finally, overexpression of Pim1 and Myc together induced growth factor independent proliferation of fetal
liver preB-I-cells. However, in contrast to preB-I-cells proliferating in the presence of IL-7 on stromal cells,
these cells appear not to remain xed in their preB-I state of dierentiation, since they lost c-kit and
acquired CD25 expression.
In order to analyse the combined in
uence of Pim1 and Myc in later stages of B-cell dierentiation,
namely in IgM+CD93+ immature B-cells, FL-preB-I-cells transduced with TetOn-Pim1 and TetOn-Myc
were induced to maturation in vitro by the removal of IL-7 in the presence of IL5. After 4 days, doxycycline
was added to the cultures to induce Pim1 and Myc. The few surviving cells were grown in vitro for 5
days in the presence of IL5 and doxycycline. Then, IgM+ cells were enriched with a FACS sorter and
cultured in the presence of doxycycline and IL5 for additional 4 days to obtain sucient numbers of IgM+
cells for further growth tests. Since overexpression of Pim1 and Myc might not be sucient to induce
proliferation of IgM+ B-cells, dierent cytokines known to enhance B-cell proliferation or activation were
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Figure 5.14 { Phenotype of Pim1+Myc-expressing fetal liver preB-I-cells cultured in
the presence of doxycycline, in medium supplemented with the cytokines and mitogens
as indicated in the legend.
added. The sorted cells kept their IgM+ phenotype and proliferated growth factor independently (gure
5.15). Only the addition of IL5 further improved the proliferation of these Pim1+Myc-expressing IgM+
B-cells, while the addition of IL-2, IL-4, IL6, CD40, and CD40+IL-4 had no eect. The addition of
LPS had a small inhibiting eect.
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Figure 5.15 { Proliferation of in vitro matured, sorted IgM+ fetal liver cells in the
presence of doxycycline to promote expression of Pim1 and Myc (a) in the presence
of interleukins, and (b) in the presence of mitogens
In short, some of the IgM+ immature cells could be induced to proliferate in vitro even in the absence
of B-cell growth and survival factors. The IgM+ phenotype was stable for at least 2 weeks and the few
remaining IgM  cells did not overgrow the cultures. However, since the cultures continued to contain
IgM  cells, it is likely that these cells also proliferated, although this was not tested as with the IgM+
cells shown in gure 5.15. In conclusion, the combined induction of expression of Pim1 and Myc activates
the mitotic cell cycle of the series of B-lineage dierentiation stages from large preB-I to immature B-cells,
i.e. in cells like IgM+ immature cells that would normally develop as non-mitotic resting cells.
5.3.3 Limiting Dilution Analysis of Clonable, Pim1+Myc-Induced PreB-I Cells
To estimate the percentage of preB-I-cells being able to respond to inducible Pim1 and Myc overexpression
in vitro, limiting dilution analysis was performed. Pim1+Myc doubletransgenic preB-I-cells grown in IL-
54
5.3 Eect of Pim1+Myc-Overexpression on Transgenic PreB-Cells in vitro
7 on feeder layers were set up in 96-well plates at dierent cell numbers per well in medium without
IL-7, but containing other growth factors. The cultures were analysed 1 week later. Positive cultures
were dened as wells with more than 20 living cells. Plating eciencies of the dierent cultures were
normalised to the plating eciency of preB-I-cells on OP9 feeder layers supplemented with IL-7, which
was set to 1/1.
In the absence of doxycycline, only preB-I-cells supplemented with IL-7 proliferated with a plating
eciency of almost 1 in 1. Cells stimulated with doxycycline could even grow without addition of growth
factors, though only around 1 in 90 cells started to proliferate in medium + doxycycline alone (table 1).
When IL5 was added, the frequency of proliferating clones increased to 1 in 35. Also, CD40 increased
the cloning capacity of the doxycycline induced cells to 1 in 60-80.
no Dox mean Dox mean
OP9 IL-7 1/1, 1/1, 1/1 1/1 1/1 1/1
medium undetectable 1/64, 1/104, 1/115 1/94
CD40 IL-4 undetectable 1/69 1/69
CD40 IL-4 IL5 ND 1/47 1/47
IL5 undetectable 1/27, 1/20, 1/53 1/33
IL-4 undetectable 1/91 1/91
Table 1 { Frequency of clonable cells as determined by limiting dilution of the
FLd18Ber3 cell line expressing Pim1 and Myc in the presence of dierent growth
factors. Cells carrying TetOn-Pim1 and TetOn-Myc were grown in the conditions
mentioned, and after 7 days, positive wells (containing colonies of more than 20 liv-
ing cells) were counted. undetectable: none in 800 cells grew.
In summary, in the preB-I-cell pool expressing Pim1 and Myc, only around 1 in 90 cells, i.e. around
1%, were clonable in IL-7-free medium. Growth factors such as CD40 antibody and IL5, but not IL-4
enhanced cloning eciency to up to 1 in 35 cells. This is much less than estimated from growth curves
of Pim1+Myc-overexpressing preB-cells growing in the absence of IL-7 as shown in gure 5.16
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Figure 5.16 { Estimation of approximate numbers of cells growing out from
Pim1/Myc-transgenic fetal liver preB-I cells cultured in the absence of IL-7 while
overexpressing Pim1 and Myc.
Analyses of preB-I-cells expressing Pim1 and Myc presented in section 5.3.2 have shown that dier-
entiation of these cells in the absence of IL-7 appeared delayed, see gure 5.14. To further characterize
this phenomenon, B-cells overexpressing Pim1 and Myc were grown in medium alone or supplemented
with growth factors such as IL5, or CD40+IL-4+IL5 for 6 days to select for Pim1+Myc-responding
cells. Most of the non-responders should have died during that period of time. Thereafter, the cells were
replated on OP9 feeder layers in the presence of IL-7 and subjected to limiting dilution analysis.
The percentage of cells still able to proliferate under these standard preB-I conditions (in the absence
of doxycycline) was taken as a measure for cells which retained the preB-I-cell stage. Hence, the higher
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the frequency of cells proliferating again on OP9/IL-7, the higher the percentage of cells being still in the
preB-I-cell stage after 6 days of cultivation in the absence of IL-7.
from to
IL-7 OP9 mean
Dox 1/457, 1/286, 1/413 1/385
Dox+IL5 1/84, 1/8, 1/11 1/34
Dox+CD40+IL-4+IL5 1/54, 1/9, 1/11 1/25
Table 2 { Frequency of clonable cells as determined by limiting dilution analysis:
Ability of cells which had been overexpressing Pim1 and Myc in dierent media to
grow back on OP9 feeders supplemented with IL-7 in the absence of doxycycline.
After 7 days, positive wells (containing colonies of more than 20 living cells) were
counted.
Limiting dilution analysis revealed that a large part of the cells cultured in medium + doxycycline
alone did not retain their status of dierentiation, since only 1 in 385 cells was able to replate on OP9/IL-
7. By contrast, 1 in 34 cells cultured in the presence of IL5 and doxycycline replated on OP9/IL-7, and
1 in 25 cells cultured in the presence of CD40+IL-4+Il5 replated on OP9/Il-7 (table 2). These data
suggest that preB-I-cells overexpressing Pim1 and Myc in the absence of IL-7 are not all arrested at the
preB-I-cell stage. Surprisingly, growth factors such as IL-5 or CD40 kept a higher number of cells at the
prebI-cell stage, suggesting that growth factors inhibit maturation to later stages of B-cell development.
In conclusion, the limiting dilution analyses of the frequencies of cells capable of clonal proliferation
showed that
1) Doxycycline-dependent induction of Pim1 and Myc together in preB-I-cells without supplemented
cytokines or ligands around 1% of the estimated 25% of cells that proliferated in mass cultures (gure
5.16). Of these, one in around 400 cells, i.e. 1 in around 40'000 originally induced preB-I-cells could be
reversed after 6 days to proliferate again in the absence of doxycycline-induced Pim1 and Myc expression
to proliferate like preB-I-cells on stromal cells in the presence of IL-7.
2) Addition of IL-5 (with or without CD40, IL-4 or other cytokines) increased the doxycycline/Pim1-
Myc-induced frequencies by more than a factor of 2 to 1 in 35-45 cells, of which, after 6 days, again 1
in around 35, hence around 1 in around 1000-1500 originally induced preB-I-cells could be raplated as
preB-I-cells on stromal cells in the presence of IL-7. Therefore, IL-5 kept around 40-50 times as many
cells in a preB-I-cell like state during the 6 days Pim1+Myc-induced , IL-7-independent proliferation
of the preB-I-cells. Nevertheless, these analyses show that the vast majority of all Pim1+Myc-induced
proliferating preB-I-cells lost their preB-I state and matured to preB-II and sIgM+ cells which, when
reversed by the removal of doxycycline, had lost their capacity to grow on stromal cells in IL-7.
5.3.4 Cell Cycle Analysis of PreB-cells Overexpressing Pim1 and/or Myc
Myc can induce mitotic cell cycle progression in density-arrested rodent broblasts. In rat and mouse
broblasts, overexpression of an estrogen-regulated version of the Myc protein resulted in re-entry into
and progression through the cell cycle [32] [126].
Hence, the ability of the transgenic Myc to induce cell cycle progression in IL-7 deprived, doxycycline-
induced cultures was tested by staining of DNA with propidium iodide (PI). PI binds to DNA by inter-
calating between the bases with little or no sequence preference and with a stoichiometry of one dye per
4{5 base pairs of DNA. Cells in G2/M phase have twice the amount of DNA as cells in G0/G1 phase,
and cells in S phase have an amount of DNA which lies in between. Hence, the intensity of PI staining is
directly proportional to the phase of the cell cycle (see gure 5.17 for an example graph).
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Figure 5.17 { PI-staining of Pim1/Myc-transgenic preB-I-cells in medium without
(a) or with (b) doxycycline for 1 day. Analysis was done on living single cells, see
Materials and Methods, page 34. Black curve: G1, light grey: G2/M phases, and dark
grey curve: S phase
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Figure 5.18 { Cell cycle analysis of two preB-I-cell lines carrying Myc ((a) Fld18Ber3-
rtta1-Myc, (b) Makn-rtta-Myc), and (c) a cell line carrying Myc + Pim1 (Fld18Ber3-
rtta1-pim/Myc) as demonstrated in gure 5.17.
PreB-I-cells were cultured on OP9 feeders in medium alone or in the presence of IL-5 or IL-7 at
dierent concentrations in the presence or absence of doxycycline. After 2 days, cells were harvested,
xed in ethanol, and subsequently stained for DNA (section 4.2.4). As shown in gure 5.18a and b,
induced overexpression of Myc in fetal liver preB-I-cells leads to enhanced cell cycle entry, even in medium
without any additional growth factors. Cell Cycle entry is also visibly enhanced in standard cultivation
conditions of fetal liver preB-I-cells, namely on a feeder layer in the presence of IL-7. In section 5.3.2, it
was shown that overexpression of Myc alone was not sucient to induce IL-7 independent proliferation of
preB-I-cells. Combining this result with the above cell cycle analysis, we can conclude that the inability
of Myc transgenic preB-I-cells to grow IL-7 independently is not due to a failure to enter mitosis. More
likely, it is a result of increased proliferation without inhibiting apoptosis.
Cells overexpressing Pim1 + Myc together also show the same pattern, i.e. cell cycle entry is enhanced
upon overexpression of Myc and Pim1 for 2 days in cultures kept in medium alone as well as in cultures
supplemented with IL-5, or IL-7 (gure 5.18c).
The ratios of cells being in S-phase divided by cells being in G2/M phase ( %(S)%(G2 M) ) did not dif-
fer between cells transgenic for Myc alone and cells expressing Pim1 and Myc together or between
doxycycline-induced and -uninduced cells.
In short, cell cycle progression is enhanced in both Myc transgenic and Myc+Pim1 transgenic preB-
I-cells in medium with or without growth factors, IL-7 or IL-5, present.
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5.4 Overexpression of Pim1 and Myc in Immature and Mature B-Cells ex
vivo and in vivo
5.4.1 Phenotype of Transplanted FL preB-I-Cells in Dierent Murine Organs
RAG KO mice were sublethally irradiated with 4 Gy, and 1 day later received 5x106 fetal liver preB-I-
cells carrying transgenic, but uninduced Pim1/Myc. These triple rtTA-Pim1/Myc and double rtTA-Myc
transgenic cells were taken to test their phenotype after transplantation into RAG KO mice in the absence
of doxycycline in dierent hematopoietic organs at 2 months after transplantation.
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Figure 5.19 { Representative FACS plots showing the phenotype of gated splenic
CD19+ cells in a BL/6 wild type mouse (top row) and a RAG KO mouse trans-
planted with 5x106 FL preB-I-cells carrying transgenic Pim1/Myc in the absence of
doxycycline 2 months after transplantation (bottom row).
The thymi and lymph nodes of transplanted RAG KO mice were very small and hardly visible. T-cells
were absent. The transplanted B-cells mainly populated the spleen and the peritoneal cavity. More than
95% of the CD19+ cells in spleen and peritoneal cavity were donor-derived as conrmed by transplantation
of CD45.1+ fetal liver preB-I-cells into CD45.2+ RAG KO recipient mice (data not shown). The bone
marrow was only scarcely populated by the transplanted preB-cells, as the main CD19+ population in
the bone marrow was host-derived.
BM spleen peritoneum
BL6 6.55x106 21.7x106
RAG KO 1.87x106 0.05x106
RAG KO pim/Myc 2 w 2.04x106  0.8x106 0.63x106  0.36x106 0.08x106  0.02x106
RAG KO pim/Myc 4 w 1.64x106  0.84x106 1.94x106  1.60x106 0.57x106  0.55x106
RAG KO pim/Myc 8 w 1.99x106  0.88x106 13.7x106  9.8x106 0.85x106  0.48x106
RAG KO Myc 2 w 0.14x106 0.07x106 0.91x106 0.140x106 0.006x106 0.006x106
RAG KO Myc 4 w 0.37x106 0.18x106 1.10x106 0.32x106 0.08x106 0.005x106
RAG KO Myc 8 w 1.44x106 0.31x106 1.75x106 0.61x106 0.63x106 0.42x106
Table 3 { Total numbers of CD19+ cells in BM (1 hind leg), spleen, and peritoneum.
Numbers are derived from 2-3 mice each. w=weeks.
In the spleen, B-cell numbers rose continually within eight weeks after transplantation. CD19+ cell
numbers in the dierent organs depended on the cell line. The Fld18Ber3-rtta1-Pim1/Myc cell pool
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expanded more rapidly in transplanted mice and yielded higher numbers of splenic B-cells than the
Fld18Ber3-rtta1-Myc cell pool. Two weeks after transplantation, the pim/Myc bearing B-cell pool yielded
4.75x the numbers of splenic B-cells of theMyc-bearing B-cell pool. Four weeks after transplantation, 7.5x
more splenic B-cells in mice transplanted with Pim1/Myc-transgenic B-cells than in mice transplanted
with Myc-transgenic B-cells were detected. Eight weeks after transplantation, 30x more splenic B-cells
in mice transplanted with Pim1/Myc-transgenic B-cells were found than in those transplanted with
Myc-transgenic B-cells (see table 3).
total IgM (g/ml) total IgG (g/ml)
BL6 480-600 1200-3100
RAG KO 0 0
RAG KO pim/Myc 2 w 105-120 0.45-0.75
RAG KO pim/Myc 5 w 135-160 61-67
RAG KO pim/Myc 9 w 175-185 225-380
Table 4 { Serum levels of total IgM and IgG in RAG KO mice transplanted with
5x106 FL preB-I Pim1/Myc transgenic cells, 2, 5 and 9 weeks after transplantation.
Values are derived from 2-4 mice for each group.
Two, four and eight weeks after transplantation, the populations within the spleen included between
35% and 75% mature IgM+CD93  B-cells as well as IgM+CD93+ transitional B-cells and up to 40%
IgM CD93+ cells. In contrast, BL/6 WT mice had more than 90 % mature B-cells and less than 10%
immature and transitional B-cells. Furthermore, only B-cells with a MZ-like phenotype (CD21+) could be
detected in transplanted RAG KO mice, but practically no follicular CD21loCD23+ B-cells. In contrast,
splenic B-cells of WT Bl/6 mice included around 80% follicular B-cells and 9% MZ B-cells (gure 5.19).
Mature B-cells derived from transplanted fetal liver preB-I-cells mainly had a B1-phenotype (CD5+).
Mice transplanted with fetal liver preB-I-cells readily generated approximately one third of wild type
serum IgM, but low serum IgG levels (table 4).
5.4.2 Eect of Overexpression of Myc only in B-Cells in vivo
To assess whether B-cells overexpressing Myc starting from the preB-I-cell stage would expand in vivo,
5x106 doxycycline-induced preB-I-cells were transplanted into RAG1 =  host mice fed with doxycycline
in the drinking water, and B-cell numbers and maturation stages were assessed 2 and 4 weeks after
transplantation. Four weeks after transplantation, doxycycline was removed from the drinking water of
the mice, and the eect of Myc downregulation on the B-cell populations was assessed 8 weeks after
transplantation. For a outline of the experiment, see gure 5.20.
Two mice per group (doxycycline-treated, untreated) were analysed 2 weeks after transplantation,
and 3 mice per group were analysed at four and eight weeks after transplantation.
PreB-I-cells overexpressing Myc alone did not expand signicantly in the bone marrow or spleen of
RAG1 KO mice over time (gure 5.20). Four weeks after transplantation, there was only a minimal
increase in CD19+ immature B-cells of bone marrow and spleen. The only compartment which was
increased in mice carrying Myc overexpressing B-cells was the peritoneal cavity. This increase was only
visible after 8 weeks (5.20).
One of the transplanted mice analysed 2 weeks after transplantation had threefold higher B-cell
numbers in the bone marrow and spleen (gure 5.20, mouse marked with exclamation mark). Some
of the transplanted preB-cells in this mouse might have acquired another deregulated oncogene which
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Figure 5.20 { Overexpression of Myc in preB-I-cells transplanted into RAG1 KO mice
does not lead to increased B-cell numbers in spleen and bone marrow.(a) Experimen-
tal outline. RAG1 KO mice were fed with doxycycline (0.2 g/liter) starting 3 days
before transplantation. Two days later, mice were sublethally irradiated and then were
transplanted one day after irradiation with 5x106 preB-I-cells carrying TetOn-Myc.
Expression of these transgenes in the cells was induced one day before transplanta-
tion in vitro in doxycycline-containing medium. As a control, mice fed with normal
acidied drinking water without doxycycline were transplanted with uninduced preB-
I-cells carrying Myc. Doxycycline treatment in doxycycline-induced mice was contin-
ued until 4 weeks after transplantation. Thereafter, doxycycline was omitted from
the drinking water. Mice were analysed 2, 4 and 8 weeks after transplantation. (a)
Experimental outline, (b) total B-cell numbers from the bone marrow from 1 hindleg
and from total spleen were calculated. : mice carrying uninduced B-cells. : Mice
carrying B-cells overexpressing Myc. !: mouse with unusually high numbers of B-cells
(see text)
cooperated with Myc, which might have caused this unusual B-cell expansion not seen in all other
transplanted mice.
The sizes of the dierent B-cell subpopulations of immature and mature B-cells were not signicantly
dierent in doxycycline-treated versus untreated mice (gure 5.21).
In summary, overexpression of Myc alone in preB-I-cells was not sucient to lead to signicantly
increased B-cell compartments in the bone marrow and spleen of transplanted RAG1 KO mice over time.
5.4.3 In vivo Expansion of B-Cells Overexpressing Pim1 together with Myc
The same experimental setup as described in section 5.4.2 was followed to examine the eect of Pim1
and Myc double-transgenic cells. I.e., 5x106 FLpreB-I-cells containing TetOn Myc and Pim1 were trans-
planted into sublethally irradiated RAG1 KO mice either treated with doxycycline or untreated. B-cell
numbers and maturation stages were assessed two and four weeks after transplantation. Four weeks af-
ter transplantation, doxycycline was removed from the drinking water of the remaining mice, and the
eect of Pim1 and Myc downregulation on the B-cell populations was assessed eight weeks after trans-
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Figure 5.21 { B-cell subsets transgenic for Myc in the bone marrow (upper panel)
and spleen (lower panel) in the presence of doxycycline. Total cell numbers of the
indicated B-cell phenotype were compared 2, 4 and 8 weeks after transplantation in
mice -/+ doxycycline. : mice carrying B-cells which overexpress Myc, : mice carrying
normal B-cells. Cell numbers are calculated from total spleen and bone marrow from
1 complete hindleg.
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Figure 5.22 { In vivo expansion of B-cells transgenic for Myc and Pim1. The same
experimental setup as in 5.20a was used. Per time point and treatment, 3 mice were
analysed. (a) Total B-cell numbers from the bone marrow from 1 hindleg and from to-
tal spleen were calculated. : mice carrying normal B-cells, i.e. doxycycline-uninduced
cells. : Mice carrying B-cells overexpressing Myc and Pim1 (induced by the addition
of doxycycline). (b) Percentage of B-cells with the indicated phenotype in the spleens
2 weeks after transplantation.
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plantation. Three mice per group (doxycycline-treated, untreated) were analysed 2, 4 and 8 weeks after
transplantation.
Total numbers of CD19+ cells in spleen, bone marrow (1 femur and tibia per mouse) and peritoneal
lavage were assessed. Mice which received doxycycline showed no higher numbers of CD19+ B-cells in
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Figure 5.23 { In vivo expansion of B-cell subsets transgenic for Myc and Pim1 in
the bone marrow (upper panel) and spleen (lower panel). Total cell numbers of the
indicated B-cell phenotype were compared 2, 4 and 8 weeks after transplantation
in mice -/+ doxycycline. : mice carrying B-cells which overexpress Myc+Pim1, :
mice carrying normal B-cells. Cell numbers are calculated from total spleen and bone
marrow from 1 complete hindleg.
the bone marrow 2 weeks after transplantation. However, a marked increase of CD19+ cells in the bone
marrow was observed 4 weeks after transplantation, i.e. 4x more than in uninduced mice (gure 5.22).
After the removal of doxycycline at 4 weeks, numbers of CD19+ cells in the bone marrow declined to
almost normal levels within 4 weeks (gure 5.22).
In the spleen, numbers of CD19+ cells did not dier from those of control mice without doxycycline
after 2 weeks, but the ratio of immature versus mature cells was shifted towards immature, IgM  cells
in the spleen, indicating that immature cells started to expand (gure 5.22c).
Notably, after 4 weeks there was a strong expansion of CD19+ B-cells in the spleens of doxycycline-
induced mice. Compared with uninduced mice, more than 10 fold higher numbers of CD19+ B-cells were
found (gure 5.22b). Four weeks after removal of doxycycline from the drinking water, i.e. 8 weeks after
transplantation, numbers of CD19+ B-cells reverted back to the numbers of splenic B-cells in uninduced
mice.
In the peritoneum, an expansion of B-cells was found after 4 weeks that was around 4.5-5 fold the
number of B-cells found in the peritoneum of doxycycline-uninduced mice. In contrast to the bone marrow
and the spleen, the numbers of peritoneal B-cells remained at increased levels up to 4 weeks after removal
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of doxycycline, i.e. at 8 weeks after transplantation.
The BM and splenic B-cells expanding under the in
uence of induced Myc and Pim1 were stained
for CD93 (marker for immature cells), IgM, and CD19. FACS analysis revealed 3 populations of CD19+
B-cells: CD93+IgM  cells, which include preB-I and preB-II-cells, CD93+IgM+ immature cells, and
CD93 IgM+ mature cells.
In the bone marrow, the immature IgM  preB-II-like fraction was the population which was increased
most in numbers 4 weeks after transplantation (gure 5.23). This fraction had 4 times the numbers of
cells compared to control mice. Also in the spleen, this immature IgM  preB-II-like population increased
most after 4 weeks, with 100x the numbers of cells found in control mice. Numbers of immature IgM+
cells were also increased around 6 times, and the mature fraction of B-cells in the spleen was enlarged
around 5 times compared to control mice. After 8 weeks, i.e. 4 weeks after removal of doxycycline, cell
numbers of almost all fractions declined to levels comparable to control mice.
In summary, Myc + Pim1 overexpressing preB-I-cells transplanted into RAGKOmice fed continuously
with doxycyline showed enhanced cellular expansion when compared to transplanted preB-I-cells not
overexpressing Pim1 and Myc, i.e. in the absence of doxycycline in vivo. Dierences in B-cell numbers
were visible 4 weeks after transplantation. The B-cell populations which expanded most in the BM and
spleen were the IgM  preB-II-like cells. After removal of doxycycline, i.e. 8 weeks after transplantation,
B-cell numbers dropped to normal levels, with the exception of mature B-cells in the BM, which were 2
times as numerous as those in control mice, and B-cells in the peritoneal cavity, which were still 4 times
as numerous in doxycycline-induced mice compared to control mice.
5.4.4 Increased Cell Size of B-Cells Overexpressing Myc in vivo
Myc has been reported to incease cell size of immature and mature B-cells of E-Myc-transgenic mice [75].
To test if Myc also has an in
uence upon B-cell size in the Myc-overexpression system used here, RAG KO
mice were transplanted with transgenic preB-I-cells carrying either Myc, or Pim1 and Myc together. One
group of 3 mice was treated with doxycycline via the drinking water to induce overexpression of transgenes,
and another group of mice received normal acidied drinking water (controls). After 1 month, B-cells of the
bone marrow, spleen, and peritoneal cavity were analysed by FACS, and cell size was compared between
the doxycycline-induced and uninduced mice (gure 5.24). The forward scatter of light (FSC) produced
by cells passing through the laserlight-beam, which is measured in a FACS instrument, is proportional
to the cell volume. Hence, bigger cells have higher FSC values. B-cells overexpressing Myc in the spleen
and peritoneal cavity had higher mean FSC values than B-cells which did not overexpress Myc. In the
bone marrow, there was only a very slight, insignicant increase of FSC in Myc-overexpressing B-cells
compared to control B-cells. B-cells overexpressing Myc together with Pim1 had higher FSC values than
control B-cells in the spleen and also the bone marrow. In the peritoneal cavity, there was a visible, but
insignicant increase in cell size.
In summary, overexpression of Myc leads to an increase of cell size in transplanted B-cells harvested
from the spleen, bone marrow and peritoneal cavity.
5.4.5 Ex vivo Proliferation of Donor-Derived Splenic B-Cells 4 Months after Transplanta-
tion
As shown above, immature IgM  and IgM+ B-cells overexpressing Pim1 and Myc together proliferate
in vitro and in vivo, but at the same time are hindered to fully mature. In vitro maturation of normal
fetal liver preB-I-cells does not generate fully mature CD93  B-cells. Hence, to elucidate the eects of
Corinne Bouquet, MPI for Infection Biology, Chariteplatz 1, 10117 Berlin, Germany: PhD Thesis, March 23, 2012 63
5 Results
-D
ox
+D
ox
70
75
80
85
90
F
S
C
 (
~
 c
e
ll
 s
iz
e
)
-D
ox
+D
ox
75
80
85
90
95
F
S
C
 (
~
 c
e
ll
 s
iz
e
)
-D
ox
+D
ox
80
85
90
95
100
F
S
C
 (
~
 c
e
ll
 s
iz
e
)
BM spleen peritoneum
-D
ox
+D
ox
80
90
100
110
120
130
F
S
C
 (
~
 c
e
ll
 s
iz
e
)
-D
ox
+D
ox
80
90
100
110
120
F
S
C
 (
~
 c
e
ll
 s
iz
e
)
-D
ox
+D
ox
85
90
95
100
105
F
S
C
 (
~
 c
e
ll
 s
iz
e
)
+ MYC
+ MYC
+ PIM1
* **
**
*
Figure 5.24 { Expression of Myc leads to an increase in cell size of transgenic B-cells
in vivo. RAG KO mice were transplanted with 5x106 transgenic preB-I-cells either
able to overexpress only Myc (top row) or Myc and Pim1 (bottom row). One group of
mice was treated with doxycycline in the drinking water, while the second group was
left untreated. After 1 month, mice were sacried, and the average forward scatter
(FSC) of gated B-cells (as a measure for cell size) was determined by 
ow cytometry.
: mice w/o doxycycline, : mice treated with doxycycline.(*: p<0.05, **: p<0.01,
2-tailed, unpaired t-test)
Pim1 and Myc overexpression upon fully mature B-cells, fetal liver preB-I-cells carrying the TetON-Pim1
and TetON-Myc transgenes were transplanted into RAG KO hosts in the absence of doxycycline to allow
complete maturation in vivo. Splenic B-cells and bone marrow B-cells were harvested 4 months later and
tested for the presence of mature B-cells. B-cells were tested in in vitro cultures for proliferation in the
presence of doxycycline and dierent growth factors.
B-cells were puried using CD19-MACS beads as described in section 4.3.19, and set up at 2x105
cells per 3 ml medium in dierent conditions with and without doxycycline. Since only certain stages of
B-cells might be responsive to induced Pim1 and Myc expression, B-cells were stimulated in vitro with a
range of known B-cell activating agents. Conditions tested included \naive" B-cells which were cultured
in medium alone, B-cells activated with LPS and IL-2 or IL-5, which leads to plasma cell formation,
B-cells activated with CD40 and dierent cytokines, which induces maturation and switching, and B-
cells activated with both LPS and CD40 in the presence of dierent cytokines. Some cultures were
additionally supplemented with IL-21 [100] and IL6 which might enhance plasma cell dierentiation if
only plasmablasts or plasma cells were responsive to overexpression of Pim1 and Myc.
No dierence in proliferation of doxycycline-induced splenic and BM B-cells as compared to non-
induced cells could be found in almost all culture conditions tested (gure 5.25). The only condition
showing enhanced proliferation in the presence of doxycycline was the one with LPS, CD40 and IL-5
5.25.
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Figure 5.25 { Lack of in
uence of Pim1 and Myc overexpression on ex-vivo splenic
B-cell cultures. Four months after transplantation of FL preB-I-cells carrying Pim1
and Myc into RAG1 =  mice, spleens were extracted. Enriched splenic B-cells were
cultured in vitro in the absence () or presence () of doxycycline and supplemented
with dierent survival- and growth factors. Every 3-5 days, cells were counted and
replated in fresh medium.
This apparent unresponsiveness to the actions of Pim1 and Myc in the transplanted B-cells could have
resulted from loss of oncogene expression. However, overexpression of Pim1 and Myc in isolated splenic
B-cells could still be induced in vitro 5 months after transplantation with the addition of doxycycline, as
shown in gure 5.9b. Hence, it was not the lack of overexpression of Pim1 and Myc in splenic and BM
B-cells which did not allow ligand-independent or -dependent long-term proliferation in contrast to in
vitro matured IgM+ cells and preB-cells, but an apparent insensitivity of the ex vivo isolated, transduced
B-lineage cells to Pim1- and Myc expression.
In conclusion, these experiments indicate that in the presence of doxycycline, there was no change in
the proliferative response of MACS-sorted splenic B-cells.
5.4.6 In vitro Culture of Transplanted Splenic, Bone Marrow and Peritoneal B-Cells one
Month after Transplantation
Unreactivity of splenic B-cells to induction of Myc and Pim1 overexpression in the experiment done
above might not only be a consequence of intrinsic Myc/Pim1-unreactivity of mature B-cells. Possibly,
after 4 months of residence in vivo, only limited, unreactive subsets of the originally transplanted Pim1
and Myc transgenic B-cells could have survived. Also, enrichment of B-cells using CD19-MACS beads
could have led to damage of the cells. Therefore, the following experiments were conducted one month
after transplantation without MACS-bead separation. Splenic, BM and peritoneal cells of two mice were
washed and counted. FACS analysis revealed the percentage of CD19+ B-cells. Cultures were set up
at 5x105 B-cells in 3 ml medium supplemented with various growth- and survival factors for B-cells,
with or without doxycycline added. In order to allow exclusive growth of transgenic B-cells, 1.5 g/ml
puroMycine was added, the antibiotic used for selection of transgenic B-cells carrying the TetON-Pim1
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Figure 5.26 { In
uence of Pim1 and Myc overexpression onto ex vivo B-cell cultures in
the presence of mitogens and survival factors (as indicated in the gure). Total BM,
splenic and peritoneal cells were set up at 5x105 CD19+ cells (percentage of B-cells
assessed by FACS) in 3 ml medium and replated every 3-4 days.  : in the absence of
doxycycline.  : in the presence of doxycycline.
vector. Cells were counted and replated in new medium every 3-4 days.
As shown in gure 5.26, none of the cultivation conditions led to sustained proliferation of B-cells in
the absence or presence of doxycycline neither in splenic B-cells, nor in peritoneal or BM-B-cells. However,
splenic B-cells cultured with IL-5 or CD40 + IL-4 in the presence of doxycycline showed a prolonged
survival of Pim1+Myc-induced cells, but none of the cultures survived for longer than 18 days (gure
5.26).
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5.4.7 Detection of in vitro Proliferation of B-Cells by CFSE Staining
Another method to detect proliferation of cells is staining with the dye CFSE. As explained in section
4.2.5, the compound CFDA-SE can be covalently bound to the inner cell components in the form of CFSE
and is evenly distributed among daughter cells during mitosis. The number of divisions an individual cell
has undergone can be assessed by FACS analysis.
FL preB-I-cells carrying TetON-Pim1 and TetON-Myc were transplanted into RAG KO mice, and 1
month later, splenic and bone marrow cells were harvested. Total splenic and BM cells were labelled with
CFSE and cultured at 2x105 CD19+ B-cells per 3 ml medium supplemented with various growth factors
and stimulants in the presence or absence of doxycycline.
After 3-4 days, surviving cells in culture were stained with DAPI and antibodies against CD19, IgM
and CD93 and analysed by FACS.
In
uence of Cultivation Conditions on the Percentage of B-Cells
The percentage of CD19+ B-cells in the cultures was assessed as a measure for selective expansion
or survival of B-cells. Hence, an increasing percentage of CD19+ B-cells can reveal two things: First, if
the conditions allow B-cell specic expansion. Second, if Pim1 and Myc in
uence ex vivo proliferation of
splenic and bone marrow B-cells, the percentage of CD19+ B-cells would accordingly increase or decrease
in doxycycline-treated cultures.
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Figure 5.27 { In
uence of Pim1 and Myc overexpression in ex-vivo bone marrow and
splenic cell cultures upon the percentage of B-cells in the presence of dierent B-cell
mitogens and growth factors. Cells were cultured -/+ doxycycline. After 4 days, the
percentages of CD19+ cells in the bone marrow (a) and spleen (c) were assessed by
FACS analysis. In addition, the percentages of immature and mature subsets of B-
cells were compared between the dierent cultivation conditions -/+ doxycycline, in
bone marrow (b) and spleen (d).
In bone marrow cultures, the highest percentage of CD19+ B-cells was found in the cultures supple-
mented with LPS + IL-5 followed by the cultures stimulated with CD40 + IL-4 + IL-5, which resulted
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in around 60% and 20% B-cells, respectively, compared to 2% in medium alone (gure 5.27a). Cultures
receiving IL-3 showed a smaller percentage of B-lineage cells compared to cultures held in medium alone.
IL-3 selectively increased the numbers of surviving immature IgM  cells, whereas LPS+IL-5 and CD40
+ IL-4 + IL-5 selectively expanded the IgM+ immature B-cells (gures 5.27b, 5.28, and data not shown).
Splenic B-cell cultures had the highest percentages of B-cells if cultured in medium alone or in the
presence of CD40 + IL-4 + IL-5 (90%) and in the presence of LPS + IL-5 (80%) (gure 5.27c). In
contrast to the bone marrow B-cells, addition of IL-3 + IL-2 did not increase the percentage of immature
IgM  B-cells (gure 5.27d).
Addition of doxycycline, and thus, overexpression of Pim1 and Myc, did not signicantly change the
percentages of CD19+ cells. Only very slight dierences could be detected, with a tendency to higher
percentages of B-cells in the doxycycline-treated cultures.
Comparing the Percentage of Proliferating Cells
To assess if overexpression of Pim1 and Myc induce proliferation in BM and splenic B-cells, the
percentages of B-cells which had undergone at least one division were compared between control cultures
not receiving doxycycline and doxycycline-induced cultures. In the bone marrow, the CD19+IgM+ and
CFSE
Ig
M
medium IL2+IL3 IL2+IL3+IL6 LPS+IL5 aCD40+IL4+IL5
Figure 5.28 { Dot plots showing bone marrow cultures stained with CFSE (x-axis)
and IgM (y-axis). Bone marrow B-cells were cultured for 4 days in the presence of the
indicated stimulants. Then, FACS analysis was performed to reveal possible eects
of Pim1 and Myc upon the numbers of divisions after 4 days. CD19+, living cells are
shown.
CD19+IgM  fractions were analysed separately. See gure 5.28 for representative FACS plots showing
IgM+ and IgM  BM-B-cells analysed for CFSE-content. Splenic B-cells were analysed in total (IgM+
and IgM  together), since there were only few IgM  cells. CFSE content of the dierent subsets was
analysed by FACS (gure 5.29(a) and (b) for bone marrow and (c) for spleen).
IgM  BM cells: In medium alone, around 80% of bone marrow B-cells being IgM  4 days after
isolation had divided at least once. In bone marrow cultures supplemented with growth factors and
interleukins named in gure 5.29a), almost all IgM  cells had undergone at least 1 division. Therefore,
no dierences between uninduced and doxycycline-induced cultures could be found. Furthermore, the
majority of these IgM  cells were most probably host-derived, and hence, would not react to doxycycline.
IgM+ BM cells: Culture conditions which led to at least one division in almost all of the B-cells
(LPS + IL-5, LPS, CD40 + IL-4 + IL-5) did not reveal any dierences in percentage of cells undergoing
at least one division. In contrast, BM B-cells grown in CD4040 + IL-4 without IL-5, or IL-3 alone, or
IL-5 alone, or IL-6 alone, or IL-2 + IL-3 or IL-2 + IL-3 + IL-6 all showed a slight increase in cells which
had undergone at least one division (gure 5.29b and d; gure 5.28).
Splenic B-cells: In spleen cell cultures, there was no dierence in the percentage of CD19+ cells
which had undergone at least 1 division between the doxycycline induced and the uninduced cultures,
which is in line with the results from the growth curves of splenic B-cells shown above.
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Figure 5.29 { In
uence of Pim1 and Myc overexpression in ex-vivo cultured bone
marrow and splenic B-cells derived from 2-4 mice upon cell-cycle entry. Bone marrow
and spleen cells were stained with CFSE and cultured for 4 days in the presence of
dierent mitogens and growth factors. Percentages of B-cells and B-cell subsets which
had undergone at least 1 division were compared between Pim1+Myc overexpress-
ing cultures and control (doxycycline-uninduced) cultures (a-c). (d) Min/Max plots
showing the quotient % of cells divided at least 1x with dox
% of cells divided at least 1x without dox
.
Comparing the Numbers of Divisions in Splenic Cultures -/+ Doxycycline
Overexpression of Myc and Pim1 might not only induce cell cycle entry in previously nonproliferating
cells, but the two proto-oncogenes might also enhance or prolong proliferation. Therefore, the CFSE-
labeled splenic B-cells were analysed upon how many times the individual cells divided, and doxycycline-
induced cultures were compared to doxycycline-free cultures. There was no relevant dierence in the
distribution in the numbers of divisions between doxycycline-induced and -uninduced cultures (gure
5.30 a). Also in the bone marrow, there was no dierence in the pattern of numbers of divisions of
doxycycline-induced versus uninduced cells (gure 5.30 b).
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Figure 5.30 { (a) In
uence of Pim1 and Myc overexpression in ex vivo splenic B-cell
cultures on the number of divisions made after 4 days of culture. Splenic B-cells la-
beled with CFSE were cultured in the presence of the indicated growth factors and
stimulants. Then, CD19+ living cells were analysed by FACS for CFSE content with
the FlowJo-Proliferation Software Module. Up to 8 populations of cells could be de-
tected which had undergone 0-7 divisions. There was no dierence in the distribution
of the numbers of divisions between doxycycline-induced and -uninduced cells. (b) Ex
vivo CFSE-staining of BM B-cells: Histogram overlays showing IgM+ bone marrow
cultures stained with CFSE. Bone marrow B-cells were cultured for 4 days in the
presence of the indicated stimulants. Then, FACS analysis was performed to reveal
possible eects of Pim1 and Myc upon the numbers of divisions after 4 days. black
line: w/o doxycycline; grey line: with doxycycline
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5.5.1 B- and T-Cell Compartments of RAG1 =  Mice Transplanted with FL-preB-I Cells
and Thymocytes
In the previous experiments, transplantations of preB-I-cells were done under conditions where mature
B-cell compartments would be generated in the absence of T-cells. We therefore attempted to generate
B-cell compartments in mice in which T-cells were present.
RAG KO mice transplanted with fetal liver preB-I-cells did not develop T-cells which could coac-
tivate B-cells during immune responses against T-cell dependent protein antigens. Hence, after initial
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Figure 5.31 { (a) Reconstitution of the T-cell compartment of RAG KO mice by co-
transplantation of thymocytes depleted of B-cells. Two months after transplantation,
CD4+ and CD8+ T-cells were still readily detected in spleen, lymph nodes, peritoneal
cavity and bone marrow. Thymi were barely detectable and contained practically
no doublepositive T-cells as expected. (b) Phenotype of splenic B-cells in RAG KO
mice transplanted with Pim1/Myc transgenic preB-I-cells together with thymocytes,
2 months after transplantation (in the absence of doxycycline).
co-transplantation tests conducted with PAX5-/- FL proB-cells, CD4+CD25+ splenic T-cells and B-cell-
depleted DN2/DN3 thymocytes and total thymocytes as a source for T-cells, total thymocytes depleted
of CD19+ cells were chosen to be co-transplanted as an easy source for T-cell reconstitution.
spleen thymus
total CD4 single-positive cells 3.74x106  1.93x106 5.43x104  5x104
total CD8 single-positive cells 2.39x106  1.78x106 6.6x104  6x104
total CD4/CD8 double-positive cells - 6x103  6x103
Table 5 { Total numbers of T-cell subsets in spleen and thymus 8 weeks after co-
transplantation of preB-I-cells and 3x105 CD19-depleted thymocytes. Numbers are
derived from 3 mice each.
Thymocytes readily reconstituted the CD4+ single-positive and CD8+ single-positive T-cell compart-
ments in the easily detectable lymph nodes, the spleen, the peritoneum, and the bone marrow (gure
5.31a and table 5). The thymus was barely detectable and contained few T-cells with practically no
double-positive T-cells. T-cells repopulated the hosts long-term and were still detectable 8 months after
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transplantation. The B-cell compartments of these mice were comparable to those of mice which did not
receive cotransplanted thymocytes (section 5.4.1 on page 58, and gure 5.31b).
5.5.2 Overexpression of Myc and Pim1 in Activated B-Cells in vivo in the Presence of
T-Cells
transplantation
5e6 FL preBI 
+ pim1, c-myc
+ thymic T cell precursors
3 and 6 days after immunisation
+/- KLH 
2 weeks
immunisation
switch on oncogenes
4 weeks
bleeding
check serum
IgM / IgG
2 weeks after
immunisation
0 weeks 7 weeks
bleeding
check serum
IgM / IgG
5 weeks after
immunisation
3 weeks
bleeding
check serum
IgM / IgG
1 week after
immunisation
+ Dox
timeDox
Figure 5.32 { Experimental setup: Generation of in vivo activated B-cells in RAG KO
host mice reconstituted with Pim1/Myc transgenic B-cells and wild type thymocytes
by immunisation with the T-cell dependent antigen KLH (keyhole limpet hemocyanin)
and subsequent overexpression of Pim1/Myc in activated B-cells.
To assess the eect of Pim1+Myc overexpression on mature activated B-cells, 5x106 preB-I-cells carry-
ing Pim1+Myc and 3e5 B-cell-depleted thymocytes from a C57Bl/6 wildtype mouse were co-transplanted
into sublethally irradiated RAG1 =  mice to allow concomitant B- and T-cell reconstitution. Two weeks
after transplantation, these mice were challenged with the T-cell dependent antigen KLH. Three and 6
days after immunisation, doxycycline was added to the drinking water of the mice to induce overexpres-
sion of Pim1 and Myc in B-cells at dierent stages of the KLH-induced immune response. Co-transplanted
control mice encompassed immunised mice which did not receive doxycycline, as well as unimmunised
mice which received only doxycycline (3 weeks after transplantation), and nally, mice which were left
unimmunised and were not treated with doxycycline. For an outline of the experimental setup, see gure
5.32.
One week, 2 weeks and 5 weeks after immunisation, peripheral blood from the tail vein was collected,
and serum was prepared. The sera were tested for KLH-specic and total IgM and IgG levels by ELISA.
As shown in gure 5.33, total IgM levels were slightly higher in KLH-immunised mice 2 and 5 weeks
after immunisation. KLH-specic IgM levels increased only marginally in KLH-immunised mice with time
after immunisation. Dierences in IgM levels between unimmunised and immunised mice were highest 5
weeks after immunisation. In contrast to the preB-I-cell-transplanted RAG1 KO mice, control wildtype
B57Bl/6 mice immunised with KLH had increased levels of total IgM as well as highly increased KLH-
specic IgM antibody levels one and two weeks after immunisation. Unimmunised transplanted RAG KO
mice receiving doxycycline showed only marginally higher total Ig-levels 1 and 2 weeks after immunisation
in the serum compared with untreated unimmunised control mice. By contrast, immunised mice receiving
doxycycline starting from 3 or 6 days after immunisation had increased total IgM levels 1, 2 and 5 weeks
after immunisation (gure 5.33 right column). Total IgM levels were comparable to those in immunised
wildtype mice. KLH-specic IgM levels were also higher than in control mice receiving only doxycycline
or only KLH.
Total IgG levels of immunised mice were slightly higher than those of control mice starting 2 weeks
after immunisation, and KLH-specic IgG levels were not changed. Five weeks after immunisation, total
and KLH-specic IgG antibody levels in all groups of mice had a high variance (gure 5.34). Mice receiving
doxycycline in addition to KLH-immunisation showed slightly increased total IgG levels especially at week
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Figure 5.33 { ELISA (IgM) of sera taken from immunised RAG1 KO mice carrying
Pim1/Myc transgenic B-cells. IgM antibody levels in the serum were measured 1, 2,
and 5 weeks after immunisation. For KLH-specic IgM (left column), serum IgM levels
were normalised to KLH-specic IgM serum levels of WT mice 1 week after immu-
nisation (=100%). BT: RAG KO mice were reconstituted with Pim1/Myc-transgenic
fetal liver preB-I-cells and thymocytes. KLH: mice were immunised 2 weeks after
transplantation with KLH (keyhole limpet hemocyanin). D3, D6: 3 or 6 days after
immunisation, mice were fed with doxycycline to switch on Myc and Pim1 in B-cells.
BL6: wild type mice, either unimmunised, or 1 week after immunisation with KLH
(grey dots).
2 after immunisation. KLH-specic IgG levels were also increased in the second week after immunisation
in this group of mice.
In summary, KLH-immunisation of RAG KO mice transplanted with fetal liver preB-I-cells and thy-
mocytes yielded only low quantities of antigen-specic IgM and barely detectable antigen-specic IgG in
the absence of doxycycline-induction, i.e. only 5% of WT levels of specic IgM and less than 1% of WT
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Figure 5.34 { ELISA (IgG) of sera taken from immunised RAG1 KO mice carrying
Pim1/Myc transgenic B-cells. Some mice were immunised 2 weeks after transplanta-
tion with KLH (keyhole limpet hemocyanin). Three and 6 days after immunisation,
some mice were fed with doxycycline to switch on Myc and Pim1 in B-cells. IgG
antibody levels in the serum were measured 2 and 5 weeks after immunisation. For
KLH-specic IgG (left column), serum IgG levels were normalised to KLH-specic
IgG serum levels of WT mice 2 weeks after immunisation (=100%).
levels of KLH-specic IgG, which was barely above background levels of unimmunised mice.
Although immunisation did not yield KLH-specic IgG-antibodies, activation of the proto-oncogenes
Pim1 and Myc had an eect upon B-cells in immunised mice. Total IgM levels were only signicantly
increased in mice which were immunised and additionally received doxycycline to activate Pim1 and
Myc. Also KLH-specic IgM levels increased in that manner. The same was true for IgG; total IgG and
KLH-specic IgG only rose well above background levels if mice were immunised and Pim1 and Myc
were activated after immunisation. KLH specic IgM levels were highest in mice which were fed with
doxycycline 3 days after immunisation, thus at an early timepoint of the immune response, probably at a
timepoint where switching to other isotypes did not yet start. On the other hand, KLH specic IgG levels
were highest when immunised mice were fed with doxycycline 6 days after immunisation, thus during or
after switching. According to this, overexpression of Myc and Pim1 together in early activated B-cells
leads to enhanced IgM production, probably by enhancing or prolonging proliferation and/or Ig secretion.
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5.5.3 Does a T-cell Dependent Antigen also Elicit B-Cell Immune Responses in the Ab-
sence of T-Cells?
As shown above in section 5.5 on page 71, immunisations of RAG KO mice harbouring Myc/Pim1
transgenic B-cells and thymic T-cells only showed marginally increased KLH-specic IgM serum levels
but did not yield relevant KLH-specic IgG levels. Therefore, a control experiment was conducted to
evaluate if immunisation with KLH was indeed T-cell dependent or wether immunisation with KLH
would also yield enhanced IgM serum levels in RAG KO mice only harbouring transgenic B-cells. As
transplantation
5e6 FL preBI 
+ pim1, c-myc
2 weeks
+4days
+/- Dox+/- KLH 
2 weeks
immunisation switch on
oncogenes
3 weeks
bleeding
check serum
IgM / IgG
1 week after
immunisation
4 weeks
bleeding
check serum
IgM / IgG
2 weeks after
immunisation
0 weeks
timeDox
Figure 5.35 { Outline of the control experiment which claried wether the in-
creased IgM and IgG serum levels in KLH-immunised transplanted mice harbouring
Pim1+Myc-overexpressing B-cells are dependent on the presence of T-cells
shown in the outline in gure 5.35, sublethally irradiated RAG KO mice were transplanted with 5x106
fetal liver preB-I-cells carrying TetON-Myc and -Pim1. Two weeks after transplantation, 2 groups of mice
were immunised with 50 g KLH in 50 l TiterMax Gold into the neck fold. Four days after immunisation,
1 group of immunised mice and 1 group of unimmunised transplanted mice were fed with doxycycline
in the drinking water. Antibody serum levels were tested for total IgM and IgG and KLH specic IgM
and IgG 1 and 2 weeks after immunisation. In general, total IgM levels of RAG KO mice harbouring
only transgenic B-cells were up to 2x lower than those of RAG KO mice harbouring transgenic B-cells
plus thymic T-cells, and total IgG cells were even more than 10x lower in T-cell free mice. As shown
in gure 5.36, total IgM levels were not increased in immunised mice compared to control mice after 1
and 2 weeks. IgG levels were very low in all mice and did not remarkably rise after immunisation with
KLH. Remarkably, IgM-antibody levels did not increase in RAG KO mice transplanted with fetal liver
preB-I-cells expressing Myc and Pim1 after immunisation. It can be concluded that the increased IgM
serum levels in immunised mice transplanted with FL-preB-I-cells expressing Pim1 and Myc together
after immunisation is at least partially dependent on T-cells or T-cell derived factors.
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Figure 5.36 { Serum IgM and IgG-levels of RAG KO mice transplanted with
Pim1/Myc transgenic B-cells in the presence of T-cell dependent antigen
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6 Discussion
6.1 Establishing the System for Overexpression of Transgenes
6.1.1 Conditional Overexpression of Proto-Oncogenes in Murine B-Cells Using a Retrovi-
ral TetON System
The retroviral TetON vector system used in this thesis work is suitable to conditionally overexpress
proto-oncogenes at dierent stages of murine B-cell development in vitro as well as in vivo.
The vector system includes 2 components:
 Two vectors carrying the genes of Pim1 and Myc under the control of doxycycline-inducible pro-
moters.
 One vector carrying the rtTA (reverse transactivator) which is a fusion protein of a transactivation
domain and a domain which binds the doxycycline-inducible promoters.
6.1.2 The Pros and Cons of Using a Retroviral TetON System in B-Cells
Normal B-cells and their progenitors cannot integrate DNA fragments by homologous recombination.
Transfection of DNA by an electrical pulse or with the aid of liposomes is also not feasible, since it
remains transient. Hence, proliferating B-lineage cells lose the transfected DNA and, thus, its possible
eects rapidly. Hence, stable integration of foreign DNA into B-cells can only be achieved either by the
generation of transgenic mice or by the use of retroviral vectors.
Because of the long time it takes to generate the appropriate transgenic mice carrying doxycycline-
inducible forms of Pim1 and Myc as well as the transactivator rtTA, such mice were not made. Instead,
retroviral transduction of transgenes into host cells was used. It allows to generate a larger number of
constructs and to transfect dierent combinations of these constructs rapidly. However, the transfected
cells are transgenetically much more heterogenous because they carry one, or often more than one,
retroviral inserts at dierent sites in the cellular genome.
Retroviruses are thought to integrate into the host genome in a sequence-unspecic, yet non-random
manner [14]. Target site selection varies among dierent retroviruses. Preferred sites of integration are
often actively transcribed and are therefore freely accessible [119]. Also, distortions of the DNA structures
owing to the wrapping of DNA around nucleosomes can enhance integration of a retrovirus into a specic
site. In the case of the mouse leukemia virus (MLV), integration occurs near the 5'end of a transcription
unit in 20% of the cases [14]. Integration of the viral DNA could therefore destroy the integrity of a
gene, either by integrating into the locus or by supplying its own promoters or viral enhancers to drive
a previously silent cellular gene. Examples for this mechanism are the activation of Pim1 [25] or the
activation of Myc in mouse T-cell lymphomas [22] by enhancers of the Moloney murine leukemia virus.
This transforming activity of retroviruses is even used for studies which aim to nd new proto-oncogenes.
Also, early attempts to use retroviruses in gene therapy have failed due to the generation of retrovirally
induced leukaemias and neoplasias [26]. For example, in a trial conducted in 1999, 11 children suering
from serere X-linked immunodeciency were treated with a MLV-based vector. Nine out of them showed
clinical improvement, but during the following years, 4 of the patients developed T-cell leukemia. A
sequence analysis of the T-cells from the patients demonstrated clonal expansion of T cell clones that
contained an insertion of the vector in the vicinity of the LMO2 proto-oncogene which led to the activation
of the LMO2 gene by the LTR enhancer [41].
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In order to avoid secondary transformations induced by the integration of retroviruses and subse-
quent activation of cellular proto-oncogenes in the vicinity of retroviral promoters and enhancers, self-
inactivating vectors (SIN) were used in this work. SIN vectors delete the enhancers and promotors upon
integration into the cellular DNA. While SIN vectors are known to have lower titers (at least 10 times
lower) than normal retroviral vectors ( [21], p. 444), and therefore are more dicult to transduce into
host cells, they proved to be suciently infective for preB-I cells (20-40% eciency).
But one problem also remains when SIN vectors are used: Enhancers, suppressors or promoters of
the host genome in the vicinity of the retroviral integration site could promote, or partially silence
the transcription of genes inside the provirus. In the TetON vector expression system, this could lead
to transcription of the doxycycline-driven proto-oncogene in the absence of doxycycline. Therefore, to
minimize eects of cellular promoters, enhancers and suppressors upon the proviral proto-oncogenes, the
expression cassette containing the proto-oncogene with the TRE-promoter was put into the vector in
reverse orientation. Still, nearby cellular promoters and enhancers could lead to transcription from the
minimal CMV promoter which is part of the TRE promoter. Hence, residual background transcription
activity of the transgene is possible and has to be considered when interpreting the data.
Many onco-retroviruses can only infect proliferating cells, since they can only enter the nucleus during
mitosis, when the nuclear membrane is disassembled ( [21], p165). In addition, the selection of cells which
carry the transgenes with selection markers such as antibiotic resistance is only successful if proliferating
cells can be kept in culture for at least one week. In the case of B-cells, this means that only stages which
can be cultivated in vitro are promising targets for retroviral infection. So far, the only B-cell stage which
can be kept proliferating for extended periods of time is the preB-I-cell stage. PreB-I-cells taken from the
fetal liver can be cultivated for weeks in the presence of bone marrow stromal feeder layers and IL-7. In
contrast, the bone marrow-derived preB-I-cells grown in IL-7 on OP9 feeders, only proliferate for 20-30
days under these conditions before they die. Therefore, these cells were not used in this work.
Later stages of B-cells have to be derived from eciently transduced preB-I cells, either in vitro by
removing IL-7, or in vivo by transplanting preB-I cells which give rise to mature splenic and peritoneal
B-cells.
Each transduced cell might integrate the viral DNA at a dierent place. Some of the loci are better
places for transcription than others due to surrounding repressor- or enhancer elements. Also, some loci
might be closed by remodelling of chromatin during dierentiation of the cells. Furthermore, in the work
of this thesis, up to three retroviral constructs had to be integrated into a single cell. The use of IRES
(internal ribosomal entry site) sequences, which allow transcription of two genes from one single promoter,
would allow the selection of cells which transcribe both the transgene and the selection marker behind
at the same time. This trick was used in the expression vector for the rtTA, which has a constitutively
active promoter. Hence, (almost) every cell which is resistant to histidinol also expresses the rtTA. For
the inducible proto-oncogenes, this technique is not realizable, since this would mean that selection of
eciently transduced cells would have to be done in the presence of doxycycline. Consequently, the
cell would also overexpress the transgene (oncogene) at an undesired time point. Hence, for the vectors
carrying inducible transgenes, a second promoter was inserted into the retroviral backbone which allows
constitutive transcription of the selection marker. However, that does not guarantee that every positively
selected cell is really able to induce transgene expression. The result is a multitude of cells which are all
more or less inducible for each of the transgenes, as shown in gure 6.1. Very likely, some of the cells
which should express Pim1 and Myc only induce the expression of one of the proto-oncogenes. Also, the
eectiveness of induction of the expression of both transgenes is most probably dierent from cell to cell.
Therefore, in contrast to a transgenic mouse, where transgenic expression can be better controlled in
each cell by controlled insertions of the constructs, retrovirally transduced cells are a mix of dierentially
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inducible cells (gure 6.1).
+ Dox
- Dox
expression levels:
Pim1
c-Myc
hi lo
proliferation?
proliferation?
proliferation?
Figure 6.1 { Possible patterns of Myc- and Pim1-overexpression by the TetON ex-
pression vectors.
On the other hand, exactly this heterogeneity of expression levels in dierent cells is not necessarily
a disadvantage. The eects of proto-oncogene overexpression in cells might also be dependent on the
level of overexpression. Low levels of Myc and/or Pim1 overexpression might be too low for induction
of proliferation, whereas too high levels could lead to genomic instability, as shown for Pim1 [109] and
Myc [35] or apoptosis, in the case of Myc [142]. Also, the ratio of Myc to Pim1 overexpression might be
important for induction of proliferation. In addition, levels of Myc and Pim1 necessary for induction of
proliferation could be dierent in B-cells at dierent stages of development. Hence, the retroviral TetON
system used here provides exactly this multitude of combinations of Pim1 and Myc inducibility.
6.1.3 Conrmation of Inducible Transcription and Translation of Transgenes
Overexpression of transgenes in preB-I cells was induced in vitro after addition of doxycycline to the
culture medium. Only 30 minutes after addition of doxycycline, preB-I cells carrying the vectors showed
increased mRNA levels of Myc and Pim1. Overexpression of transgenes was also increased in ex vivo
transgenic splenic and bone marrow B-cells after induction with doxycycline.
Overexpression of Myc after doxycycline induction was also conrmed by SDS page and western blot.
The Daudi cells used as a positive control are clonal and therefore all have the same Myc translocation.
Hence, they should show a uniform expression of Myc, whereas the transduced, doxycycline treated FL
preB-I cells expressing Myc consist of a pool of dierentially inducible cells, as explained earlier. This
heterogeneity in terms of Myc expression might result in the observed lower overall expression of Myc
compared to the Daudi cell line.
Conrmation of Pim1 overexpression on the protein level by SDS page/western blot did not succeed
with the Pim1 specic antibody used in these studies. Hence, upregulation of Pim1-mRNA and induction
of growth-factor-independent proliferation only in transgenic preB-I cells carrying Myc and Pim1 together
had to be taken as a proof for successful Pim1 expression after doxycycline-induction.
Upon induction of expression of EGFP in stably transduced preB-I cell lines, EGFP protein was
detectable after 2 hours and subsequently rose during the next 22 hours. Finally, about 35-50% of the
cells carrying EGFP showed EGFP 
uorescence intensities above the threshold, as dened by the cells
without EGFP-vector, with no distinct peak of EGFP 
uorescence intensity. The lack of a distinct \peak"
of EGFP-positive cells might be a consequence of the heterogenous cell population with cells carrying
dierent copy numbers of retroviral inserts as well as cells carrying silent or badly transcribed vectors as
discussed above.
Induction of transgenes in vivo was achieved by adding doxycycline to the acidied drinking water of
mice carrying transgenic B-cells.
Doxycycline concentrations normally used for in vivo induction of TetOn systems range from 0.02
g/liter up to 2 g/liter. Mice fed with 2 g/liter doxycycline showed severe signs of dehydration after only
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a couple of days [17]. Therefore, for the in vivo experiments conducted in this work, only 0.2 g/liter were
administered.
Over the course of the in vivo experiments, mice receiving doxycycline did not show signs of indispo-
sition.
The addition of sucrose to doxycycline-containing drinking water to improve palatability is widespread,
but controversial. Comparative studies done with reporter mice receiving doxycycline either with or
without 5% sucrose showed that the addition of doxycyline alone did not aect the water uptake of
mice, which lies in between 4-5 ml per day. On the other hand, addition of 5% sucrose lead to excessive
water uptake of around 14 ml per mouse and day (around 3 times the normal uptake) and concomitant
reduction of food-intake. Furthermore, the sweetened water was often contaminated with moulds [59].
Hence, to ensure the uptake of sucient amounts of doxycycline and, at the same time, not to allow
growth of mould, only 1% sucrose was added to the drinking water in the studies here.
6.1.4 Reversibility of Induced Overexpression of Transgenes
The induction of transgene expression was reversible. PreB-I cells carrying an inducible EGFP transgene
already showed a reduction of EGFP-expression 2 hours after removal of doxycycline, followed by a very
slow decline during the next 6 hours. After 3 days, no residual EGFP-expression was detectable anymore.
The time it takes to completely switch o transgene expression after removal of doxycyline is dependent
on the stability of the transgenic RNA and protein. In the case of EGFP, the half life of the protein has
been shown to be around 26 hours [23]. In contrast, the half-life of Myc RNA and protein in mammalian
cells have been measured to be only around 20-30 minutes [46] [38] [124], and the half-life of Pim1 protein
in Bcr-Abl tumour cells has been shown to be 1.3 hours [122]. Hence, it can be reasoned that the time it
takes to completely switch o expression of Pim1 and Myc is much shorter than that of EGFP. Fire
y
luciferase has a half-life of around 3 hours [131] which makes it a better candidate to estimate the time
it takes to induce or shut o expression of Myc and Pim1 than the long-lived EGFP. Experiments done
with CHO cells carrying a doxycycline-repressible (TetO-) re
y-luciferase have shown that luciferase-
activity started to increase 30 minutes after removal of doxycycline from the medium [24]. Vice versa,
luciferase-activity in doxycycline-treated cells started to drop as soon as 30 minutes after addition of
doxycycline and reached baseline levels already after 9 hours.
6.1.5 Leakyness of the Doxycycline-Inducible Expression System
FACS analysis of preB-I-cell lines carrying the rtTA-TetON vector and the TetON-EGFP vector showed
measurable, but only weak EGFP expression in the absence of doxycycline in a small portion of cells.
Hence, within the polyclonal population of EGFP-transfected cells, integration of the EGFP-vector might
have occurred at genomic sites that allowed EGFP expression at low levels even in the absence of the
inducer of gene expression, e.g. in the absence of doxycycline. As mentioned above, some murine leukemia
viruses often integrate in the 5' end of a transcription unit, i.e. in the vicinity of the corresponding pro-
moter and/or enhancer. Such an enhancer could activate the inactive minimal CMV promoter which is
part of the TetON-expression vectors used here in the absence of doxycycline (gure 6.2a). Even the
enhancer elements of the promoter which drives the resistance gene inside the proviral cassette could
possibly in
uence expression of the CMV promoter in the absence of doxycyline (gure 6.2b). A di-
rect in
uence of a promoter upon the inducible transgene is more unlikely, since the inducible expression
cassette is integrated into the vector in reverse orientation, and therefore, transcription started by this cel-
lular promoter would need to proceed through the whole resistance cassette before reaching the inducible
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transgene (gure 6.2c).
LTR LTRcellular DNA transgene resistance
a)
b)
c)
dox-inducible promoter
TRE
cellular DNAenhancer
promoter
proviral DNA
promoter
Figure 6.2 { Possible causes for leaky expression of the retrovirally integrated in-
ducible transgene in the absence of doxycycline: Enhancers of cellular promoters in
the vicinity of the provirus (a) or within the provirus (b) could activate the min-
imal CMV promoter. It is unlikely that a promoter in the vicinity of the provirus
transcribes the inducible transgene, since transcription would collide with that of the
resistance gene (c).
Leaky, but low overexpression of the oncogenes Pim1 and especially Myc in the absence of doxycycline
can be neglected in short-term experiments, since there is not enough time to select for the few cells
which exhibit background-Myc/Pim1 expression with concomitant enhanced survival. But in long-term
experiments such as transplantations, the few cells with unwanted overexpression of the proto-oncogenes
might accumulate in the host over time, which might mask the eect of doxycycline-dependent induction
of Pim1+Myc in the cells.
6.1.6 The Use of Fetal Liver-Derived preB-I-Cells versus Bone Marrow-Derived preB-I-
Cells for the Generation of B-Cells in vitro and in vivo
As stated above, only fetal liver-derived preB-I-cells can be cultivated in vitro for extended periods
of time [112]. Fetal liver-derived preB-I-cells have been reported to repopulate preferentially the B1
compartment [55]. On the other hand, bone marrow-derived preB-I cells have been shown to repopulate
mainly the B2 compartment [50], but proliferated in the presence of IL-7 and stromal cell feeder layers for
only 20-30 days in our hands. Furthermore, bone marrow-derived hematopoietic cells are not as readily
transduced with the vectors used in this thesis than fetal liver-derived preB-I cells (personal observation,
data not shown). Hence, for repetitive transductions and selection of transduced cells in vitro, fetal
liver-derived preB-I cells had to be taken.
Transplantation of fetal liver preB-I cells grown in IL-7 on OP9 feeders into RAG KO hosts indeed
replenished almost exclusively the B1-B/MZ-B-cell compartment in peritoneal cavity and spleen as judged
by expression patterns of CD5, IgD, CD21, and the lack of CD23 expression in splenic B-cells. Co-
transplantation of thymocytes at the day of transplantation of preB-I cells did not support the generation
of B2-B-cells. Upon immunisation of B/T-transplanted RAG KO mice with the TH -dependent antigen
KLH, there was no relevant increase in KLH-specic IgM and IgG-antibodies in the serum of those
mice within 1-5 weeks after immunisation compared to wild type BL/6 mice. Reasons for this inability
to properly react to T-cell dependent antigens might be the following: First, the pool of transplanted
B-cells might not harbour the tting antibody to recognize KLH-epitopes, simply because the number
of transferred, surviving cells is too small, as it is not replenished from precursors in the bone marrow.
Second, the B-cells might not be able to process the signals of activated TH -cells or not be able to react
to T-cell dependent antigens, because CD23+CD21lo B-cells are needed for T-cell dependent responses,
and, last but not least, the transferred T-cells might be unable to respond properly to the antigen.
At the moment, dierent transplantation schemes with B-cell precursors from the bone marrow or fetal
liver, as well as T-cell precursors or T-cells, are tested in our group to nd a satisfying transplantation
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protocol which warrants proper reconstitution of all B- and T-cell compartments necessary for T-cell
dependent B-cell responses in RAG KO mice.
6.2 In vitro and in vivo Maturation of Fetal Liver PreB-I Cells
As discussed earlier, mature, resting B-cells cannot be transduced retrovirally, and lipofection only trans-
fers the vectors temporarily into the cells. Therefore, all maturation stages of B-cells later than the
preB-I-cell stage had to be derived from those successfully transduced fetal liver preB-I cells.
Maturation of fetal liver preB-I cells is simply triggered by the removal of IL-7 from the cultivation
medium. Within 3 days, 80% of the cells lost expression of the preB-I cell marker c-kit, and within 6 days,
around 60% of the surviving cells were IgM+ and 30% were IgD+. Though, more than 95% of the cells
retained CD93 (aa4.1) in their surface, which indicates that the cells are not fully mature. Furthermore,
more than 90% of the cells died within the rst 3 days of maturation. Hence, the generation of B-cells
with a fully mature phenotype (CD93  IgD+) was not possible in vitro.
To obtain fully mature B-cells, successfully transduced preB-I cells were transplanted into the tail
veins of irradiated RAG KO mice. The cells mainly populated the spleen and the peritoneal cavity, but
scarcely the bone marrow (most probably the few mature B-cells found there were recirculating cells). In
the spleen, cell numbers rose continually within eight weeks after transplantation. CD19+ cell numbers
in the dierent organs depended on the cell line. Two, four and eight weeks after transplantation, the
populations within the spleen included up to 50%mature B-cells IgM+IgD+CD93  as well as IgM+CD93+
transitional B-cells and up to 40 % IgM CD93+ cells. In contrast, BL/6 WT mice had more than 90 %
mature B-cells and less than 10% immature and transitional B-cells. Furthermore, only B-cells with a
MZ-like phenotype (CD21+) could be detected in transplanted RAG KOmice, but practically no follicular
CD21loCD23+ B-cells as explained earlier, whereas WT Bl/6 mice had around 80% follicular B-cells and
9% MZ B-cells.
This lack of follicular B-cells was not caused by a lack of T-cells, since co-transplantation of thymic
T-cell precursors did not rescue the follicular B-cell phenotype, though the T-cell precursors matured to
CD4+ or CD8+ single-positive T cells in the spleen, lymph nodes, peritoneal cavities, and bone marrow,
where they persisted for at least 8 months. Mice transplanted with fetal liver preB-I cells readily generated
satisfying IgM- and low IgG- serum antibodies. In the presence of co-transplanted T cells, serum levels
of IgM and IgG were increased around 4 times and 10 times, respectively.
Immunisation of RAG KO mice transplanted with fetal liver preB-I cells with the TH -dependent KLH
generated a low IgM-serum response, and an only very limited specic IgG-serum response as explained
above. In contrast, wildtype mice readily generated KLH-specic serum IgG upon immunisation.
Hence, reconstitution of RAG KO mice with fetal liver preB-I cells was poor and failed to generate
B-cell compartments which could switch and hypermutate to antigen-specic IgG responses. Still, it
provided a rst experimental system to test the eects of Pim1 and Myc overexpression in vivo and to
generate fully mature B-cells in vivo, which could then tested for eects of Pim1 and Myc in vitro.
6.3 Overexpession of Pim1 and Myc in B-Cells at Dierent Stages of Devel-
opment
6.3.1 Overexpression of a Single Transgene, Pim1 or Myc, in PreB-I-Cells
Normal mouse fetal liver preB-I-cells proliferate and are kept in their preB-I state of dierentiation in
the presence of IL-7. Upon removal of IL-7, preB-I-cells begin to dierentiate to IgM+ cells within 3 to 6
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days. The majority of the cells are induced to apoptosis and die. After 6 days, there is hardly any living
cell left.
Overexpression of murine Pim1 in preB-I-cells with the TetOn system used in this thesis does not
lead to an increased survival or proliferation of preB-I or dierentiating B-cells. PreB-I cells remain
dependent on IL-7. This observation is in line with the results obtained by van Lohuizen et al. with
E-Pim1 transgenic mice, which revealed no abnormalities in hematopoietic tissues of healthy mice [133].
Overexpression of Myc alone in preB-I cells led to stable cell numbers over time (for at least two
weeks) if the cells were supplemented with growth factors such as IL5 or CD40+IL4. In the absence
of these growth factors, the cells did not survive longer than 5-8 days. This eect of Myc-overexpression
could be a consequence of enhanced proliferation, enhanced survival, or a combination of both, as well
as a combination of enhanced proliferation with increased apoptosis.
Cell cycle analysis of preB-I cells overexpressing Myc for 2 days in the presence or absence of IL-7
indicated that Myc indeed increases the percentage of cycling cells. Addition of the B1-B-cell growth
factor IL5 led to even higher percentages of cycling cells, whereas the B2-B-cell stimulants CD40+IL4
did not increase the cell cycle entry of Myc-transgenic cells compared to Myc-transgenic cells cultivated
in medium without growth factors.
These data indicate that overexpression of Myc increases cell cycle entry also in the absence of
growth factors. This has also been observed by other groups. For example, in an EBV-transformed
resting human B-cell line, overexpression of Myc alone induces cell cycle entry and proliferation [102].
Also, overexpression of Myc in density-arrested and serum-starved rat broblasts has been shown to
induce proliferation. The duration of the productive cell cycles is hereby not changed, but only the
frequency of cell cycle entry [57]. A detailed analysis of these cells showed that Myc overexpression
indirectly activates preexisting cyclinE-CDK2 kinase activity which is necessary to proceed through the
G1 phase [126]. Furthermore, Myc has been shown to upregulate expression of Cdc25a phosphatase, which
activates cyclin-CDK2 complexes by dephosphorylating CDK2 [40].
On the other hand, it has been shown by several groups that Myc can induce apoptosis in dierent cell
lines, which can be inhibited by the addition of the right kind of cytokines. Rat broblasts overexpressing
Myc in the absence of growth factors are induced to apoptosis independently of the cell cycle state
at much higher percentages than without Myc overexpression [52]. The addition of growth factors can
inhibit Myc-induced apoptosis. Myc-dependent apoptosis was also reported in hematopoietic cells upon
deprivation of growth factors [6]. Hence, the observed increased cycling together with a lack of increasing
cell numbers over time might well be a consequence of a balance between enhanced proliferation and
increased apoptosis.
In conclusion, even the combination of Myc overexpression and addition of survival factors was not
sucient to lead to an increase in cell numbers of preB-cells over time in vitro. Though overexpression of
Myc alone was sucient to induce cell cycle-entry and -completion of fetal liver preB-I cells, the generated
cells were not able to survive long-term in the absence of IL-7.
6.3.2 Overexpression of Pim1 and Myc together in PreB-I-Cells in vitro
In the work presented here, it could be shown that overexpression of Myc and Pim1 together in fetal
liver preB-I cells in vitro leads to proliferation of the cells with a resulting increase of cell numbers over
time. Proliferation as such of Pim1/Myc transgenic cells is independent of growth factors such as IL-5 or
CD40+IL-4. However, the extent of proliferation and/or survival was cytokine-dependent, as cultures
supplemented with IL-5 and also with CD40+IL-4 reached higher cell numbers over time than those
Corinne Bouquet, MPI for Infection Biology, Chariteplatz 1, 10117 Berlin, Germany: PhD Thesis, March 23, 2012 83
6 Discussion
cultivated in medium alone.
Cell cycle studies done with preB-I cells in vitro showed that cells which overexpress both Myc and
Pim1 have higher percentages of cells in S- and M-phase than normal (doxycycline-uninduced) preB-
cells. However, the percentages of Pim1+Myc overexpressing cells which were in S and G2/M phase were
comparable to those of Myc-only transgenic cells. Interestingly, the cell cycle phosphatase Cdc25a, which
is able to dephosphorylate and therefore activate the cyclin dependent kinase CDK2, forms a complex
with Pim1 and acts as its substrate. Phosphorylation of Ccd25a by Pim1 increases Cdc25a-phosphatase
activity [95]. Furthermore, Cdc25a activity has been shown to be limiting in serum-starved cells, and is
also known to form a complex with the growth-factor-inducible protein kinase raf [126].
Taken together, though Myc and Pim1 can cooperate during cell cycle progression as shown by other
groups, Myc alone is sucient to lead to cell cycle entry in mouse fetal liver cells cultivated in vitro in the
presence of 2% fetal calf serum. Overexpression of Pim1 in addition to Myc in mouse preB-cells in vitro
did not further increase the percentage of cells in S/M/G2 phase, but led to an increase in cell numbers
over time, most probably due to enhanced survival. AnnexinV-stainings, which will allow to estimate
the percentage of pre-apoptotic cells, will reveal if the failure of Myc overexpression to increase preB-cell
numbers over time is really due to enhanced apoptosis.
The phenotype of proliferating cells in the absence of IL-7 only slowly shifts from the c-kit+ preB-I cell
stage to the c-kit CD25+ preB-II cell stage, and only few cells acquire IgM on the surface. These data
propose that the cells are somehow inhibited to further dierentiate. This is in line with the observation
that Myc must be downregulated from the transition of preB-cells to mature B-cells and in plasmablasts
to acquire the plasma cell stage [81]. The few IgM+ cells which are found over time might be generated
from preB-cells which do not express sucient levels of Myc and Pim1, either from the beginning on, or
during cultivation by silencing of the retroviral cassette.
6.3.3 Overexpression of Pim1 and Myc in IgM+ Cells in vitro
W ith the inducible proto-oncogene overexpression system used in this thesis, it could be shown that
in vitro dierentiated IgM+ immature B-cells start to proliferate if Myc and Pim1 are switched on.
Proto-oncogene-induced proliferation is independent of growth factors, since immature IgM+ B-cells also
grew in the absence thereof. Anyhow, addition of the B1-B-cell growth factor IL-5 and also addition
of CD40 -/+ IL-4 led to increased total cell numbers compared to cultures without the addition of
growth factors. On the other hand, addition of LPS or IL-2 led to diminished total IgM+ B-cell numbers
compared to the cultures without growth factors. IL-2 had been shown to expand a subfraction of IgM+
plasmablasts in vitro taken from germinal centres of human tonsils [60]. LPS on the other hand drives
plasma cell dierentiation. It is not clear why IgM+ cells stimulated with these plasma cell-inducing
factors proliferate worse. A possible reason might be that either overexpression of Pim1 and Myc in
B-cells triggered to become plasmablasts does not promote in vitro proliferation as well as in preB-I-
cells and IgM+ immature B-cells, or the stimulated cells might be more susceptible to (Myc-induced)
apoptosis.
This growth-factor independent proliferation of Pim1+Myc-overexpressing IgM+ immature B-cells is
a further argument that overexpression of Myc hinders B-cell maturation. If normal B-cell maturation
was not inhibited, preB-I cells overexpressing Pim1 and Myc in the absence of IL-7 would be expected
to mature to IgM+ B-cells during proliferation. Since also IgM+ immature B-cells grow under these
conditions, their percentage would slowly increase over time. But an increase in IgM+ cells was not
observed.
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6.3.4 Limiting Dilution Analysis of Clonable, Pim1+Myc-Induced PreB-I-Cells
All experiments presented in this thesis were done with a pool of cells carrying resistance markers provided
by the retroviral vectors. This doesn't necessarily mean that all cells were able to overexpress Pim1
and Myc suciently to lead to growth factor independent proliferation as discussed earlier. Dierent
levels of rtTA-expression, or rare homologous recombination events during incorporation of the retroviral
backbone, may have led to individual cells not being able to overexpress one of the proto-oncogenes
adequately. Studies with dierent cell pools expressing TetON EGFP showed inducibility of EGFP-
expression in ranges of 30% - 85% of the cells (data not shown). To get a rough estimate which fraction of
preB-I-cells is induced to proliferate in the absence of IL-7 by overexpression of Pim1 and Myc, limiting
dilutions were performed. Around 1 in 100 cells successfully produced a clone of at least 20 cells within 7
days in medium without growth factors. In the presence of growth factors such as IL-5 or CD40+IL4,
the frequency of successful clones rose to 1 in 30-70. This is far less than the frequency of successfully
proliferating cells estimated from the growth curves of Pim1+Myc transgenic preB-I cells in the absence
of growth factors (1 in 2-8). Why that? A possible reason is that many cell lines are not clonable at all
though they grow well in bulk cultures. Hence, for a cell, living alone in 200 l of unconditioned fresh
medium might be a hostile environment due to lack of soluble cell-metabolites and cell-cell interactions,
which makes it more dicult to survive and proliferate.
In short, Pim1 and Myc overexpression lead to growth factor-independent proliferation with con-
comitant increase of total cell numbers in around 1-10% of the original preB-I cells, depending on the
conditons.
To determine if the low percentage of responding Pim1+Myc-expressing cells is the result of a low
frequency of cells which can really induce Pim1 and Myc suciently, or if it is rather the eect of stochastic
cell death, or even dependent on the appropriate ratio of Pim1- and Myc overexpression (or a mixture
of all), transgenic preB-I cells have to be cloned and thereafter need to be subjected to limiting dilution.
Cloning eorts done until now did not result in clones which were able to proliferate in limiting dilution
assays.
6.3.5 Transplantation of PreB-I Cells Overexpressing Myc and/or Pim1 into RAG KO
Mice
It could be shown that preB-cells overexpressing Pim1 and Myc together started to proliferate in vitro
growth factor independently and were hindered to dierentiate to IgM+ cells. To elucidate what happens
to those preB-cells in vivo, preB-I cells overexpressing Pim1 and Myc together were transplanted into
RAG KO mice fed with doxycycline via the drinking water. In mice receiving doxycycline (= overex-
pressing Pim1 and Myc), the immature IgM  and IgM+ B-cell compartment was enlarged compared to
doxycycline-uninduced mice. The enlarged preB-cell compartment could be observed in the peritoneum,
in spleen and in the bone marrow and was especially obvious 4 weeks after transplantation. In spleen,
also the mature B-cell compartment was enlarged 4 weeks after immunisation. Since in vitro experiments
have indicated that Myc-overexpressing cells might not mature to IgM+ cells, the observed increase of
splenic mature B-cells in doxycycline-treated mice might be a cause of silencing of Myc-overexpression
or variabilities in doxycycline-serum levels of the mice. The enlargement of the immature B-cell com-
partment is not surprising, since E-Myc E-Pim1 doubletransgenic mice develop preB-cell tumours in
utero [135].
After downregulation of Pim1/Myc overexpression, cell numbers fell down to those of doxycycline-
uninduced mice within 4 weeks in the bone marrow and spleen, but not in the peritoneal cavity, where the
cell numbers were around 4 times those of uninduced control mice. The most prominent B-cell phenotype
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4 weeks after downregulation of Pim1 and Myc expression was IgM+CD93 . Hence, the majority of cells
which had expanded under the in
uence of Pim1 and Myc overexpression disappeared after switching
o expression of Pim1 and Myc, probably due to the lack of appropriate niches for the B-cells or due
to the inability to properly mature and subsequent negative selection. Single cell PCRs of the expanded
immature IgM  B-cell compartment will reveal if these cells already have out-of-frame VDJH or VJL-
rearrangements and are therefore lost after Pim1/Myc-downregulation.
In the case of RAG KO mice transplanted with Myc-single-transgenic FL-preB-I cells, no abnormal
outgrowth of B-cell populations could be detected in the presence of doxycycline. This was not as expected,
since E-Myc transgenic mice have been shown to harbour enlarged pro- and preB-cell compartments
already before birth in the fetal liver and later in the bone marrow and the spleen, although this expansion
of early B-cells was not accompanied by a dramatic increase of total B-cells [75]. Though, there are a
number of dierences between the two systems. First, the E-enhancer is thought to be active already
prior to H-locus rearrangement [69]. Hence, expression of E-Myc commences much earlier in B-cell
development than that of TetON-Myc introduced into preB-I cells. Secondly, transplantations of FL
preB-I cells into irradiated hosts only supplies one wave of maturing B-cells and does not replenish the
bone marrow with long-term hematopoietic stem cells as existing in transgenic E-Myc mice. Hence,
only a limited pool of (pre)B-cells is available. Thirdly, the transplanted cell pool does not contain 100%
equally Myc-inducible cells, whereas E-Myc mice most probably harbour B-cells which all have the same
active translocation. Furthermore, inducible Myc-expression in host mice transplanted with transgenic
preB-I-cells is dependent on the uptake of doxycycline and the serum levels of active doxycycline over
time. It is inevitable that there is some variation of doxycycline-concentration in the serum of these mice,
which might lead to death of some of the cells due to subsequent variations in Myc protein levels.
Though there was no detectable increase in B-cell numbers in mice transplanted with Myc-expressing
preB-I cells, the size of Myc-expressing cells in the spleen and the peritoneum of these mice was larger
than that of mice which received control preB-I cells. Myc has been shown to increase protein synthesis
and cell size of murine lymphocytes at all stages of development independently of the cell cycle phase
[75] [62] [120]. Hence, the enlarged size of transplanted B-cells in the presence of doxycycline indicates
that Myc-overexpression was indeed successful in these cells and, hence, the unresponsiveness of the
cells was not simply due to a failure to overexpress Myc. In the bone marrow, no increase in cell size
could be observed. This might be a consequence of the low number of transgenic B-cells present in the
bone marrow compared to the number of host-derived proB/preB-cells existing RAG KO mice combined
with the inability to outgrow the host-derived B-cell precursors. In contrast to the mice transplanted
with Myc-expressing preB-I cells, the mice which received Pim1/Myc-transgenic B-cells also had B-
cell precursors with a detectably larger size in the bone marrow in addition to those in the spleen and
peritoneal cavity, most probably because the frequency of transgenic cells in the pool of BM CD19+
cells, which was normally low, had increased due to the advantage in proliferation and/or survival of
Pim1/Myc transgenic cells.
6.3.6 Mature B-Cells and Pim1+Myc Overexpression
As shown above, overexpression of Pim1 and Myc together in fetal liver preB-I cells and immature IgM+
cells leads to proliferation of those cells with concomitant reduced maturation in vitro and in vivo.
But what about mature B-cells?
Pim1+Myc-transgenic mature B-cells extracted from spleens, bone marrow and peritoneal cavities
of transplanted RAG KO mice could not be induced to sustained in vitro-proliferation with subsequent
increase in total cell numbers upon stimulation of Pim1 and Myc overexpression. Still, subtle eects of
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Pim1+Myc-overexpression could be detected. The cultures of splenic B-cells supplied with doxycycline
survived longer.
CFSE-stainings of such cultivated bone marrow and spleen cells also did not show a doxycycline-
induced increase in proliferation. There were only subtle changes in the number of cells which had pro-
liferated at least once within 4 days or the average number of proliferations done within that timespan
in bone marrow and splenic B-cells induced with doxycycline.
In short, B-cells taken from spleen, bone marrow or peritoneal cavity from transplanted RAG KO
hosts could not be induced to sustained in vitro proliferation by overexpression of Pim1 and Myc, either
without external stimulation or with the stimuli used in this work.
This does not yet mean that Myc/Pim1 overexpression in mature B-cells does not have any in
uence
upon these cells, since not every ex vivo cell type can be adapted to proliferate in vitro.
Eorts to generate activated B-cells by cotransplanting thymocytes together with Pim1+Myc trans-
genic B-cells and subsequent immunisation of those mice with a T-cell dependent antigen were hampered
by the inability of the transplanted B- and T-cells to properly react to the antigen. While a very minor
antigen-specic antibody response either of the IgM or of the IgG isotype was detected, overexpression
of Pim1 and Myc in transplanted B-cells resulted in increased total and KLH-specic IgM and IgG levels
only in immunised mice, and not in unimmunised mice receiving doxycycline or KLH-immunised mice.
Furthermore, in a control experiment conducted with mice which were transplanted with transgenic preB-
cells, but without thymocytes, the same immunisation scheme in combination with doxycycline treatment
did not result in enlarged IgM and IgG antibody levels.
Thus, a so far uncharacterized B-cell type or maturation stage which is generated or activated during
an immune response in the presence of T-cells or T-cell-derived growth factors might have a proliferative
or survival advantage if Pim1 and Myc are overexpressed. This proposed advantage seems to be short-
term, since the dierence in total IgM and IgG serum levels in Pim1+Myc overexpressing immunised
mice did not further increase 5 weeks after immunisation as compared to 2 weeks after immunisation.
Further experiments aiming at characterising this Pim1+Myc-responsible activated B-cell type should
be done with transgenic mice carrying inducible Pim1 and Myc genes to assure proper and stable ex-
pression of these transgenes. It might also be necessary to generate the proper B2-B-cell and T-cell
compartments, maybe by using progenitor cells other than those generated from fetal liver. Fetal liver-
derived preB-I-cells have been shown to generate insucient B2-B-cell compartments which would be
necessary to allow relevant T-cell dependent antibody responses if transplanted using the protocols pre-
sented herein. Since the retroviral vectors used so far could not eciently transduce bone marrow B-cell
precursors grown in the presence of IL3, IL6 and SCF, which generate B1- and B-2-B-cell compartments
as well as the T-cell compartment, such vectors have to be designed.
With transgenic B-cells which are able to eciently reconstitute also the B2-B-cell compartment, and
which can cooperate in T-cell dependent antigen responses if transplanted into RAG KO mice, future
experiments can be conducted to elucidate if, indeed, there is a B2-B-cell fraction which can respond to
Pim1 and Myc overexpression with short-term or sustained proliferation. Changes in the compartment
size of mature follicular B cells, germinal center B-cells (as characterized by FAS/CD95, GL7, CD86
(B7.2) and PNA), MZ cells (CD21+), plasmablasts, and other subsets can then be distinguished by
FACS analysis and by immuno
uorescence stainings of frozen spleen sections.
Myc as a proto-oncogene is involved in a whole set of neoplasias of immature, mature, and activated
B-cells. Burkitt's Lymphomas are predened by the presence of a translocation of the Myc gene to the
IgH gene (found in 80% of cases) or to the Ig or Ig gene (in the remaining 20% of cases) [36], bringing
Myc expression under B-lineage control. Burkitt's lymphoma cells typically express monotypic surface
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IgM, and the proliferation fraction is nearly 100%. In multiple myeloma (plasma-cell-derived neoplasia
in the bone marrow), Myc protein levels are elevated due to a mutation which makes the mRNA more
active (Willis et al. in [92]). Furthermore, Myc is often deregulated in E-bcl2 mice which developed
plasmacytomas (Harris et al. in [92]). BCL2 and Myc also cooperate in follicular lymphoma [65]. Finally,
Myc and the oncogene V-ABL of the Abelson murine leukemia virus together generate plasmacytomas
and preB-cell lymphomas in mice (Harris et al. in [92]).
Thus, Myc is very well able to cooperate in the neoplastic transformation of mature lymphocytes.
From my results it appears that Pim1 is either not sucient to cooperate with Myc in mature fetal liver-
derived B-cells in vitro and in vivo, or that other partner oncogenes are needed for full transformation of
mature fetal liver-derived B-cells.
7 Conclusion and Outlook
In conclusion, overexpression of Myc alone in fetal-liver-derived B-cells in vitro and in vivo does not
eciently lead to growth factor-independent proliferation though it increases cell cycle entry in preB-cells.
Experiments done so far imply that the Myc-intrinsic ability to induce cell cycle entry and apoptosis at
the same time might be skewed to apoptosis in some stages of B-cells. The scheme in gure 7.1 illustrates a
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Figure 7.1 { Model of how Myc in
uences the balance between cell
growth/proliferation and apoptosis. Results from several publications (see text) are
pooled. Myc activates the ARF/MDM2/p53 pathway, which promotes growth arrest
or apoptosis. At the same time, Myc blocks proteins which are important for growth
arrest, and therefore promotes apoptosis. Furthermore, Myc activates pro-apoptotic
BCL2-family members and sensitizes the cell for proapoptotic stimuli via death re-
ceptors. On the other hand, Myc upregulates proteins necessary for cell cycle entry
and cell growth. Survival factors, mitogens, and death signals ne-tune this network,
which results either in cell death or cell cycle entry.
simplistic model of how Myc might be implicated in tuning the intricate balance between cell cycle entry,
growth arrest and apoptosis. Myc has been shown to indirectly activate p53 protein [123], which is a main
switch between growth arrest and apoptosis. Myc downregulates ARF2 via FoxO-transcription factors,
and hereby leads to activation of p53 by indirectly blocking the activity of ARF [58]. In the presence
of Myc, p53 activity is skewed to induction of apoptosis [63]: Expression of P21/CIP1 and GADD45a,
which are both activated by p53 and normally promote growth arrest, are blocked by Myc. Furthermore,
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Myc leads to increased sensibility to death signals and activates a range of pro-apoptotic members of
the BCL2 family Homan2008, which also block their antiapoptotic counterparts. In normal cells, Myc
activity is tightly regulated by negative feedback loops, and might be induced only in certain settings
such as stimulation of the BCR, or CD40 signalling, or LPS stimulation [68], and, in immature B-cells,
upon IL-7-signalling [98]. Many of these triggers also induce the expression of pro-survival proteins [101].
However, in cells where Myc is deregulated for instance by translocation to a dierent locus, e.g. the
IgH locus with its promoter, Myc can no longer be controlled by negative regulation anymore, and a cell
might nd itself in an environment which does not provide the necessary survival-signals.
And this is where PIM1, and probably a range of other Myc-cooperating proto-oncogenes such as
BCL2, BCL6, and V-ABL, might come in. As shown in the model in gure 7.2, PIM1, in addition to
stabilizing Myc protein and activating the phosphatase CDC25a which is essential for cell cycle entry [95],
PIM1 is also able to block pro-apoptotic BCL2-family members [1]. Interestingly, PIM1 is also upregulated
in response to CD40- and LPS-signalling [141]. Hence, expression of PIM1 might be sucient - at least
in some B-cell dierentiation stages - to shift the balance in favour to cell cycle progression and against
induction of apoptosis.
Future experiments with PIM1+Myc transgenic B-cells will also include the generation of clonal preB-
I-cell populations, each with a dened capacity to overexpress PIM1 and Myc. These clones can then be
examined upon induction of proliferation at dierent immature B-cell stages, which will reveal if growth
factor-independent proliferation is a clonal feature, i.e. might be dependent on the levels of Pim1/Myc
overexpression or their ratio, or if it is a\stochastic" process, i.e. of a clonal population of preB-cells, only
a certain percentage is able to proliferate.
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Figure 7.2 { Model of how PIM and Myc in
uence the balance between cell
growth/proliferation and apoptosis. Results from several publications cited in this
thesis are pooled. Pim1 might override the pro-death signals which Myc triggers by
activating proapoptotic bcl2-family members. Furthermore, PIM is in involved in the
activation of the cell cycle
Pim1 might not always be the right partner for Myc to generate B-cells which prefer proliferation
to apoptosis. The results shown here imply that Pim1 and Myc might mainly cooperate to generate
B-cell tumours with immature characteristics, since mature B-cells only showed marginal eects upon
Pim1+Myc-overexpression in vitro and in vivo. Since it is not only Pim1 which regulates survival signals,
it might well be that the general balance in more mature cells is skewed more drastically towards the
apoptosis program, and PIM might simply not be strong enough to overcome this. Another possibility
Corinne Bouquet, MPI for Infection Biology, Chariteplatz 1, 10117 Berlin, Germany: PhD Thesis, March 23, 2012 89
7 Conclusion and Outlook
is, that some important proteins which are activated by Pim1 in immature B-cells are not present or less
abundant in mature B-cells.
Future experiments will include overexpression of Myc-mutants often found in Burkitt's Lymphoma
which do not induce apoptosis anymore. Other cooperation partners for Myc instead of Pim1 which
might also lead to a survival advantage of mature B-cells will also be tested as soon as usable T- and
B-cell-reconstitution of host mice for antigen-specic responses is established.
Candidates for Myc-cooperating proteins which might allow sustained proliferation of cells are NFB-
signalling pathway components such as NEMO and IKK2, BCL-6, TCL-1, and PIM-2 and other survival
factors or BCL-2 family members. Also, the eect of Pim1 and Myc overexpression in B-cells derived
from other mouse lines might be interesting, since expression levels of proliferation- and apoptosis-related
genes might be variable in dierent hosts.
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